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1 
Abstract 
The Somogyi effect or long-term glucose counter-regulation to hypoglycemia is a 
reaction hypothesized to manifest itself as a hypoglycemia-induced (relative) 
hyperglycemia. Such an effect would pose a potential challenge to blood glucose 
control in people with type 1 diabetes. Since good blood glucose control is crucial 
to the health of this patient group, the hypothesis of the long-term glucose 
counter-regulation has been explored for half a decade. No consensus on the 
existence and characteristics of the hypothesized effect has been reached.  
This PhD-project aims at exploring different methodological approaches to the 
analysis of the hypothesized long-term glucose counter-regulation and its 
correlation to hypoglycemia. Therefore, we conducted an apparently ideal study, 
during which we compared continuously monitored glucose in a period following 
spontaneous hypoglycemia with that in a control period free from hypoglycemia. 
Three additional studies were conducted to explore potential solutions to 
methodology challenges to the apparently ideal study. These were 1) a 
background data balancing method study employing a metabolic model for 
normalization of background data, 2) a control data substitution study utilizing a 
metabolic model's simulations as control data, and 3) an animal study using 
Göttingen minipigs as a chronic model of type 1 diabetes with tight blood glucose 
control, equipped to offer the opportunity of easy and frequent blood sampling.  
All four evaluated approaches appear feasible and relevant in the study of the 
long-term glucose counter-regulation. The thesis provides indications of a long-
term glucose counter-regulation to hypoglycemia, which means that further 
exploration of the hypothesis is of importance to the glycemic control of type 1 
diabetic patients.  Further explorations may apply the methods suggested in this 
thesis. 
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Danish Summary/Dansk resume 
Hypoglykæmi-induceret hyperglykæmi kaldet Somogyi-effekten eller 
langtidsmodreguleringen i blodsukker efter hypoglykæmi har været foreslået på 
baggrund af observationer hos patienter med type 1-diabetes. En sådan 
hyperglykæmisk effekt af hypoglykæmi vil udgøre en potentiel udfordring for 
blodsukkerkontrollen hos denne gruppe.  God blodsukkerkontrol er essentiel for 
sundheden for patienter med type 1-diabetes, så hypotesen om 
langtidsmodregulering i blodsukker efter hypoglykæmi er blevet undersøgt 
gennem det sidste halve århundrede. Der er dog ikke opnået konsensus om 
eksistensen af den.  
Formålet med dette PhD-projekt var at beskrive forskellige metodetilgange til 
analysen af den mulige langtidsmodregulering i blodsukker efter hypoglykæmi. Vi 
udførte et tilsyneladende ideelt studium, hvor vi sammenlignede kontinuerligt 
målt vævsglukose i en periode efter hypoglykæmi med kontinuerligt målt 
vævsglukose i en periode uden foregående hypoglykæmi. Tre yderligere studier 
blev udført for at udforske mulige løsninger på metodemæssige udfordringer i det 
tilsyneladende ideelle studium. Disse tre studier var et studium, der balancerede 
baggrundsdata ved hjælp af en metabolisk model, et studium, der introducerede 
metaboliske modelsimuleringer som kontroldata, og et dyrestudium, der 
beskriver implementeringen af en dyremodel for type 1-diabetes med stram 
blodsukkerkontrol og let adgang til blodprøvetagning i Gøttingen minigrise. 
Alle fire anvendte metodetilgange udgør anvendelige og relevante til analysering 
af langtidsmodreguleringen i blodsukker efter hypoglykæmi. Afhandlingen 
indikerer, at langtidsmodregulering efter hypoglykæmi forekommer, så yderligere 
udforskning af fænomenet bør foretages af hensyn til blodsukkerkontrollen hos 
type 1-diabetikere. En sådan yderligere udforskning kan anvende metoderne 
præsenteret i dette PhD-projekt. 
Preface 
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Preface 
This PhD-thesis presents the work done during my PhD-study August 2005-
September 2008. The work was performed in the Medical Informatics Group, 
Department of Health Science and Technology, Aalborg University, Denmark. The 
title of the thesis is Analyzing the long-term glucose counter-regulation to 
hypoglycemia – methodological approaches.  
The thesis comprises 3 sections: Introduction, Studies, and Discussion and 
Conclusion. The Introduction offers a general introduction to diabetes and the 
subject of the thesis i.e. the long-term glucose counter-regulation to 
hypoglycemia. Furthermore, it gives a brief overview of the literature on the 
subject and outlines the methodological approach applied in the studies 
presented in this thesis. The Studies section presents the four studies that 
constitute the thesis. The studies are in their original form (submitted or 
accepted) though without abstracts and bibliographies. The Discussion and 
Conclusion section provides a discussion of the work and its relation to previous 
work, suggests future work, and briefly concludes all work presented in the thesis. 
Full papers (with abstracts and bibliographies) can be found after the Discussion 
and Conclusion par. Tables and figures are numbered consecutively in each 
chapter. 
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INTRODUCTION 
This section of the thesis provides the 
background of the work, gives a 
literature overview, and presents the 
work included in the thesis 
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1. Diabetes mellitus 
Disease characteristics 
Diabetes mellitus is a chronic disease characterized by insufficient or absent 
insulin production and secretion and/or decreased insulin sensitivity of the tissue, 
causing blood glucose to be abnormally high. Other metabolism abnormalities are 
also observed, primarily in the lipid metabolism.  
The disease exists in two variants, type 1 and type 2, mainly distinguished by the 
degree of intact insulin production in the pancreas. Type 1 diabetes is 
characterized by little or no endogenous insulin production, whereas type 2 
diabetes is characterized by depressed insulin sensitivity and, at least in the early 
disease stages, nearly normal and perhaps even supranormal insulin production. 
The etiology of type 1 diabetes is unknown but an autoimmune reaction is known 
to be involved. The etiology of type 2 diabetes has an important genetic 
component but is also related to lifestyle and ageing.  
Treatment 
In order to normalize blood glucose and to avoid acute or chronic complications 
due to abnormal blood glucose, people with type 1 and also some individuals with 
type 2 diabetes (in total approximately 20% of a diabetic population depending on 
treatment schemes applied (1)) must take over the regulation of blood glucose 
from the pancreas. This is achieved primarily by balancing exogenous insulin 
supplies, meals, and exercise. Insulin is usually injected by the patient via an 
insulin pen or a syringe, but insulin pumps for basal infusion and infusion of meal-
related boluses may also be applied. Insulin is injected or infused into the 
subcutaneous adipose tissue, typically in the abdomen, thigh or upper arm. It 
might also be injected intra muscularly.  
Individuals with type 2 diabetes that are not supplied with exogenous insulin are 
encouraged to keep a diet and reduce weight. Oral anti-diabetic medication 
(increasing the insulin sensitivity, increasing the pancreatic activity, or decreasing 
the glucose uptake from the intestine) may also be prescribed. Not all type 2 
diabetic patients are diagnosed (2). This population is at a serious risk of long-
term diabetic complications which could be avoided by routine therapeutic 
interventions. 
Patient group 
It has been estimated that the worldwide number of individuals with diabetes is 
180 million (2006 figures). Of these, approximately 10% have type 1 diabetes (2). 
In 2007, 8% of the American population suffered from diabetes (type 1 or 2) (3), 
whereas in Spain, the 2002 prevalence of diabetes (type 1 and 2) was 5-6% (4). 
The 2003 U.S. incidence of diagnosed diabetes (type 1 and 2) was 6.9 per 1,000 
persons per year and it is expected to increase in the following years (5). In 
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Denmark, the total incidence of type 1 diabetes is approximately 15 per 100,000 
persons per year. 
The focus of remaining parts of this thesis is type 1 diabetes. 
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2. Blood glucose control and the long-term glucose 
counter-regulation 
Importance of euglycemia 
Keeping the blood glucose in the euglycemic range is essential for both type 1 and 
type 2 diabetic patients to avoid complications and minimize morbidity, 
premature death, and costs of care. Suboptimal blood glucose control with 
frequent or persistent episodes of hyperglycemia mainly leads to a substantially 
increased risk of long-term complications (8). These complications are micro and 
macro vascular diseases like diabetic retinopathy, diabetic nephropathy, diabetic 
neuropathies, and atherosclerosis. Intensive control of the blood glucose prevent 
long-term complications. However, it may also increase the frequency and 
severity of hypoglycemia (8), which to many patients constitutes the most feared 
complication to diabetes (9,10). 
Diabetes (both type 1 and type 2) is the primary cause of death in 77,000 cases in 
the U.S. each year. In addition, 16.5% of all U. S. cardiovascular-related deaths are 
caused by long-term diabetic complications (3). The acute complications of 
hypoglycemia are associated with 2-4% of all deaths among people with type 1 
diabetes (6,7). Diabetes accounted for 11% of the 2007 cost of the American 
healthcare system (3), whereas 6-7% of the 2002 Spanish healthcare cost was 
used for diabetes (4).  
Means for achieving good blood glucose control 
To a large extent, the patient has to take responsibility for managing his or her 
diabetes (11-14), since it is not practical or economically viable for specialists to 
manage patients’ diabetes on a day-to-day basis (14). Various approaches 
intended to facilitate patients’ everyday decisions have been suggested, ranging 
from educational courses to interactive computer programs (15). Educational 
courses or diabetes schools, like the Diabetes Teaching and Training Program (the 
Düsseldorf model) (16), Dafne (17) and the Newcastle Empowerment Programme 
(18) are usually conducted during inpatient stays (16) or in outpatient clinics 
(17,18). They aim to educate the patient to adjust insulin doses according to the 
expected carbohydrate intake and the current blood glucose level in order to 
achieve normoglycemia as well as to avoid hypoglycemia (16-18). Interactive 
computer programs are computer-based decision support systems such as 
DiasNet (19), AIDA (20), and Librae (21), all of which have been developed for 
educational (general) and advisory (specific) purposes alike. These decision-
support systems all simulate a blood glucose profile from input data on meals and 
insulin doses, some of which are on a patient-specific basis (19,21,22), and some 
also from information on physical activity (21). Patients may then apply the 
computer simulation program as a test environment for exploring their bodies’ 
reactions to insulin doses, insulin regimen alterations, or meal-size alterations. 
Chapter 2: Blood glucose control and the long-term glucose counter-regulation 
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From this they can select the insulin or meal action that will provide the desired 
blood glucose outcome. 
Challenges to blood glucose control 
Both educational courses and decision support systems aim to facilitate patients’ 
disease management, but their effectiveness encounters challenges. Both 
educational courses and decision support systems help the patient predict the 
outcome of various actions (primarily meal intakes and insulin injections) and help 
select the optimal action based on these predictions. Consequently, the prediction 
quality is crucial; if the prediction leading to the action selected is astray, the 
outcome of the action will not be as it was intended. 
A number of possible causes of erroneous predictions exist. Variations in plasma 
insulin profiles after identical insulin injections have been reported (23,24) as 
have difficulties in quantifying insulin sensitivity variations due to stress or disease 
(25). On a hypothetical level, unanticipated variations in blood glucose have been 
speculated to arise from the long-term glucose counter-regulation to 
hypoglycemia (26-32). Such unanticipated variations in blood glucose would 
certainly cause erroneous predictions. 
The long-term glucose counter-regulation to hypoglycemia as a 
challenge to blood glucose control 
The hypothesized long-term glucose counter-regulation to hypoglycemia has 
gained recent interest (28,30) in addition to the historical interest it was paid in 
the 50’s, 80’s and 90’s when it was known as the Somogyi effect. The long-term 
glucose counter-regulation to hypoglycemia is defined as a hypoglycemia-induced 
hyperglycemia. The hyperglycemia is not necessarily above an absolute blood 
glucose threshold of approximately 10 mmol/l; it may be elevated only relative to 
a control, hypoglycemia-free case with the same conditions regarding meal intake, 
insulin injections, exercise and other issues affecting blood glucose. A delay from 
hypoglycemia onset to the onset of the long-term counter-regulation 
hyperglycemia may be seen. However, it should be stressed carefully that no 
consensus exists on the quantitative characteristics of the manifestation of the 
long-term glucose counter-regulation to hypoglycemia, so firm definitions cannot 
be given (33-37). Despite the lack of sound definitions, a diurnal or otherwise 
recurrent pattern of the long-term glucose counter-regulation to hypoglycemia 
can be speculated due to the recurrent nature of hypoglycemia in some patients 
(7,38,39). 
Because of the suggested characteristics of the long-term glucose counter-
regulation to hypoglycemia, the reaction may pose a challenge to efficient blood 
glucose control. This would be the case if a recurrent (relative) hyperglycemia is 
not recognized as hypoglycemia-induced, but perceived instead as regulated 
solely by recent insulin and meal intake. The individual with diabetes may then 
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attempt to treat the hyperglycemia with increased doses of insulin, but this might 
worsen the hypoglycemia problem, thus triggering a vicious circle.  
However, such a vicious circle will be set off only if the long-term glucose counter-
regulation to hypoglycemia occurs with prominent characteristics. To establish 
the relevance of the long-term glucose counter-regulation to hypoglycemia in 
normal life, the very mechanism is the focus of this thesis. 
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3. Literature overview 
Throughout the 80’s and 90’s, several groups have investigated the hypothesis of 
a long-term glucose counter-regulation since Michael Somogyi first proposed the 
hypoglycemia-induced hyperglycemic effect (40,41).  This section presents a short 
overview of the literature of the long-term glucose counter-regulation to 
hypoglycemia.  General methodological approaches and apparent results 
constitute the main focus of the overview, so specific studies are not explicitly 
summarized. 
The studies of the long-term glucose counter-regulation roughly fall into four 
design categories:  
 nocturnal glycemia stratification studies 
 intervention glycemia control and true control studies 
 diabetic subjects’ insulin resistance studies 
 healthy subjects’ insulin resistance studies 
The categories are standard study designs, but even within each design category 
studies vary in terms of specific research protocol characteristics; patient 
selection, blood sampling frequency, hypoglycemia threshold, assays in addition 
to glucose, and others.  
Other varying designs have also been employed, but the majority of studies falls 
into one of the four.  
Nocturnal glycemia stratification studies 
In the nocturnal glycemia stratification studies subjects are stratified from 
nocturnal blood glucose measurements and morning glycemia in the different 
strata are compared. (In a variation of this study design stratification is from 
morning glycemia and comparison is of nocturnal glucose profiles for the different 
strata.) The nocturnal glycemia stratification study design is retrospective and 
observational. 
The studies by Hoi-Hansen et al. (30), Guillod et al. (28), Havlin and Cryer (42), and 
Stephenson and Schernthaner (31) employ this design. The study by Gale et al. 
(27) employs the variation of the design with morning glycemia stratification and 
comparison of nocturnal blood glucose between strata. 
In the nocturnal glycemia stratification design, sampling of blood glucose is 
initiated in the evening and performed at fixed-time intervals throughout the 
night until mid-morning. Stratification (hypoglycemia/no hypoglycemia) is 
performed from one of the nocturnal blood glucose values. The morning blood 
glucose is compared for the strata with confirmed nocturnal hypoglycemia and 
the strata with confirmed normo- or hyperglycemia. Hereby, the effect of 
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spontaneous hypoglycemia in one stratum is compared to the effect of no 
spontaneous hypoglycemia in another stratum. (In the study design variation 
employing morning glycemia stratification, only data from subjects with nocturnal 
hypoglycemia are analyzed, and morning glycemia is stratified into strata of 
normo-/hyperglycemia and hypoglycemia.) Sampling intervals involving 
hospitalization of the subjects vary from 1.5 hours (27), over 3 hours (31) and up 
to 4-6 hours (42). Lately, continuous glucose sensors allowing patients to live their 
everyday lives have been applied for glucose sampling in studies of this design 
category. This has introduced frequent glucose sampling (sampling intervals of 1-5 
minutes depending on glucose sensor system) (28,30). The study duration is 
determined by the time of glycemia stratification in the night and the time of 
morning glycemia analysis, and it ranges from 4 hours (30,31,42), over 6 hours 
(27) and up to 8 hours (28). Subjects in nocturnal glycemia stratification studies 
are diabetic, typically with type 1 diabetes. However, in the study by Havlin and 
Cryer (42) type 2 diabetic subjects treated with insulin were also inrolled. In all 
studies, the subjects take their usual insulin doses at the usual injection times. In 
this regard, it should be noted that some of the subjects in the study by Guillod 
and colleagues (28) used insulin infusion pumps for basal infusion and meal-
related bolus infusions instead of subcutaneous insulin injections.  In the studies 
using hospitalized subjects, no meals are ingested between glycemia stratification 
time and morning blood glucose measurement (27,31,42), whereas this is not 
controlled in non-hospitalized subjects (28,30).  
According to this study design, elevated morning glucose after nocturnal 
hypoglycemia (compared to morning glucose after nocturnal normoglycemia) 
should be taken to indicate a long-term glucose counter-regulation to 
hypoglycemia. Hoi-Hansen and colleagues (30) did not find significantly increased 
morning sensor glucose after nocturnal hypoglycemia compared to the morning 
sensor glucose with nocturnal normo- or hyperglycemia. This was also seen by 
Guillod and colleagues (28), who also found that only about one quarter of sensor 
hyperglycemic mornings were preceded by sensor hypoglycemic nights. Havlin 
and Cryer (42) found significant blood glucose elevations of blood glucose (night 
to morning) in subjects with nocturnal blood glucose <5.5 mmol/l, but morning 
levels in these subjects were lower than in those subjects with nocturnal 
normoglycemia. Similarly, Stephenson and Schernthaner (31) found no difference 
in blood glucose elevation between subjects with and without nocturnal 
hypoglycemia. Gale and colleagues (27) found blood glucose elevated 7-8 mmol/l 
on mornings after hypoglycemia in some subjects and sustained hypoglycemia in 
others. 
A major weakness of the nocturnal glycemia stratification design is the lack of 
comparability ensurance of hypoglycemia conditions and non-hypoglycemia 
conditions. This is due to the stratification of subjects and their normal ingestion 
of insulin and meals, which may not be the same in all strata, at least not in non-
hospitalized subjects. Even if the study design does not ensure comparability of 
subjects, data on insulin doses and meals for the subjects in each stratum would 
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be helpful when interpreting results. The limitation of hypoglycemia occurrence 
time to the night is also a weakness of the nocturnal glycemia stratification study 
design. This is because not all hypoglycemic events occur during the night and no 
indications exist that only nocturnal hypoglycemia may trigger the vicious circle 
imposed by the possible long-term glucose counter-regulation to hypoglycemia. 
As only nocturnal glycemia and its effect on morning blood glucose has been 
explored applying the nocturnal glycemia stratification design, it has not been 
ensured that the period before the study initiated was hypoglycemia-free for all 
subjects. If the long-term glucose counter-regulation to hypoglycemia is of a 
duration longer than 8 hours (the approximate study duration, ending with 
morning blood glucose sampling), hypoglycemic events before the study period 
may trigger a long-term glucose counter-regulation to hypoglycemia without 
presentation in the stratification glycemia sampling period. In such cases, the 
stratification may not reflect all of the actual triggered long-term glucose counter-
regulations to hypoglycemia, but only those triggered by nocturnal hypoglycemic 
events. The study period, at least in studies applying the morning glycemia 
stratification design, like employed in Gale et al. (27), may also be insufficient for a 
counter-regulation to be prominent by the end of the study, as the blood glucose 
may not yet have normalized and increased to supranormal levels after 
spontaneous hypoglycemia. 
Intervention glycemia control and true control studies 
In the intervention glycemia control and true control design the blood glucose 
profile after induced hypoglycemia is compared with the blood glucose profile 
after ensured normoglycemia. For reference, also a non-intervention blood 
glucose profile is compared with the two other profiles. The study design is 
prospective and interventional. 
The design has been employed in Perriello et al. (43), Hirsch et al. (29) and 
Tordjman et al. (32). 
In the intervention glycemia control and true control study design, the subjects 
are hospitalized and subjected to a session of either a hypoglycemia induction 
with intravenous insulin infusion, normoglycemia insurance by a glucose infusion 
or reference without intervention. All subjects participate in all session types, 
typically in random order. The sessions all begin in the evening so that nocturnal 
hypoglycemia is investigated in all cases. Each session is associated with preceding 
(1-5 hours) and subsequent blood sampling for blood glucose measurements and 
other assays (plasma insulin, glucagon, epinephrine, growth hormone, cortisol 
(29,32,43) and norepinephrine (29,32)). Sampling intervals are typically 30 
minutes (29,32,43), increasing to 60 minutes from 2 hours after hypoglycemia 
(29). The study period ranges from 4 (32) to 8 (43) and 18 (29) hours after 
hypoglycemia. Subjects in the intervention glycemia control and true control 
studies have type 1 diabetes. Subjects inject their usual insulin doses at fixed 
times together with fixed, standard meals in all sessions (29,43), or they take their 
usual insulin doses at their usual injection times with their usual meals (32). In the 
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study by Perriello et al. (43), subjects were all treated with subcutaneous insulin 
infusions comprising both basal infusion and meal boluses. 
According to the conventions of the intervention glycemia control and true 
control design category, higher blood glucose levels following hypoglycemia 
compared with those following normoglycemia support the hypothesis of a long-
term glucose counter-regulation to hypoglycemia. Perriello and colleagues (43) 
found significantly higher (3-4 mmol/l) blood glucose levels beginning 
approximately 6 hours after hypoglycemia and continuing throughout the 
remaining 2 hours of the study period. Hirsch and colleagues (29) found no blood 
glucose difference comparing hypoglycemia with hypoglycemia prevention 
sessions. Careful inspection, however, reveals that the blood glucose was 
approximately 2-3 mmol/l higher after hypoglycemia nights than after the 
intervention-free control nights. This small relative hyperglycemia begins 6-10 
hours after hypoglycemia nadir time and lasts until study finish time. During the 
intervention-free control night, only four of the subjects had no spontaneous 
nocturnal hypoglycemia, however, the hypoglycemic events in the remaining 
subjects were not as severe as in the intervention night. It could be speculated 
that prevention of hypoglycemia may have been excessive, as glucose levels in 
this session were approximately 2 mmol/l higher than in the intervention-free 
control session. Tordjman and colleagues (32) found no significantly higher blood 
glucose within 4 hours after hypoglycemia compared to after prevention of 
hypoglycemia. Also in this study it should be noted that hypoglycemia-prevention 
may have been excessive. 
A major weakness of the intervention glycemia control and true control design is 
the induction of hypoglycemia that may not be in accordance with the subjects’ 
own diurnal susceptibility to hypoglycemia. The use of a control day for sampling 
of blood glucose without intervention mitigates this as the subjects’ overall 
susceptibility to nocturnal hypoglycemia can be confirmed, but as observed  in the 
study by Hirsch and colleagues (29), some subjects have a tendency to 
hypoglycemia during the afternoon and the early evening and this may interfere 
with the induction of hypoglycemia. The possible interference of previous 
hypoglycemia cannot be assessed when the study periods of each session begins 
only shortly before hypoglycemia induction time. The use of glucose for 
hypoglycemia prevention is a relevant methodological feature, especially with the 
widespread tendency towards spontaneous hypoglycemia on the control days of 
all studies. However, from the studies conducted, a proven challenge is to infuse 
glucose in sufficient amounts to prevent hypoglycemia but on the other hand not 
cause hyperglycemia relative to the control case. The target value for blood 
glucose during glucose infusion is not evident as the control glucose profiles also 
contain data after spontaneous hypoglycemia and thus should not be used as 
target references. The frequent blood sampling and controlled settings in the 
intervention glycemia control and true control design provide detailed data but 
cause heavy workload, possibly resulting in small numbers of subjects in each 
study and short durations of experiment sessions. Thus, the duration may be 
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insufficient to detect the long-term glucose counter-regulation to hypoglycemia. 
Induction of hypoglycemia with intravenous insulin infusion and reversal of 
hypoglycemia with glucose infusion clearly does not mimic the real-life situation 
with subcutaneous insulin depots. It remains unclear whether this poses a 
considerable confound for the study design, but subcutaneous insulin waning has 
been associated with the hypothesized long-term glucose counter-regulation to 
hypoglycemia (27,44). 
Diabetic subjects’ insulin resistance studies 
Two forms of insulin resistance studies exist but in both, the hypothesized long-
term glucose counter-regulation is assumed to reveal itself in the form of insulin 
resistance. In one form of this design category, insulin resistance is evaluated as 
the blood glucose resulting from a fixed insulin infusion rate. Insulin resistance is 
thus evaluated by comparing blood glucose values after hypoglycemia with those 
after hypoglycemia prevention, both obtained with the same insulin infusion rate. 
In the other form, insulin resistance is evaluated as the glucose infusion rates 
needed for glycemia maintenance for a period after hypoglycemia and after 
hypoglycemia prevention. The study design is prospective and interventional. 
The diabetic subjects’ insulin resistance study design has been employed in the 
studies by Kollind et al. (45) and Fowelin et al. (26). 
In both types of diabetic subjects’ insulin resistance study designs, the subjects 
are hospitalized and subjected to a session of hypoglycemia induction by high 
insulin infusion rate (insulin clamp and blood glucose clamp) or to a control, 
normoglycemia session with a slow insulin infusion rate (insulin clamp) (45) or 
high insulin infusion rate (as for hypoglycemia induction) together with glucose 
infusion (blood glucose clamp) (26). In the hypoglycemia session, after 
hypoglycemia induction, subjects have glucose injected for reversal of 
hypoglycemia. The sessions are performed in random order. Somatostatin is 
infused with insulin and glucose for suppression of glucagon and growth hormone 
production, thus rendering the resulting blood glucose a measure of tissue insulin 
resistance. Hypoglycemia is induced during the night (45) or in the morning (26). 
Hypoglycemia counter-regulatory hormones (glucagon, epinephrine, cortisol and 
growth hormone) are measured before and after hypoglycemia. Blood sampling 
intervals are one hour, more frequently during hypoglycemia induction, and the 
study period after hypoglycemia is 8 hours. The subjects in the diabetic subjects’ 
insulin resistance studies are subjects with type 1 diabetes and have their regular 
insulin regimen withdrawn 24 (26) to 32-36 (45) hours before hospitalization in 
order to the insulin and blood glucose clamps to be precise. 
According to the conventions of the diabetic subjects’ insulin resistance study 
category, the existence of a long-term glucose counter-regulation to 
hypoglycemia is indicated by increased blood glucose after hypoglycemia 
compared with blood glucose after normoglycemia (under the same insulin clamp 
conditions), and by decreased glucose requirements for glycemia maintenance 
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after hypoglycemia compared with glucose requirements after normoglycemia 
(under the same blood glucose clamp conditions). Kollind and colleagues (45) 
found markedly increased blood glucose (approximately 5 mmol/) levels after 
hypoglycemia compared with the post-euglycemia cases, beginning 5 hours after 
hypoglycemia and extending throughout the remaining 5 hours of the study 
despite similar blood glucose at the beginning of fixed insulin and glucose 
infusion. This is interpreted as a higher insulin resistance following hypoglycemia 
than following normoglycemia. Fowelin and colleagues (26) found significantly 
lower glucose infusion requirements after hypoglycemia compared with after 
normoglycemia which is also interpreted as a higher insulin resistance following 
hypoglycemia than following normoglycemia. 
A major weakness of the diabetic subjects’ insulin resistance study design is the 
induction of hypoglycemia at a time of day that may not be in accordance with the 
subjects’ diurnal proneness to hypoglycemia. Somatostatin suppresses only the 
short-acting hyperglycemic hormones glucagon and growth hormone, so in search 
of a long-term reaction, infusion of somatostatin should not confound matters, 
and its effects are needed for true insulin resistance determination purposes. The 
removal of the regular insulin regimen at least 24 hours before hypoglycemia 
induction and subsequent blood glucose control by intravenous insulin infusion 
appears to be a feasible approach to hypoglycemia prevention before the 
experimental hypoglycemia/control periods. However, it creates an artificial 
baseline constitution with altered plasma insulin levels not resembling the normal 
situation for individuals with diabetes. Thus, the clinical significance of the 
indications of a long-term glucose counter-regulation to hypoglycemia from the 
studies employing this study design remains unknown. 
Healthy subjects’ insulin resistance studies 
In the healthy subjects’ insulin resistance studies, insulin resistance in healthy 
subjects is evaluated as the glucose infusion rates needed for glycemia 
maintenance for a period after hypoglycemia and after hypoglycemia prevention. 
The study design is prospective and interventional. 
The study design is employed in the studies by Attvall et al. (46) and Clore et al. 
(47). 
In the healthy subjects’ insulin resistance study design, healthy subjects are 
subjected to a session of hypoglycemia induction by high insulin infusion rate 
(insulin clamp and blood glucose clamp) or to a control, normo- (from insulin 
clamp and blood glucose clamp via infusion with fixed insulin rate and varying 
glucose rate (46)) or hyperglycemia (blood glucose clamp via infusion with varying 
dextrose rate) (47)) session.  
The glucose/dextrose infusion rates required for glycemia maintenance is the 
measure of insulin resistance. Each subject is exposed to both hypoglycemia and 
sustained euglycemia/mild hyperglycemia in random order (46) or during only one 
(47) of the sessions. Hypoglycemia induction time is in the morning (47). 
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Hypoglycemia counter-regulatory hormones (glucagon, epinephrine, cortisol, 
growth hormone (46,47) and norepinephrine (47)) are measured before and after 
hypoglycemia. Blood sampling intervals are 20 (46) or 30 minutes (47), more 
frequently during hypoglycemia induction. The study period after hypoglycemia is 
2 (46) to 8 (47) hours. The subjects are healthy volunteers and they are kept 
fasting throughout the entire study period. 
According to the healthy subjects’ insulin resistance study design category, the 
long-term glucose counter-regulation hypothesis is supported by decreased 
insulin sensitivity (i.e. decreased glucose/dextrose requirements) after 
hypoglycemia compared with insulin sensitivity after normo- or mild 
hyperglycemia. Attvall and colleagues (46) found lower glucose requirements  
after hypoglycemia compared to the hypoglycemia-free case, whereas the 
required glucose infusion rates were similar prior to hypoglycemia. This is 
interpreted as an elevated insulin resistance following hypoglycemia compared 
with that following normoglycemia. Clore and colleagues (47) also found lower 
dextrose requirements after hypoglycemia as opposed to in the control period, 
however in different groups. For maintenance of the same blood glucose level, 
the dextrose infusion rate in the hypoglycemia group was slightly lower after 
hypoglycemia than before hypoglycemia. Thus, the results as one can be 
considered indicative of a higher insulin resistance following hypoglycemia than 
following non-hypoglycemia. 
A major concern regarding the healthy subjects’ insulin resistance studies is the 
essential non-comparability of healthy subjects with diabetic subjects since 
impairment of hypoglycemia counter-regulatory mechanisms are common in 
diabetic populations (6,39,48-51). Also the use of different subjects in the 
hypoglycemia study group and the control study group is a weakness of the study 
design in the study by Clore and colleagues (47) due to the variations also 
observed in healthy subjects’ ability to counter-regulate hypoglycemia. This is 
especially profound as somatostatin is not infused for suppression of growth 
hormone, glucagon and insulin secretion, and variations in these hormones are 
therefore possible. Profound variations in these hormones are indicated by the 
very different and temporally varying C-peptide levels seen within the two groups 
of the study by Clore and co-workers (47). Especially in healthy subjects and in 
particular if not all subjects have been subjected to both hypoglycemia and 
control sessions, it is alluring to compare the glucose infusion rate needed before 
hypoglycemia to the one after hypoglycemia. Results from such analysis should be 
interpreted with great caution, however, as the sessions are separated in time so 
long, that infusion rates may be artificially elevated in the second clamp due to 
the fasting state, especially if somatostatin is not used for insulin and counter-
regulatory hormones suppression. 
Literature overview conclusion  
A variety of study designs have been applied until now. The four different study 
design categories overviewed here include the following variations in addition to 
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overall study design: patient selection, blood sampling frequency, hypoglycemia 
threshold, assays in addition to glucose, and others, as well as their varied results. 
Definitely indicative of a long-term glucose counter-regulation to hypoglycemia 
are the prospective intervention studies in various design categories by Perriello 
and colleagues (43), Kollind and colleagues (45), Fowelin and colleagues (26), 
Attvall and colleagues (46), and Clore and colleagues (47). All have employed 
methods with different confounds. The same is the case for the retrospective 
observational studies in the nocturnal glycemia stratification design category by 
Havlin and Cryer (42), and Gale and colleagues, though their results are less 
indicative of a long-term glucose counter-regulation. The studies by Hoi-Hansen 
and colleagues (30), Guillod and colleagues (28), Stephenson and Schernthaner 
(31), Hirsch and colleagues (29), and Tordjman (32) and colleagues clearly suggest 
that a long-term glucose counter-regulation to hypoglycemia does not exist. 
Especially the very carefully conducted intervention glycemia control and true 
control study conducted by Hirsch and colleagues (29) raises a powerful voice 
against the existence of the long-term glucose counter-regulation to 
hypoglycaemia. This is due to its nearly ideal design, which employs a reliable 
interventional hypoglycemia prevention paradigm for hypoglycemia-free data 
collection, frequent blood sampling and a long study period. However, the 
analysis of induced hypoglycemia and the use of intravenous insulin infusions for 
hypoglycemia induction and a hypoglycemia reversal glucose dose prohibit 
immediate translation of the results to the real-life settings which led to the 
hypothesis of a long-term glucose counter-regulation to hypoglycemia. 
From the different study designs and study protocols applied, it becomes evident 
that the different research groups expect different manifestations of the 
hypothesized long-term glucose counter-regulation to hypoglycemia, especially 
regarding its temporal characteristics. To exemplify this, short study durations of 4 
hours in the studies by Hoi-Hansen and colleagues (30), Havlin and Cryer (42), 
Stephenson and Schernthaner (31) and Tordjman and colleagues (32) indicate that 
the researchers expect the long-term glucose counter-regulation to hypoglycemia 
to appear shortly after the long-term glucose counter-regulation. The negative 
findings of these groups may consequently be argued to indicate little about the 
hypothesized long-term glucose counter-regulation in general, but instead 
indicate clearly its lack of manifestation within 4 hours after hypoglycemia. This is 
supported further as, except from the work by Hirsch and colleagues (29), longer 
study durations after hypoglycemia seem to be correlated with results supporting 
the hypothesis of a long-term glucose counter-regulation to hypoglycemia. 
Another example is the rather rigid expectation of the manifestation of the long-
term glucose counter-regulation to hypoglycemia as an absolute hyperglycemia 
compared to other, hypoglycemia free controls in the nocturnal glycemia 
stratification studies, which may be an explanation for the commonly found 
indications not supporting the hypothesis in studies of this type. From this, it is 
evident that study designs evolve from expectation of the manifestation of the 
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hypothesized mechanism, and that the lack of consensus regarding the 
manifestation has been an important determinant of the study outcomes. 
The previous work in the exploration of the hypothesized long-term glucose 
counter-regulation thus constitutes a relevant basis for further investigations as 
the study designs already employed have revealed advantages and pitfalls with 
different methods. 
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4. Methodological approach 
The focus of this PhD-thesis is the long-term glucose counter-regulation to 
hypoglycemia. From the literature overview in the previous chapter it is evident 
that no optimum study design has been identified and applied and that this may 
have prevented proper investigation of the mechanism. The objective of the work 
presented in this thesis is therefore to explore different methodological 
approaches to examining the correlation between hypoglycemia and a long-term 
glucose counter-regulation to add to the knowledge of the relevance of long-term 
glucose counter-regulation to hypoglycemia in the real lives of diabetic patients. 
Methodology requirements 
The aim is to explore the correlation between hypoglycemia and the hypothesized 
long-term glucose counter-regulation, its magnitude, and its relevance in diabetic 
every-day life.  
First, this requires the methodological approaches evaluated to be based on the 
direct comparison of blood glucose after hypoglycemia and blood glucose after no 
hypoglycemia. This is in contrast to comparison of insulin resistance in the 
diabetic and healthy subjects’ insulin resistance studies. Second, it requires for the 
methodological approaches in the work presented in this thesis to use the same 
groups as source of hypoglycemia and hypoglycemia-free control data. This is in 
contrast to the use of separate hypoglycemia and hypoglycemia-free control 
groups in the nocturnal blood glucose stratification studies. Third, it requires for 
the methodological approaches to the investigation to employ real life settings 
and an observational design. This is in contrast to the use of induced 
hypoglycemia in interventional studies. All three requirements may be employed 
in different study designs. However, the current lack of quantitative 
characterization of the mechanism, especially regarding temporal aspects (i.e., 
effect duration and delay before effect manifestation), should be considered 
independently of the study design.  
The apparently ideal study 
The methodology requirements identified above render one study design 
apparently ideal: Retrospective observational analysis of frequently measured 
glucose data collected in every-day lives of people with diabetes, comparing 
glycemia after spontaneous hypoglycemia with glycemia after hypoglycemia-free 
control. The subjects should have been instructed to live uniformly during the 
data collection period to ensure comparable hypoglycemia and control data. The 
current uncertainties concerning the temporal characteristics of the mechanism 
should be addressed by comparing the glucose for sufficiently long periods after 
hypoglycemic events. 
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Methodology requirement challenges 
The apparently ideal study presented above has at least three pitfalls in terms of 
the actual conduction of the data collection, and each pitfall results in potential 
challenges for the data analysis: 
 Insufficient uniformity in each subject’s life during data collection for 
comparable background data (i.e., meals and insulin) in hypoglycemia and 
hypoglycemia-free data. This renders simple blood glucose profile comparison 
inappropriate. 
 Too frequent occurrences of hypoglycemia to allow for identification of control 
periods. This results in impossible comparison of blood glucose after 
hypoglycemia with hypoglycemia-free control blood glucose due to the non-
existence of control periods. 
 Inappropriate and perhaps faulty or insufficiently detailed expectations 
regarding the long-term glucose counter-regulation to hypoglycemia leading to 
inappropriate data collection and inappropriate data analysis, for instance 
regarding the temporal characteristics and the co-effects of several 
hypoglycemic events within a short period of time. This causes the existing 
conditions for blood glucose profile comparison in hypoglycemia and non-
hypoglycemia periods to be inappropriate. 
Studies employed in the PhD-thesis 
This PhD-thesis employs one study resembling the apparently ideal study design 
and one study for addressing each of the methodology requirement challenges. 
The apparently ideal study design is employed by retrospective analysis of already 
collected continuous glucose monitoring (CGM) sensor data in type 1 diabetic 
patients living their every-day lives. In general, CGM glucose corresponds well to 
the blood glucose (52,53), thereby making the CGM technology appropriate for 
the apparently ideal study. Hypoglycemic events are identified along with 
corresponding hypoglycemia-free control periods, and the glucose following these 
paired periods are compared. This is presented in the paper “Retrospective 
analysis of the long-term glucose counter-regulation to hypoglycemia in 
continuous glucose data”. 
To overcome the challenges caused by insufficient uniformity of each subject’s 
life, a method is developed for balancing unmatched background data by the use 
of a metabolic model. The method is intended for retrospective observational 
studies. The study is presented in the paper “Model-based balancing of 
unmatched data in model-generated hypothesis evaluation”. In this thesis, the 
study is referred to as the background data balancing study and the method is 
called the background data balancing method. 
Solving the potential lack of control periods due to frequent hypoglycemic 
episodes, a method is employed to substitute control data using a metabolic 
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model that does not consider the effects of hypoglycemia suggested to be 
associated with the long-term glucose counter-regulation to hypoglycemia. In the 
analysis glucose sensor data for high temporal resolution in glucose data is used. 
This is a retrospective observational approach. The study is presented in the paper 
“CGM glucose overshoot after hypoglycemia assessed by a simulation tool”. It is 
referred to as the control data substitution study in this thesis. 
The potential (or even likely) insufficient understanding of the long-term glucose 
counter-regulation to hypoglycemia to correctly manage the situations occurring 
in real life retrospectively (i.e. in observational studies) is addressed by the 
implementation of an animal model. The animal model can be used as a 
continuous, prospective source of data in which different glycemia combinations 
and correlated long-term glucose counter-regulations can be studied. A 
prerequisite for such detailed data collection is a very controlled environment, not 
achievable in human subjects. No specific study in such an animal model has been 
designed as it should be used for evaluating and refining various hypotheses and 
study designs regarding the long-term glucose counter-regulation to 
hypoglycemia. This can only be done when a suitable model is safely established 
in the laboratory. The implementation of the animal model is described in the 
paper “Implementation of an intensive chronic type 1 diabetes model with tight 
blood glucose control in Göttingen minipigs” and in the thesis it is referred to as 
the animal study. 
Together these four studies assess a relevant range of methodological approaches 
to exploring the long-term glucose counter-regulation to hypoglycemia, despite 
the quantitative characteristics of the hypothesized mechanism not being 
established. 
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5. Relevance of the methodological approach to 
other hypotheses rather than the long-term 
glucose counter-regulation to hypoglycemia 
The long-term glucose counter-regulation to hypoglycemia is the core focus of this 
PhD-thesis. However, other hypotheses of the same nature may arise: hypotheses 
regarding the long-term correlation to a single, measurable result-variable profile 
of an event or behavior which occurs spontaneously (involuntarily) or intendedly 
in every-day life. This may be in diabetes or in other diseases or even in the 
healthy population. 
For a description of the correlation between the hypothesized event or behavior 
and the hypothesized effect in every-day life, the notion of the apparently ideal 
methodological approach presented can be applied by retrospectively comparing 
the observed dependent result-variable profile after spontaneously or intended 
occurrence of the event or behavior to the dependent result-variable profile in 
the absence of the event or behavior. 
However, the same challenges as described in the previous chapter may arise in 
the application of the apparently ideal methodological approach to a different 
hypothesis than the long-term glucose counter-regulation to hypoglycemia. The 
background data balancing model can be used in any field where both data and a 
suitable experimental model are available. This is also the case with the control 
data substitution method. When it comes to the case when previously collected 
data may be insufficient due to the lack of detailed knowledge on the 
hypothesized correlation and a continuous, prospective source of highly 
controlled data may be needed, an animal model will only be helpful in areas of 
disease or physiology which are carefully and definitively mimicked by the animal 
model. 
In the field of type 1 diabetes, the methods explored in this thesis appear 
immediately applicable for investigation of exercise and alcohol and their 
correlation to glycemia; correlations that are currently not fully established. 
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STUDIES 
This section of the thesis presents the 
four scientific works included. Each 
chapter corresponds to a study and a 
paper and is identical with the papers 
published or submitted except from 
abstract and list of references. Full 
papers are located after the 
bibliography 
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6. Retrospective analysis of the long-term 
glucose counter-regulation to hypoglycemia in 
continuous glucose data 
This chapter presents the apparently ideal study. The chapter is equivalent to 
the paper Retrospective analysis of the long-term glucose counter-regulation to 
hypoglycemia in continuous glucose data except from the abstract and 
bibliography, which is omitted in this chapter. The full paper can be found as 
paper number one in the end of the thesis. The full paper is of status 
“Submitted” to Journal of Diabetes Science and Technology by September 
2008. 
Introduction 
Hypoglycemia-induced delayed hyperglycemia, first hypothesized by Somogyi 
in 1951, has received renewed interest (28,30). The recent interest is largely 
governed by the data resolution potential introduced by the continuous 
glucose monitoring (CGM) technologies, as these technologies enable reliable, 
long-term and very frequent sampling of glucose values comparable to blood 
glucose values (54,55). 
Over the years, different labels have been applied to what is apparently the 
same phenomenon: ‘Somogyi phenomenon’, ‘Somogyi effect’ (26-33,35,56-
61), ‘rebound hyperglycemia’ (62), and ‘long-term glucose counter-regulation 
to hypoglycemia’ (63). This paper uses the latter term. 
Various study designs have been applied for analyzing long-term glucose 
counter-regulation to hypoglycemia (26-30,32,35,36,56,59,61,64-66). Study 
designs vary in hypoglycemia time, as some researchers have explored only 
nocturnal hypoglycemia, which is suggested to cause morning hyperglycemia 
(27-30,42,43,45), whereas others have not restricted themselves to nocturnal 
hypoglycemia (26,44,47,56,67). Study designs also vary regarding the extent of 
hyperglycemia, as some groups have considered only absolute hyperglycemia 
to indicate the existence of a long-term glucose counter-regulation to 
hypoglycemia (27,42,56), whereas other designs have considered 
hyperglycemia only relative to glucose values in cases with no preceding 
hypoglycemia (29,43-45). Finally, study designs vary regarding duration, as 
they range from rather short (0-6 hours) (27,30-32,47,56) to longer (8-24 
hours) (29,42-44,61,68). Study designs have also varied due to different 
hypotheses regarding manifestations and due to practical methodological 
limitations, for instance regarding (blood) glucose sampling frequency. 
A more cautious approach to the exploration of the long-term glucose 
counter-regulation to hypoglycemia may be a long-term analysis of high-
resolution data with no assumptions regarding the time of day of the 
occurrence of hypoglycemia, but this has never been applied using the CGM 
technology. 
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This paper presents a retrospective analysis of a blood glucose sensor data set 
for the evaluation of a hypothesis of a long-term glucose counter-regulation to 
hypoglycemia, manifested as a delayed hyperglycemia relative to control, 
hypoglycemia-free glycemia. 
Materials and methods 
The study was conducted at four centers (Medical Department M, Aarhus 
University Hospital, Denmark; Profil Institute for Metabolic Research, Neuss; 
German Diabetes Research Institute at the Heinrich-Heine University of 
Duesseldorf; and Department of Pharmaceutical Technology and Biopharmacy, 
University Center of Pharmacy, University of Groningen, The Netherlands). The 
four centers participated in the clinical in vivo evaluation of the SCGM 1 
system (Roche Diagnostics, Mannheim, Germany). 
Patients who participated in the experiment were recruited from their 
respective outpatient clinics. Both type 1 and type 2 diabetics were included. 
The patients were encouraged to live their normal every-day lives with their 
normal therapy (primarily insulin), and they were further encouraged to 
perform the same amount of activities on all study days. They were not given 
access to CGM data during data collection.  
All patients received written and oral information according to the Declaration 
of Helsinki II and signed consent forms. The study was approved by the local 
ethics committees of the four centers participating in the study and was 
performed according to Good Clinical Practice Guidelines. 
SCGM 1 system 
The SCGM 1 system is based on the glucose oxidase principle and consists of a 
sensor unit device and a belt-held sensor holding the microdialysis system. The 
system allows up to 120 hours of minutely dialysate glucose measurements. 
Data are stored by custom designed software, and on-line display of dialysate 
glucose is transferred wirelessly from the sensor unit to the portable data 
manager. Additional information (insulin administration, meals, exercise, etc.) 
can be entered as separate events in the data managing device. The sensor 
unit uses a roller pump that provides a push-pull flow, resulting in a perfusion 
of the microdialysis membrane with 0.3 µl/min. The perfusion fluid (Ringer 
chloride, Na+147 mmol/liter; K+ 1.4 mmol/liter; Ca2+ 2.3 mmol/liter; Cl- 156 
mmol/liter, pH 6; osmolality 290 mosmol/kg) passes through the catheter, 
achieving approximately 95% equilibration with the interstitial fluid (69). 
Glucose oxidase is mixed with the dialysate and passes the ex vivo sensor, 
creating a current in the nanoampere range. The current is averaged over 60 
seconds, and data are stored. 
Study procedure 
The microdialysis probe was inserted into the subcutaneous abdominal 
adipose tissue after skin puncture with a 16-gauge needle. The sensor was left 
in place for 4 days. For calibration of the SCGM 1 system, spot capillary glucose 
measurements were used. 
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Data analysis 
The sensor glucose profiles were calibrated by fitting the paired meter data 
and sensor data to a line and adjusting the sensor data to the gain and offset 
identified by the fitting. 
All hypoglycemic events were identified in the calibrated data. An episode of 
hypoglycemia was defined to be at least 15 minutes of sensor glucose ≤54 
mg/dl, and at least 10 minutes of sensor glucose ≥54 mg/dl or missing data 
defined the end of a hypoglycemic episode. All episodes of missing data were 
identified in the uncalibrated data. A data missing episode was defined to be 
at least 10 minutes of missing data (the value 0 saved by the glucose sensor), 
and at least 10 minutes of non-missing data defined the end of a data missing 
episode. Near-hypoglycemic events for definitely hypoglycemia-free control 
periods, despite sensor inaccuracies, were defined to be at least 15 minutes of 
sensor glucose ≤72 mg/dl, and at least 10 minutes of sensor glucose ≥72 mg/dl 
or missing data defined the end of a near-hypoglycemic episode 
Hypoglycemic events beginning ≤20 hours after the data collection start were 
excluded. Of the hypoglycemic events beginning >20 after the start of data 
collection, the hypoglycemias preceded by missing data episodes within 15 
hours were excluded. Of the hypoglycemic events not preceded too recently 
by data collection start or missing data episodes, hypoglycemias preceded by 
any hypoglycemia (not necessarily without too recent data collection start or 
missing data episode) within 15 hours were excluded. Of the hypoglycemic 
events free of recent data start, missing data episodes or hypoglycemia, 
hypoglycemias followed by any hypoglycemia (not necessarily free of recent 
data collection start, missing data episodes, or hypoglycemia) within 15 hours 
were excluded. Control periods were identified at the same time of the day as 
the hypoglycemia to which they corresponded. Control periods were excluded 
if they occurred <20 hours before data collection start, or if they were 
preceded or followed by near-hypoglycemia or missing data episodes within 
15 hours (from the time of candidate control period start). 
Hypoglycemic events in subjects with no information on insulin injection 
during the data collection period were excluded, as were patients not treated 
with multiple insulin injections but with continuous subcutaneous insulin 
infusion (insulin pump). 
For each hypoglycemia, the sensor glucose difference between hypoglycemia 
day and control day (control days, if more control days were found for a 
specific hypoglycemia) was calculated as hypoglycemia day sensor glucose 
minus control day sensor glucose. 
Data calibration and hypoglycemia analysis was performed using Matlab (the 
Mathworks, Inc., Natick, MA). Hypoglycemia and control period data analysis 
was performed using the Excel spreadsheet program (Microsoft Corporation, 
Redmond, WA). 
Results are given as mean ±SD (range). 
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Results 
159 subjects were included of which 146 were diabetic (135 type 1 diabetic). 
Of the diabetics, 91 were male. Age was 36 ± 12 (17-72) years, diabetes 
duration 15 ± 10 (0-41) years. BMI was 24.9 ± 4.4 (17.9-44.5). HbA1C was 8.1 ± 
1.7 (5.3-14.1). Only one subject was not treated with insulin, and 28 were on 
continuous subcutaneous insulin infusion. 
In total, 134 hypoglycemic episodes were identified. Of the 134 hypoglycemic 
episodes, 36 were excluded because they occurred <20 hours before the start 
of data collection, none were excluded because they were preceded by 
missing data within 15 hours, 70 were excluded because they were preceded 
or followed by other hypoglycemias within 15 hours. This left 64 
hypoglycemias for control period identification. There were 23 hypoglycemias 
in 20 subjects that had corresponding control periods. Of these, 11 
hypoglycemias in 11 subjects (6 female) were supported by insulin data, but 
one female was treated with continuous subcutaneous insulin infusion and 
excluded. Thus, 10 patients (5 female) were included in the study. Four 
patients also had carbohydrate intake data. All 10 were type 1 diabetics. Age 
of included diabetics was 34 ± 12 (20-59), diabetes duration 16 ± 9 (7-34), BMI 
24.6 ± 4 (20.4-34.0), HbA1C 7.9 ± 2 (6.1-10.9). 
One hypoglycemia was nocturnal (12 pm – 6 am), one was before noon (6 am 
– 12 am), 7 were after noon (12 am – 6 pm) and one was in the evening (6 pm 
– 12 pm). No apparent difference in sensor glucose difference was seen with 
respect to hypoglycemia time. 
Data for insulin injections and for carbohydrate intake, where recorded, is 
shown in table 1. Mean total carbohydrate intake after hypoglycemia was 152 
g, in the control period 190 g (n=4). Mean total insulin intake after 
hypoglycemia was 38.6 IU, in the control period 32.9 IU (n=10). 
There was no difference in long-acting insulin on intervention (hypoglycemia) 
and control periods. 
No difference was seen in sensor glucose (hypoglycemia minus control) (Figure 
1). 
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Table 1: Injected short acting insulin (IU) and carbohydrate intake (g) during 
24 hours of intervention or control in 2-hour time slots 
 Time slot, hours after hypoglycemia time 
Sub- 
ject 
Event 0-2 2-4 4-6 6-8  8-10 10-
12  
12-
14 
14-
16 
16-
18 
18-
20 
20-
22 
22-
24 
Sum 
1 
CHO-H 
Ins-H
1 
CHO-C 
Ins-C
1 
  30 
8 
 20 
4 
70 
15 
 60 
12 
60 
12 
 80 
18 
85 
24 
   200 
42 
215 
51 
2 
CHO-H 
Ins-H
2 
CHO-C1 
Ins-C1
2 
CHO-C2 
Ins-C2
2 
50 
14 
50 
13 
70 
13 
30 
 
10 
 
15 
10 
 
10 
 
20 
 
16 
60 
16 
60 
16 
10 
 
35 
 
20 
 
 
40 
  60 
16 
10  
 
50 
16 
50 
18 
 
 
30 
170 
46 
285 
45 
235 
47 
3 
CHO-H 
Ins-H 
CHO-C1 
Ins-C1 
 
 
 
36 
8
2 
 
10
2
 
 12 
12
1
 
   
1
2 
48 
11
2
 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
24 
2
2 
- 
- 
 
 
- 
- 
72 
23 
48
m 
23
m 
4 
CHO-H 
Ins-H
1 
CHO-C1 
Ins-C1
1 
15 55 
12 
55 
 30     65 
14 
65 
12 
  
12 
50 
 
 
 
30 
165 
38 
200 
12 
5 
Ins-H
1
 
Ins-C1
1 
Ins-C2
1 
12 
12 
12 
      
 
 8 
8 
8 
 
 
- 
10 
10 
- 
 30 
30 
20
m 
 
6 
Ins-H
1 
Ins-C1
1
 
Ins-C2
1
 
8 
8 
8 
    
 
10 
  8 
8 
- 
 
2 
- 
 
6 
- 
8 
 
- 
 
 
- 
24 
24 
18
m
 
7 
Ins-H
1 
Ins-C
1
 
8 
 
10 
9 
     8
 
 
4 
4
 
8 
8
 
 6 
8 
44 
29 
 
8 
Ins-H
1 
Ins-C1
1 
Ins-C2
1 
8 
8 
8 
       
 
8 
8 
8 
 4 
4 
8 
 20 
20 
24 
 
9 
Ins-H
1 
Ins-C1
1 
Ins-C2
1 
10
 
12
 
 
  
 
 6   10 
12 
16 
22 
 
6 
 
12 
10 
 48 
36 
32 
 
10 
Ins-H 
Ins-C1 
Ins-C2 
 12
1
 2
1 
11
1
 
5
1 
 
10
1
 
 
 
4
1
 
  
1
1 
10
2
 6
1
 
8
1
 
2
1 
5
1 
 
 
10
1
 
16
1
 
2
1 
41 
32 
21 
–H: hypoglycaemia (intervention), –C1 (and –C2, if two control periods were found): control 
period(-s) 
1
  Regular insulin, 
2 
Humalog insulin 
- No data due to short data collection period, 
m 
Total period includes missing insulin and/or 
meal data. 
Discussion 
This study employs a retrospective analysis of blood glucose sensor data set 
for the evaluation of a hypothesis of a long-term glucose counter-regulation to 
hypoglycemia. The hyperglycemia manifesting the long-term glucose counter-
regulation to hypoglycemia was expected to be delayed and to appear relative 
to the glycemia in control, hypoglycemia-free cases rather than in absolute 
terms. 
The occurrence of hypoglycemia corresponds to the prevalence of 
hypoglycemia detected by continuous glucose monitoring systems in 
unspecific patient groups (70). The included number of hypoglycemic events, 
however, is low and arises from the exclusion of hypoglycemias preceded or 
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followed by hypoglycemias, indicating that patients rarely have a single 
hypoglycemia in otherwise non-hypoglycemic periods. The long required 
hypoglycemia-free period before and after the included hypoglycemias  is 
shown to be reasonable considering the long duration of long-term glucose 
counter-regulation to hypoglycemia-like physiological simulation errors 
previously reported by the authors of the present paper in 2008. The 
requirement of control periods free of not only hypoglycemia but also near-
hypoglycemia mimics the advantages of prospective studies typically 
preventing hypoglycemia by glucose infusion on control days (26,27,29,32,43-
45,67). 
 
Figure 1: Sensor glucose difference after hypoglycemia (hypoglycemia 
minus control). Average difference is 0.1 mmol/l 
 
The glucose difference varied between -1 and 1 mmol/l for the 4-22 hours 
after hypoglycemia. The hypoglycemia and control day carbohydrate and 
insulin intakes were not comparable. The insulin intake difference was, on 
average, 5.7 IU higher in the 24 hours following hypoglycemia compared to the 
hypoglycemia-free control period, and the carbohydrate intake was on 
average 38 g higher.  
The little difference in glucose levels between hypoglycemia and control data 
indicates no apparent relative hyperglycemia. Also, no trend in the variations 
can be identified; thus, no indications regarding delay of hyperglycemia are 
found. This could initially be interpreted as contradictory to the hypothesis of 
a long-term glucose counter-regulation to hypoglycemia evident as a delayed 
(relative) hyperglycemia. However, the rather similar glucose profiles result 
from substantially different background data on insulin and carbohydrate 
intake, both contributing to lowering the glucose on the hypoglycemia day 
compared to the control day. There is a substantially (5.7 IU, 17%) higher 
intake of insulin on the hypoglycemia day than on the control day and a 
substantially lower carbohydrate intake (38 g, 20%). A clinical rule of thumb 
says that each IU of insulin reduces the blood glucose 18-36 mg/dl (71). Hence, 
the sole effect of the increased insulin doses following hypoglycemia is likely to 
have suppressed the blood glucose significantly to control day levels following 
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hypoglycemia. Despite hypoglycemia and control day non-comparability 
regarding carbohydrate and insulin intake, we therefore interpret the results 
as indicative of a long-term glucose counter-regulation to hypoglycemia. 
Comparability of independent variables on hypoglycemia and control days is 
not ensured in a substantial part of the previous studies of the long-term 
glucose counter-regulation to hypoglycemia. This may explain the negative 
findings of the effect, at least in some studies. However, doses and times of 
insulin injections are reported to be the same in the study by Hirsch and 
colleagues (29), and non-comparability of insulin background data can thus not 
explain the negative finding of a long-term glucose counter-regulation. It 
should be noted that the hypoglycemias studied by Hirsch and colleagues (29) 
were nocturnal and induced, while the hypoglycemias in the current study 
were primarily in the daytime and occurred spontaneously. Reactions to 
induced hypoglycemia, especially in patients where regular subcutaneous 
insulin injections have been discontinued before the study, may be disrupted 
by a different native pattern of hypoglycemia. It appears, therefore, that a 
reasonable approach is to investigate only spontaneous hypoglycemias, as in 
the current study and in the studies conducted by Høi-Hansen and co-workers 
(30), Guillod and co-workers (28), Gale and co-workers (27), Stephenson and 
Schernthaner (31), Havlin and co-workers (42), or to investigate induced 
hypoglycemias only in patients with hypoglycemia that is also evident on an 
intervention-free control period, as in the study by Hirsch and co-workers (29). 
The limited number of hypoglycemic events included and the lack of 
comparable data in hypoglycemia and control days in this study underline the 
weakness of retrospective analysis of phenomena such as the long-term 
glucose counter-regulation to hypoglycemia, even in large data sets. Further 
work in the exploration of the long-term glucose counter-regulation to 
hypoglycemia should thus approach this limitation and carefully design data 
collection that takes into consideration comparability of days and the 
influence of native hypoglycemia patterns. 
Conclusions 
The CGM glucose after hypoglycemia was similar to the CGM glucose in 
hypoglycemia-free control periods, but larger insulin doses and smaller meals 
after hypoglycemia indicate that the hypothesis of a long-term glucose 
counter-regulation to hypoglycemia cannot be rejected but is justified for 
further research. 
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7. Model-based balancing of unmatched data in 
model-generated hypothesis evaluation 
This chapter presents the background data balancing method. The chapter is 
equivalent to the paper Model-based balancing of unmatched data in model-
generated hypothesis evaluation except from the abstract and bibliography, which 
is omitted in this chapter. The full paper can be found as paper number two in the 
end of the thesis in the form that is published in the proceedings of SHI/term 
konferansen 2008 . 
Introduction 
Pharmacokinetic models, including physiological models of human metabolism of 
a wide range of endogenous compounds, have been developed to aid patients, 
health care professionals and researchers in monitoring, adjusting and developing 
treatments.  
Observation of systematic deviations in the simulations of such models can 
generate hypotheses if prominent deviations from data occur exclusively and 
consistently in relation to one particular event. We have previously used a 
physiological model of the human carbohydrate metabolism in diabetes as a 
generator of hypotheses regarding the effect of alcohol (72) and hypoglycemia 
(unpublished data).  
Evaluation of a deviation-related hypothesis can be performed in at least two 
ways: comparing intervention data (including the event of interest) and control 
data (not including the event of interest), and comparing intervention data 
(including the event of interest) with model simulations. The first approach, 
comparing two data groups, requires the groups to be extensively comparable as 
regards all other independent variables/event than the one of interest. This 
similarity may be only scarcely achieved in data collected from patients living their 
everyday lives, an approach often preferred over controlled, in-hospital 
experiments due to cost minimization and patient convenience, if patients comply 
inadequately with instructions regarding their behavior during the experimental 
period. Incomparability of control data with intervention data precludes reliable 
interpretation of any significant difference as resulting from the event of interest. 
Conventional comparison of intervention data with control data may thus not be 
appropriate for evaluation of deviation-related hypotheses. The second approach, 
comparing data with model simulations, requires the model to include all relevant 
independent variables except for the one of interest. This requirement is difficult 
to meet in practice, as model complexity and computability are opposites. 
Insufficient model complexity precludes reliable interpretation of any significant 
difference as resulting from the event of interest, as in the case of incomparable 
intervention and control data. Thus, both approaches have their imperfections. 
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The aim of this paper is to present a novel model-based method for evaluation of 
hypotheses when intervention data and control data are not comparable 
regarding independent variables. 
Method outline 
The method utilizes comparison of deviations of dependent variables in data from 
model simulations. The basis of the method is to use simulations from a model as 
expectancies and by these cancel out deviations between intervention and control 
data that originate from differences in independent variables. Hereby, only those 
deviations originating from the investigated event or behavior affect the result, 
and the imperfections of the purely data-based approach to deviation-related 
hypothesis evaluation are addressed. Using model simulations as expectancies for 
both intervention and control data addresses the imperfections of the model-
based approach to deviation-related hypothesis evaluation, as systematic errors in 
model simulations will be present in both expectancies and thereby cancelled out. 
 
For each includable incident of the investigated event or behavior, a model 
simulation is calculated for intervention and control periods, Si and Sc, 
respectively, from input of independent variables. These model simulations serve 
as expectancies that include no incidences of the investigated event or behavior, 
as the event or behavior is not considered by the model. 
 
The deviation from the model simulation is calculated for both intervention data 
and control data as Di and Dc, as data minus model simulation in Devi and Devc: 
   iii SDDev       (1) 
   ccc SDDev        (2) 
The deviations in Equations (1) and (2) constitute measures of error, error being 
all aspects included in the data but not included in the model. Thus, the deviation 
is due to the errors ei and ec as described in Equations (3) and (4): 
   iii eSD        (3) 
   ccc eSD        (4) 
where ei and ec are systematic errors in the model. If the independent variables 
are reasonably similar, the systematic errors are comparable. However, the error 
component arising from the event or behavior described by the tested hypothesis, 
ehypothesis, contributes only to ei, not ec: 
   hypothesisci ece       (5) 
The error component arising from the event or behavior described by the tested 
hypothesis is then calculated for each includable incident by re-arranging 
Equation (5) and combining Equations (1)-(4): 
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  )( cciicihypothesis SDSDDevDeve     (6) 
This difference is a measure of aspects represented in the intervention data (and 
not in the model) but not in the control data (nor in the model). The differences 
resulting from all included incidences of the investigated event or behavior can 
then be analyzed using normal statistical methods. Equation (6) thus describes the 
calculations involved in the method. 
As its primary assumption, the method for comparison of initially non-comparable 
intervention and control data assumes similarity of all independent variables not 
included in the model in both intervention and control data for each incident of 
the investigated event or behavior. 
Method evaluation and example use 
To illustrate the method, example use of it has been performed on the hypothesis 
of a long-term glucose counter-regulation to hypoglycemia in diabetes suggested 
by Hejlesen et al. (73). The hypothesis describes that a hypoglycemic event causes 
a hyperglycemia relative to if no hypoglycemic event occurred. The 
hyperglycaemia is hypothesized to onset 6-8 hours after hypoglycemia and to 
wear off approximately 24 hours after hypoglycemia (73). 
Example use of the method outlined above involves comparison of 
posthypoglycemia blood glucose data with corresponding simulations of blood 
glucose in two patients. A system for continuous glucose monitoring (CGM) was 
used as blood glucose data source, and DiasNet (19,74) was used as the source of 
model simulations.  
CGM data (CGMS®, Medtronic-MiniMed, Northridge, California) was collected in 
type 1 diabetic patients living their everyday lives. 
Simulations were performed inputting all meal and insulin data and glucose data 
from the CGM data sampled at the time of hypoglycemia, and 60 and 120 minutes 
before and after the hypoglycemia (the time of hypoglycemia in control data). 
Calculations, except from DiasNet simulations, were performed using Microsoft 
Office Excel 2003 (Microsoft Corporation, CA). 
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 Figure 1 – Deviations (CGM minus simulated glucose) for intervention (Di, 
full) and control (Dc, broken) data for 24 hours following an early morning 
hypoglycemic event in a female diabetic. The difference between the two 
(intervention deviation minus control deviation) is indicated (ehypothesis, ●) 
 
Figure 2 – Deviations (CGM minus simulated glucose) for intervention (Di, 
full) and control (Dc, broken) data for 24 hours following a late afternoon 
hypoglycemic event in a male diabetic. The difference between the two 
(intervention deviation minus control deviation) is indicated (ehypothesis, ●) 
Figures 1 and 2 depict the deviations between data and simulations for a single 
patient each, for both the intervention period (Devi) and the control period (Devc), 
together with the difference between the two (ehypothesis). The intervention period 
and the control period cover the same time of the day, and the control period is 
free of prior hypoglycemia within 24 hours. 
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The intake of carbohydrates and insulin injections (according to diary data) for 24 
hours before and after hypoglycemia and for the corresponding control period 
can be seen in tables 1 and 2. 
Table 1 – Diary data for example patient 1 
 Hypoglycemia Control 
Total CHO (g) 435 470 
Total rapid-acting 
insulin IU) 
104 104 
Total long-acting 
insulin (IU) 
100 100 
Total intake of carbohydrates and insulin for 24 hours before and after (total 48 hours) 
hypoglycemia for the early morning hypoglycemic event in a female diabetic and for the 
corresponding control period. Units of insulin per gram carbohydrate are 0.47 for 
hypoglycemia data and 0.43 for control data.
 
Table 2 – Diary data for example patient 2 
 Hypoglycemia Control 
Total CHO (g) 488 448 
Total rapid-acting 
insulin IU) 
86 86 
Total long-acting 
insulin (IU) 
28 30 
Total intake of carbohydrates and insulin for 24 hours before and after (total 48 hours) 
hypoglycemia for the late afternoon hypoglycemic event in a male diabetic and for the 
corresponding control period. Units of insulin per gram carbohydrate are 0.23 for 
hypoglycemia data and 0.26 for control data. 
Discussion 
A method for deviation-related hypothesis evaluation is presented in this paper. 
The method describes comparison of deviations of data from simulations for 
intervention data (following the event or behavior in question) and control data. 
The method proposed in this paper assumes comparability for all non-hypothesis 
related errors. This requires similarity of the independent variables not included in 
the model in both intervention and control periods. This may be a reasonable 
assumption in some habit-oriented patient groups such as those with Type 1 
diabetes. In general, however, careful handling of non-included behavior should 
be stressed.  In addition, an open mind towards identifying any possible relevant 
behavior should be stressed, together with patients’ compliance to uniformity 
during data collection. Diary data could aid in the latter. 
Example application of the method on two diabetics’ data results in very different 
indications regarding the hypothesis of a long-term hypoglycemic counter-
regulation. One patient exhibits the expected pattern of hyperglycaemia relative 
to the simulated glucose profile for 15 hours, beginning 4 hours after the onset of 
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hypoglycemia, and has no profound deviations from simulated glucose profile on 
the control day. This is consistent with the hypothesis of the long-term 
hypoglycemic counter-regulation. The second patient exhibits a less profound and 
shorter hyperglycaemia relative to the simulated glucose profile, both after 
hypoglycemia and in the control period. This is contrary to the hypothesis if truly 
no hypoglycemia is present before or in the beginning of the control period, and 
this is not indicated by sensor data, at least for the first 6 hours before the control 
period. These very different results indicate the expected reliance of the method’s 
result on the patterns in data as well as the inappropriateness of the method 
when used on only a very small dataset. Also, the importance of context 
considerations is stressed, as the units of insulin per gram carbohydrate are 
similar within patients but nearly doubled for patient 1 compared to patient 2. 
This is consistent with the observed association of the hypothesized long-term 
hypoglycemic counter-regulation with low insulin sensitivity as calculated by 
DiasNet. 
The major limitation to the application of the method described is the 
requirement of a control period free of the event or behavior in question. This 
control period may be difficult to establish. However, this is no different from the 
requirement of control data in conventional retrospective data analysis. Inclusion 
of model simulations to cancel out incomparability of independent variables in 
intervention data compared to control data alleviates the difficulties herein, as no 
matching of independent variables is needed but is instead accounted for by the 
model. 
Conclusion 
This paper outlines a method for hypothesis evaluation including model 
simulations as expectancies to cancel out incomparability of independent 
variables other than the one described by the hypothesis. An example use of the 
model, without a large-scale evaluation, has been performed and indicates the 
method’s relevance in data analysis. Large-scale evaluation is necessary to 
determine advantages and disadvantages. The evaluation should include 
comparison of results obtained with this method and results obtained using 
conventional data comparison on the same data, in order to determine the 
comparability of results.
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8. CGM glucose overshoot after hypoglycemia 
assessed by a simulation tool                  
This chapter presents the control data substitution study. The chapter is equivalent 
to the paper CGM glucose overshoot after hypoglycemia assessed by a simulation 
tool except from the abstract and bibliography, which is omitted in this chapter. 
The full paper can be found as paper number three in the end of the thesis. The full 
paper is of status “Submitted” to Journal of Diabetes Science and Technology by 
September 2008. 
Introduction 
People with Type 1 diabetes mellitus must take over the regulation of blood 
glucose from the pancreas in order to avoid acute or chronic complications due to 
abnormal blood glucose levels. This is achieved primarily by balancing insulin 
injections, meals, and exercise. Suboptimal blood glucose control with frequent or 
persistent episodes of hyperglycemia, leads to a substantially increased risk of 
long-term complications, such as micro- and macro vascular diseases (8). Intensive 
control of the blood glucose, however, may increase the frequency and severity of 
hypoglycemia(8), which for many patients is the most feared complication to 
diabetes (9,10). 
To a large extent, the patient has to take responsibility for managing the diabetes 
(11-14).  Quite apart from economic considerations, it is not practical for 
specialists to manage patients’ diabetes on a day to day basis (14). Various 
approaches intended to facilitate patients’ everyday decisions have been 
suggested, ranging from didactic lectures to interactive computer programs (15). 
Among these computer programs are computer-based decision support systems 
such as DiasNet (19), AIDA (20), and Libraa (21), all of which  have been developed 
for both educational (general) and advisory (specific) purposes. These decision-
support systems all simulate a blood glucose profile from input data on meals and 
insulin doses, some of which are on a patient-specific basis (19,21,22) and some 
from information on physical activity (21). 
The DiasNet simulation tool is based on a metabolic model, implemented as a 
compartment model of human glucose metabolism and insulin kinetics in a 
Bayesian network (19). The tool has been tested in diabetes clinics in Italy, 
Denmark and England and has been shown to help improve control in patients 
with poorly controlled diabetes (75). A study has indicated that systematic errors 
in the metabolic model in hypoglycemia free data are small compared to the day-
to-day variation of blood glucose seen in diabetes (22). 
It should be noted, however, that these rather encouraging results were based on 
a basic model, implementing only basal, normal physiology and not taking into 
account the broad range of events or conditions that may affect blood glucose 
concentrations and which may be necessary to fully describe and predict blood 
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glucose metabolism. These include alcohol intake, exercise, disease/fever and 
hypoglycemic episodes. The importance of a particular event or situation and its 
impact on physiology can be assessed with a simulation tool by comparing blood 
glucose simulations with actual measurements taken where the event or situation 
is present and precisely documented, and where the simulation tool is accurate in 
implementing all known relevant physiology.  Substantial deviation of actual data 
from the simulations would indicate that physiological mechanisms are affecting 
the data but not the simulations, implying that not all relevant physiology is 
implemented in the model. In this way, systematic deviations of data from model 
simulations can be used to generate hypotheses. We have earlier used this 
approach to investigate the importance of alcohol intake (72). 
We have previously reported that in SMBG data with episodes of hypoglycemia, 
measured blood glucose levels are consistently greater than the levels simulated 
by the model for a period of 10-12 hours, beginning 6-8 hours after hypoglycemic 
episodes (73). This systematic discrepancy is seen only in data following 
hypoglycemia, supporting the hypothesis that hypoglycemia leads to a long-term 
counter-regulatory effect of some sort.  This phenomenon has been recognized 
for many years and was originally described by Somogyi.  It was studied by several 
groups in the 1980s and 1990s (27,29,32,56). Taken together, the findings have 
been inconclusive, due probably to discrepancies in the studies’ hypotheses 
regarding the temporal characteristics of the hyperglycemic response and in study 
design and patient selection. Currently, the long-term glucose counter-regulation 
to hypoglycemia is omitted from or even refuted in medical and diabetes 
textbooks. 
In the present work, we describe long-term post-hypoglycemic glucose 
discrepancy between data and simulations using glucose sensor data in order to 
ensure maximum resolution in glucose data. 
Materials and methods 
Study design 
We retrospectively analyzed continuous glucose profiles (48-120 hours) by 
calculating the deviation in simulated (DiasNet) blood glucose profiles compared 
to measured CGM (CGMS®, Medtronic-MiniMed, Northridge, California) glucose 
profiles after hypoglycemic episodes. The study was approved by the local ethics 
committee.  
Patients 
17 Type 1 diabetics with poorly controlled diabetes (judged by their diabetologist) 
from the diabetes clinic at the Royal Bournemouth Hospital, England were 
included after giving written informed consent. The diabetics were referred to the 
study if the clinic’s diabetologist assessed that there was a clinical indication for 
continuous glucose monitoring. The mean age of the subjects was 39.5 years 
(range: 25-63 years). Mean diabetes duration was 11.1 years (range: 3-42 years). 
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Mean BMI was 25.5 (range: 18.6-30.0). All subjects had multiple daily injections of 
insulin. Mean daily dose of short-acting insulin (primarily Humalog, Eli Lilly) was 
34.5 IU (range: 10-56 IU), and mean daily dose of long-acting insulin (Humulin 
NPH, Eli Lilly or Insulatard, Novo Nordisk or Lantus, Sanofi-Aventis) was 19.5 IU 
(range: 8-50). 
Diary 
The patients were instructed to maintain a diary regarding all meals (grams of 
carbohydrates and time of ingestion) and all insulin injections (units of insulin and 
time of injection) for three days and to do at least 4 daily capillary blood glucose 
measurements with their regular glucose meters. The diary should include any 
meal or insulin related action taken in connection with hypoglycemia. The 
patients were instructed to live as close to their everyday lives as possible, despite 
the sensor. 
CGM data 
A continuous glucose sensor (CGMS®, Medtronic-MiniMed, Northridge, California) 
was inserted into the subcutaneous fat in the peri-umbilical region, using the 
insertion needle provided with the sensor. The sensor utilizes the principle of 
glucose oxidase for its measurements. The sensor was left in place for three to 
five days for collection of data. The sensor data was transferred to a PC using the 
data transfer tool from the manufacturer. The patients were not able to see the 
CGM measurements during the collection period. 
Data analysis and statistics 
The sensor data was calibrated using the Medtronic MiniMed CGMS® software, 
which is recommended to be used with at least 4 capillary blood glucose 
measurements (SMBG) per day. We regarded days of CGM data as valid if the 
number of measurements available for calibration ranged from 2 to 7 (8 if a 
nocturnal (0 am-6 am) measurement was present). The lower limit of 2 was the 
absolute minimum, as at least 2 measurements are needed in order to determine 
off-set and gain in the Medtronic MiniMed CGMS® calibration algorithm. The 
upper limit was set to 7 (or 8), as diabetics doing frequent SMBG do up to 7 
(eventually 8, including a nocturnal) blood glucose measurements per day. Hereby 
the included patients, while instructed to do only 4 daily measurements, may 
actually have done up to 7 (or 8), and the additional measurements could indicate 
special situations that might compromise the validity of the sensor data. Time 
with missing (or low voltage) sensor signal was excluded as invalid. 
Hypoglycemic episodes were identified in the valid CGM data. We defined an 
episode of hypoglycemia to consist of at least 4 consecutive measurements 
(equivalent to 20 minutes) below 63 mg/dl. The beginning of the hypoglycemic 
episode was defined as the first measurement below 63 mg/dl and the end of the 
hypoglycemic episode as the last measurement below 63 mg/dl before at least 3 
measurements equal to or above 63 mg/dl. Episodes of hypoglycemia preceded 
by confirmed or possible hypoglycemic episodes up to 20 hours beforehand were 
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excluded in order to avoid interference from the long-term effects of 
hypoglycemia on simulation error investigated in this study. Thus, hypoglycemic 
episodes within 20 hours after sensor insertion or lack of data or data invalidity 
were excluded. CGM data were averaged every 15 minutes (equivalent to every 
three CGM glucose measurements) in order to obtain the same temporal 
resolution of CGM data as of simulated glucose data. 
The DiasNet simulation tool (19) was used to calculate glucose profiles that could 
be used as ‘control data’ when analyzing the hypoglycemia data collected by 
CGM. The input to the model is the diary data: meals (grams of carbohydrates and 
time of ingestion) and insulin injections (units of insulin and time of injection). The 
simulation model is calibrated to each individual patient using a few glucose 
measurements as described below. The output is blood glucose profiles calculated 
in 15 minute steps based on state-of-the-art knowledge of normal physiology. 
According to simulation theory, since the simulation tool calculates the average 
expected blood glucose for each patient, the intra-patient variation in the control 
data is cancelled or reduced significantly and since the model is calibrated to each 
individual patient the inter-patient variation in the control data is cancelled or 
reduced significantly. It should be noted, that also the potential effect of different 
insulin types on the inter-patient variation is cancelled or reduced significantly by 
a simulation model implementing average insulin absorption profiles for each type 
of insulin. This reduction in intra-patient and inter-patient variation in the 
simulated control data implies that valid results can be produced with a smaller 
number of hypoglycemic events in the CGM dataset. 
A simulated glucose profile, the simulated control data, was calculated for the 
entire data period for each included episode of hypoglycemia. For each of these 
episodes, the input was all diary-reported meals and insulin injections for the 
entire data period. The simulation model was calibrated to each patient using five 
measurements from the glucose sensor (each constituted by an average of three 
CGM glucose measurements) around the hypoglycemic episode (one and two 
hours before the beginning of the episode, at the beginning of the episode, and 
one and two hours after the beginning of the episode) to adjust the metabolic 
model to the specific patient. This adjustment is carried out with a patient-specific 
model parameter, the so-called insulin sensitivity, which is estimated 
automatically by the DiasNet simulation tool. 
CGM and simulated glucose profiles were compared for 24 hours after 
hypoglycemic episodes. The average CGM and simulated glucose profiles were 
compared using Student’s one-sided t-test. All analysis was performed using the 
Excel spreadsheet program (Microsoft Corporation, Redmond, WA). 
Results are given as mean±SD. 
Results 
Total monitoring time was 54 days, valid monitoring time 45 days. Periods of non-
valid monitoring were caused by missing (or low-voltage) sensor signals (15 hours) 
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or by an invalid number of SMBG measurements for calibration (approximately 8 
days). 
Episodes of hypoglycemia 
All 17 patients had at least one hypoglycemic episode according to the CGM data. 
A total of 52 episodes of hypoglycemia occurred (median per patient: 3; range: 1-
9). 42 of the episodes were excluded due to: (i) occurrence less than 20 hours 
after sensor insertion (23 episodes of hypoglycemia), (ii) invalid CGM data (3 
episodes of hypoglycemia) or (iii) preceding hypoglycemia (16 episodes of 
hypoglycemia).  
The 10 hypoglycemic episodes included in this study were found in data from 9 
patients. The temporal distribution of all hypoglycemic episodes together with 
indications of inclusion/exclusion (and reason for exclusion) is shown in Figure 1 
(only patients with includable episodes of hypoglycemia).  
The hypoglycemic episodes were evenly distributed during the day (Figure 1); six 
episodes of hypoglycemia were found in the daytime (6 am-6 pm) and four at 
night (6 pm-6 am). 
Mean hypoglycemia blood glucose nadir was 45 ± 7 mg/dl (according to the CGM 
data). Five episodes of hypoglycemia with nadir=40 mg/dl (the lower detection 
limit of the CGMS®) were found. Mean duration of the hypoglycemic episodes was 
86±61 min (according to the CGM data).  
 
 
 
 
 
Figure 1: The temporal distribution of included and excluded hypoglycemic 
episodes (CGM glucose <63 mg/dl for at least 20 minutes) with indication of 
reason for exclusion (only profiles with included hypoglycemic episodes). × 
indicates included episode of hypoglycemia. ■ indicates hypoglycemic 
episodes excluded because of prior (0-20 hours) lack of data, ♦ indicates 
hypoglycemic episodes excluded because of prior (0-20 hours) episodes of 
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hypoglycemia, ▲ indicates hypoglycemic episodes excluded because of 
prior (0-20 hours) start of data. Full lines designate valid data, dotted lines 
designate invalid data (days with <2 or >7 (8 if one is nocturnal) SMBG 
measurements). 
 
Comparison of mean glucose profiles after hypoglycemic episodes 
Mean glucose profiles (CGM and simulated) can be seen in Figure 2.  
The CGM glucose was significantly higher (p<0.05) than the simulated glucose for 
a period of 13 hours, beginning 8 hours after the onset of hypoglycemic episodes. 
No significant difference was recorded within the first 8 hours after the onset of 
hypoglycemic episodes, except for one hour immediately after the onset of 
hypoglycemic episodes, where the CGM glucose is significantly lower (p<0.05) 
than the simulated glucose. 
Discussion 
A systematic discrepancy between measured glucose and DiasNet simulations 
following hypoglycemic episodes, measured glucose levels being higher than 
anticipated by the simulation tool, was investigated using CGM data. Episodes of 
hypoglycemia were identified in CGM data, and CGM data were compared to 
simulated blood glucose profiles for a period of 24 hours following the onset of 
hypoglycemic episodes.  
 
Figure 2: The mean glucose profiles (CGM: full line, simulated: broken line) 
for the first 24 hours after beginning of hypoglycemic episodes. × indicates 
significantly higher or lower measured blood glucose than simulated blood 
glucose (p<0.05). 
CGMS® has been validated as a reliable method for continuous glucose 
assessment, if calibrated properly with SMBG (52,76,77), both in hypoglycemia 
(52) and hyperglycaemia (77). Further, the prevalence of hypoglycemia in our 
CGM data (17 of 17 patients) is consistent with findings of Hoi-Hansen et al. (70) 
in diabetics with supra-normal HbA1c and, at least to some extent, hypoglycemia 
unawareness. It should be noted however, that although the general accuracy of 
CGM is acceptable, the weakest point in most sensors seems to be in the 
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hypoglycemic range, and, therefore, future improvements in sensor technology in 
this region would benefit the validity of clinical studies on hypoglycemia. 
For the first hour after the onset of hypoglycemic episodes in our study, the CGM 
glucose was significantly (p<0.05) lower than expected by the simulation tool. 
Despite being significant, the limited magnitude of the maximum difference of 22 
mg/dl indicates a relatively good fit with the simulation tool. Eight hours after 
hypoglycemia, our data revealed significantly higher CGM glucose than expected 
by the simulation tool for a period of more than 13 hours. Maximum difference 
was 139 mg/dl, 17 hours after beginning of hypoglycemic episodes, and average 
difference during the time interval 8-21 hours after hypoglycemia onset was 46 
mg/dl. Even in the last hour of analysis (23-24 hours after hypoglycemic episode 
start), the CGM glucose was significantly higher (p<0.05) than anticipated by the 
simulation tool. 
The 8-hour delay of the pronounced difference between CGM measured data 
(after episodes of hypoglycemia; intervention data) and simulated data 
(hypoglycemia free; control data) reported here is consistent with the findings of 
Gale et al. (27), Tordjman et al. (32), Stephenson and Schernthaner (31), and 
Havlin and Cryer (42) that no significant differences in glucose concentration are 
seen within the first 4-8 hours after hypoglycemia when comparing blood glucose 
profiles after hypoglycemic episodes with control blood glucose profiles. It should 
be noted, however, that though our results for the 0-8 hour period after the 
beginning of episodes of hypoglycemia are similar to these previous reports, these 
studies concluded that prolonged hyperglycaemia did not occur following 
hypoglycemia. Our data, based on the 8-24 hour findings do not support this 
conclusion. The 8-21 hours overshoot of CGM glucose compared to the simulated 
glucose profile corresponds very well to the results for the 0-12 hour period after 
hypoglycemia reported by Bolli et al. (56). The overshoot, however, is not in 
accordance with the findings of Hirsch (29).  
Even though a simulation model reduces intra-patient and inter-patient variation, 
any significant systematic error in the simulation model would decrease the 
validity of an analysis based on simulated data. The DiasNet simulation tool has 
been tested using data not containing hypoglycemic events: In capillary blood 
glucose (self-monitored blood glucose, SMBG) data, the metabolic model predicts 
blood glucose profiles with a standard deviation (prediction error) which is about 
the same as the standard deviation of blood glucose measurements between days 
in the same data (the intra-patient variation) (22). This indicates that systematic 
errors in the metabolic model in hypoglycemia free data are small compared to 
the day-to-day variation of blood glucose seen in diabetes, and that the DiasNet 
simulation tool therefore can be used to generate the control data in the present 
study. 
Our data support the hypothesis of a long-term glucose counter-regulation to 
hypoglycemia by comparison of CGM data to model simulations of glucose. 
Recognition of a long-term glucose counter-regulation to hypoglycemia is 
Chapter 8: CGM glucose overshoot after hypoglycemia assessed by a simulation tool (the control 
data substitution study) 
 
56 
important to avoid overly aggressive treatment of (relative) hyperglycemia caused 
by prior hypoglycemia. We suggest that in order to minimize a possible 
interference from the simulation tool in a more thorough examination of the 
hypothesis, further studies of the existence and characteristics of the long-term 
glucose counter-regulation to hypoglycemia should include analysis of both 
hypoglycemia-free CGM control data and hypoglycemia CGM intervention data. 
The assessment could be based on a model/simulation tool. 
Conclusions 
In conclusion, our findings do not contradict the findings of previous studies. We 
consider the hypothesis of a long-term glucose counter-regulation to 
hypoglycemia, as indicated by the overshoot of CGM glucose compared to a 
verified simulation tool, to be justified for further analysis. 
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9. Implementation of an intensive chronic type 1 
diabetes model with tight blood glucose control 
in Göttingen minipigs 
This chapter presents the animal model implementation study. The chapter is 
equivalent to the paper Implementation of an intensive chronic type 1 diabetes 
model with tight blood glucose control in Göttingen minipigs except from the 
abstract and bibliography, which is omitted in this chapter. The full paper can be 
found as paper number four in the end of the thesis. The full paper is of status 
“Submitted” to Diabetes by September 2008. 
Introduction 
Models of type 1 diabetes exist in a variety of species, such as mice, rats, guinea 
pigs, swine and various miniature pigs. Such models have been used extensively 
for studies where human subjects are not acceptable or appropriate (78). This 
applies traditionally to type 1 diabetes pharmacological research (79,80) and to 
toxicology studies, but wide perspectives are also found within physiological 
studies. 
For much type 1 diabetes research, core characteristics of a suitable animal model 
include induced type 1 diabetes, tight glucose control with insulin regimens 
comparable to those applied in human diabetics, access to blood sampling for 
glucose control and experiment-related assays and minimal stress induction in all 
experimental procedures. In many applications, the animal model is established in 
Göttingen minipigs because of their resemblance to human physiology and their 
appropriate size (78). We call this model a “basic type 1 diabetes minipig model”, 
and it can be used to intensively study physiological events such as hypoglycemia 
and exercise, where a stable pathological model with good resemblance to human 
diabetic conditions is required. 
Various aspects of such Göttingen minipig type 1 diabetes models are well-
described in the literature, and the model has been implemented in various 
facilities (78,81-84), also in the pharmaceutical industry (83). In general, however, 
long-term tight blood glucose control is not addressed in the models employed 
and described. Despite the substantial literature, it appears to be a considerable 
challenge to implement a “basic type 1 diabetes minipig model” in a biomedical 
laboratory with no prior experience in chronic disease models requiring frequent 
and rather complicated procedures as those involved in the model described 
above. This has at least two explanations. First, scientific papers reporting 
development or use of animal models with characteristics similar to the basic type 
1 diabetes minipig model report their methods rather unspecifically, leaving open 
questions regarding the extent and execution of, for example, aseptic techniques. 
Second, the model work is so complex that continuing assistance is needed from 
friendly external colleagues experienced in working with models like the “basic 
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type 1 diabetes minipig model”. Researchers unfamiliar with the model work need 
to learn the necessary precautions and principles of the intensive work required 
for daily management (blood glucose control and blood sampling possibility 
maintenance) of the model, so that the precise efforts needed for success can be 
established. 
This paper demonstrates how a laboratory that did not have prior experience in 
intensive chronic experiments implemented the “basic type 1 diabetes minipig 
model”, an intensive chronic type 1 diabetes model in Göttingen minipigs.  
Research Design and Methods 
Methodological approach 
We applied a stepwise, exploratory approach to refining the experimental 
implementation of a chronic type 1 diabetes model in Göttingen minipigs in a 
facility that had prior experience only with acute intensive or chronic extensive 
experiments. Refinement of the experimental implementation from one setup to 
the next was aimed at addressing the problems that arose in the previous setup. 
Each setup evaluation included three animals. A summary of the methodological 
approach is shown in Figure 1. 
 
Figure 2: The experimental design with iterative process of the three setups, 
each involving an implementation of the model. 
The procedures involved in the implementations were approved by the Animal 
Experiments Inspectorate of the Danish Ministry of Justice. 
The implementations in the three setups were designed stepwise on the basis of, 
particularly, the experience gained from previous setups, consulting relevant 
literature, the laboratory’s prior experience with intensive acute or extensive 
chronic experiments, formal and informal training of researchers and from 
assistance offered by external researchers experienced with the model. The 
design basis of each implementation can be seen in Table 1. 
 
 
 
Table 1: Design basis of each setup 
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 Design basis Outcome input to next setup 
Setup 1  Protocols for diabetes induction from 
external researchers experienced with 
chronic models similar to the “basic 
type 1 diabetes minipig model” 
 Standard procedures from intensive 
acute and extensive chronic 
experiments 
 Experimental protocols as described in 
the literature 
 Mandatory laboratory animal science 
course 
 Training of animals to accept all 
procedures was insufficient 
 Blood glucose measurements 
were too scarce for insulin 
adjustment 
 Placement of catheter tip was 
imprecise 
Setup 2  Experience from setup 1 
 General advice from external 
researchers experienced with chronic 
models similar to the “basic type 1 
diabetes minipig model” 
 Efforts to ensure aseptic 
technique with catheter 
placement and maintenance 
were insufficient 
Setup 3  Experience from setup 2 
 Training of researcher by external 
animal facility staff experienced in 
surgery and catheter maintenance in a 
similar animal model 
 Principles of human surgery, catheter 
maintenance and blood glucose control 
 
Table 1: Design basis of each setup. 
Materials 
A total of nine Göttingen minipigs were used; three in each setup. All were 
obtained from the barrier unit of Ellegaard Göttingen minipigs (Dalmose, 
Denmark) and acclimated for at least two weeks prior to experiment start. The 
minipigs were housed in single pens with holes for snout contact, under 
controlled conditions (temperature 18-22°C, relative air humidity 30-70%, 12:12 
hours light-dark cycles) and fed twice daily with SDS minipig diet (Special Diets 
Services, Essex, United Kingdom) at 7:00-7:30 and 14:00-14:30, respectively and 
had access to water ad libitum. The animals were all acquainted to humans and 
observed by trained animal technicians and a researcher as to their health status 
(weight, appetite, behavior, color). 
 
 
Methods applied in all three setups 
Surgical technique for implantation of central venous catheters 
Anesthesia was induced with intramuscular injection of 1 ml/10 kg pig zoletil-
mixture (xylazin 12.5 mg/ml (Rompun Vet, Bayer Health Care, Leverkusen, 
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Germany), ketamin 12.5 mg/ml (Ketaminol, Intervet International, Boxmeer, 
Holland), butorphanol 2.5 mg/ml (Torbugesic Vet., ScanVet Animal Health A/S, 
Fredensborg, Denmark), tiletamin 25 mg/ml (Zoletil 50 Vet., Virbac, Carros, 
France), zolazepam 25 mg/ml (Zoletil 50 Vet. Virbac, Carros, France)). The animals 
were intubated and maintained with isoflurane 1-2% in 50% oxygen. An ear vein 
was cannulated for infusion of perioperative analgesia and muscle relaxation with 
fentanyl 250 μg (Fentanyl “Hameln”, Hameln Pharmaceuticals, Germany) and 
rocuronium bromide 50 mg (Esmeron, Organon, Oss, Holland). Postoperative 
analgesia was provided with intramuscular injections of 100 mg ketoprofen 
(Orudis, Sanofi-Aventis, Paris, France) for 4 days. Postoperative infection was 
prevented with intramuscular injection of 2 mill. units of benzylpenicillin 
(Benzylpenicillin, Panpharma, Fougéres, France) immediately before surgery and 
for the following 4 days. Animals were shaved carefully, washed and prepared 
with iodine alcohol. During open surgery and aiming at aseptic procedures (sterile 
gloves, sterile unpacking of utensils, sterile draping of the entire field), one or two 
6.5 Fr catheters (Cook Medical, Bloomington, IN), depending on setup number, 
were inserted, pre-filled with heparin 5000 U/ml (Heparin SAD, SAD, Copenhagen, 
Denmark). The catheters were exteriorized via an incision in the dorsal midline, 
approximately 6-10 cm cranial to the scapulae, and fastened by suture loops and 
the catheters’ Dacron cuffs. The catheters were tunneled subcutically to a ventral 
caudal-cranial jugular furrow catheter introduction incision. Blunt dissection to 
the vena jugularis exterior (and in setup 2 also interior) was performed and the 
catheters were introduced in them using the insertion kit provided with the 
catheters. The intended position of the catheter tip was in the anterior vena cava. 
The vein was ligated around the catheter caudally to the insertion site, and a 
catheter loop was fastened by sutures. Both incision sites were closed in the 
muscle and cutical layers. A pouch fastened to the neck using adhesive bands held 
the exteriorized catheters.  
Measurement of baseline blood glucose 
The blood glucose was measured pre-prandially and at two hours after feeding on 
three consecutive days before diabetes induction.  
Diabetes induction 
The animals were fasted 18 hours before diabetes induction. Type 1-like diabetes 
was induced by a single infusion of streptozotocin (STZ) (S-0130, Sigma-Aldrich, St. 
Louis, MO), 125 mg/kg, dissolved in sodium citrate buffer (pH 4.5), 2 ml/kg, over 5 
minutes in one of the catheters. Doses of STZ between 100 and 150 mg/kg are 
commonly used for type 1-like diabetes induction (79,85-88). Isotonic sterile 
saline was infused before (5 ml) and after (20 ml) STZ infusion. 
Animals were offered their normal morning feed with 2 g/kg glucose (Glukose, 
Matas, Allerød, Denmark) in 1 dl yogurt 3 hours after STZ administration and at 
normal feeding times for the following 48 hours. During this period, the animals 
were observed carefully, and blood glucose was measured every 1-4 hours for 
detection of hypoglycemia due to hyperinsulinemia resulting from β-cell 
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destruction. Hypoglycemia < 2.5 mmol/l was treated with 20 g of glucose in 1 dl 
yogurt. 
Blood glucose measurements 
Blood glucose was measured by an ABL725 (Radiometer, Copenhagen, Denmark) 
with 90 μL or 150 μL glass capillaries (Clinitubes, Radiometer, Copenhagen, 
Denmark). The ABL725 was calibrated and maintained according to the 
manufacturer’s instructions. 1.5 ml of catheter lock solution and blood was drawn 
prior to sampling of blood for analysis. 
Insulin treatment 
Insulin treatment was initiated after STZ infusion when pre-prandial blood glucose 
>20 mmol/l. Insulin treatment aimed at pre-prandial blood glucose <7 mmol/l and 
2 hours post-prandial blood glucose <10 mmol/l. 
Insulin was injected subcutaneously approximately 2-5 cm caudal to the ear, from 
ear height to approximately 5 cm ventral to the ear. Both sides were used, and 
injection sites were varied to avoid infiltrates. 
For all insulin injections, we used a NovoPen Junior insulin pen (Novo Nordisk, 
Bagsværd, Denmark) with 12.7 mm needles (BD Ultra-Fine, BD, New Jersey, USA). 
Euthanasia 
The animals were euthanized with a bolus of 20 ml of pentobarbitone (200 
mg/ml; Pharmacy of the Royal Veterinary and Agricultural University, 
Copenhagen, Denmark) in the central venous catheter. 
Methods applied specifically in each setup 
Setup 1 
The first group consisted of 3 female pigs aged 7-8 months, weight 17-18 kg.  
No other training in addition to human acquaintance was performed, so the pigs 
were placed in a box 50x80 cm for restraint during blood sampling and insulin 
injection. 
The animals were fed 110 g at each feeding before diabetes induction and 140-
150 g after diabetes induction for weight maintenance. 
One catheter was implanted. This was done with the pig first in ventral 
recumbency for exteriorization incision and catheter tunneling, then in dorsal 
recumbency for insertion incision, catheter insertion and incision closure, and 
again in ventral recumbency for exteriorization incision closure. The pig and also 
the sterile drapes were thus manipulated twice. Catheter tip location in the 
anterior vena cava was determined by a sensation of catheter reluctance to blood 
withdraw using a syringe, indicating a position of the catheter tip in the heart (89) 
and subsequent catheter retraction of 1-2 cm. The catheter was implanted in its 
full length with excess catheter length coiled and placed in a muscle/subcutical fat 
pocket dissected in the dorsal incision. 
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The catheter lock solution and blood drawn before sampling of blood from the 
catheter for analysis was re-injected before injection of new lock solution (5000 
U/ml). 
Baseline blood glucose level measurements were initiated 6 days after catheter 
implantation. 
Diabetes was induced 10 days after surgical catheter insertion. 
Blood glucose was measured pre-prandially each day following diabetes 
induction. 
Insulatard (Novo Nordisk, Bagsværd, Denmark, 100 IE/ml), initial dose 0.2 
IU/kg/feeding, was injected subcutaneously immediately before feeding. 
Subsequently, insulin doses were adjusted in steps of 0.1/IU at each feeding 
according to pre-prandial blood glucose. 
For an hourly blood sampling session of 32 hours duration for detailed blood 
glucose profile purposes, a 1.5 m extension of the catheter was constructed to 
allow for blood sampling without animal contact. For the entire system, 3.1 ml of 
lock solution (5000 U/ml) was used, and the lock solution withdrawn before blood 
sampling for analysis was injected before the new lock solution. 
Setup 2 
The second group consisted of 3 female pigs aged 9-10 months, weight 21-24 kg.  
The animals were trained over a 3-week period to accept blood sampling and 
insulin injections before surgical catheter implantation.  
The animals were fed 130 g at each feeding prior to diabetes induction. 
Two catheters were implanted to ensure blood sampling possibility. The catheters 
were implanted and maintained as in setup 1, but with the extra catheter in the 
right vena jugularis exterior and applying distances measured by necropsy 
measurements on setup 1 pigs for catheter tip placement. 
Baseline blood glucose levels were determined 4 days after catheter insertion. 
Diabetes was induced 9 days after catheter insertion. 
Blood glucose was measured pre-prandially every day after insulin induction. 
Insulatard (Novo Nordisk, Bagsværd, Denmark, 100 IE/ml), initial dose 0.2 
IU/kg/feeding, was injected subcutaneously immediately before feeding. No 
insulin dose adjustment was relevant. 
Setup 3 
The third group consisted of 3 male pigs aged 9-10 months, weight 20-22 kg.  
A staged, evaluation-centered protocol-based training scheme was developed, 
aiming at acceptance of blood sampling and insulin injections. The protocol 
utilized positive reinforcement (apple pieces) and consisted of 14-18 incremental 
sessions over 3 weeks, each of 15-20 minutes duration and with a formulated 
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objective (protocol presented at the Minipig Research Forum Annual Meeting 
2007, Copenhagen, Denmark).  
The animals were fed 200 g at each feeding prior to diabetes induction. During the 
first 30 days after diabetes induction, the feeding rations were adjusted to 
determine an optimal feeding regimen, in total 500 g on two feedings. 
Two catheters were implanted, both in the right vena jugularis exterior. The pigs 
were positioned in lateral recumbency during the entire surgical procedure. The 
two catheters were introduced via one needle puncture of the vein, applying two 
guidewires with a sheath each. Catheter tip location in the anterior vena cava was 
ensured applying necropsy measurements on a pig in setup 2. The catheters were 
cut with a sharp pair of sterile scissors to appropriate length, leaving no coiling 
necessary (90). 
Catheter maintenance aimed at aseptic procedures utilizing sterile surgical gloves, 
alcohol swabs for wiping the catheter before connecting syringes to it, and 
sustained sterility of utensils (syringes for catheter lock removal, syringes for 
blood sampling, syringes with new lock solution, catheter caps). The catheters 
were flushed 7 days after insertion but otherwise untouched. 
Baseline blood glucose level measurements were performed 12-14 days after 
catheter insertion. 
Diabetes was induced 22 days after catheter insertion.  
Ampicillin (Pentrexyl, Bristol-Myers Squibb, Bromma, Sweden) 10 mg/kg was 
injected intravenously every 10 days for infection-related complications 
prophylaxis. 
The catheter lock and blood drawn before blood sampling for analysis was 
discarded. The catheter was flushed with 2 ml of isotonic sterile saline before 
injection of lock solution (expected duration less than 2 hours: 100 IU/ml, 2-5 
hours: 500 IU/ml, 5-24 hours: 1000 IU/ml, more than 24 hours: 5000 IU/ml). One 
catheter was preferred for use, the other was flushed and locked with heparin 
5000 IU/ml every week and held in reserve. New, sterile catheter caps were 
placed after each blood sampling (91). 
Blood glucose was measured every three to four hours for 24 or 48 hours after 
insulin dosage adjustment, beginning on day 2. 
A continuous glucose monitoring system (CGMS, Medtronic, Northridge, United 
Kingdom) was used for easy and precise glucose monitoring for 3-4 days. Sensors 
were inserted according to the manufacturer’s instructions under anesthesia (1 
ml/10 kg pig-zoletil mixture as for anesthesia induction before surgery) and 
calibrated with 4 or 5 daily blood glucose measurements. They were placed 
caudally to the area of insulin injection and covered by first a sterile semi-
permeable dressing, then the adhesive band holding the catheter pouch. The 
glucose sensor box was fastened in a home-made vest. Insulin was not injected in 
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the side with the glucose sensor during wear and on the day before sensor 
insertion. 
For blood glucose control after diabetes induction, insulin (Insulatard, Novo 
Nordisk, Bagsværd, Denmark), initial dose 0.2 IU/kg/feeding, was injected 
subcutaneously immediately before feeding. To better control post-prandial and 
morning pre-prandial blood glucose, other insulin regimens were applied. These 
regimes were: 1) Mixed insulin (Mixtard 50, Novo Nordisk, Bagsværd, Denmark, 
100 IE/ml), 2)  a combination of separate short acting insulin (Actrapid, Novo 
Nordisk, Bagsværd, Denmark, 100 IE/ml) and separate regular insulin (Insulatard, 
Novo Nordisk, Bagsværd, Denmark), both injected at feeding start. Insulin doses 
were adjusted in steps of 0.05 or 0.1 IU/kg/feeding according to blood glucose 
measurements, and up to 0.2 IU/kg/feeding in case of extensive hypoglycemia or 
hyperglycemia. Insulin dosages and feeding rations were adjusted concurrently.  
The procedure for diabetes induction with STZ was repeated after 62 days in two 
animals due to spontaneous, partial recovery from diabetes. 
Results 
Setup 1 
The pigs did not accept blood glucose sampling and insulin injections easily, and 
some degree of force was indicated. 
STZ caused hyperglycemia (blood glucose>20 mmol/l) in all animals, and insulin 
treatment was initiated. Intended blood glucose control was not achieved. 
One catheter lost its patency 10 days after diabetes induction, the others 
remained patent. The animal with the dysfunctional catheter was euthanized. 
Necropsy revealed unintended catheter tip location in a small hepatic vein. 
One animal developed epistaxis and rectal bleeding due to over-heparinization 
during hourly blood sampling 25 days after diabetes induction and was 
euthanized. 
One animal became lethargic and developed anorexia, hypoxia, tachycardia and 
superficial breathing 30 days after diabetes induction. The animal was euthanized, 
but the disease cause could not be determined by gross pathology. 
 
 
Main results 
The main results of setup 1 were that the animals were insufficiently trained to 
accept the procedures involved in the experiment and that the blood glucose was 
measured too rarely to allow tight blood glucose control. An additional result was 
that correct catheter tip placement could not rely solely on the feeling of 
reluctance to blood withdrawal. 
Setup 2 
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The pigs accepted touching in the neck area and insulin pen needle insertion 
without injection of insulin before surgery, but after surgery, blood sampling was 
complicated by pig movement. 
One pig died during surgery. No obvious cause was observed, including bleeding, 
anesthesia overdose and apparatus malfunction. Unfortunately, no necropsy was 
performed, so the cause of death remains unknown. 
One pig exhibited irreversible tachycardia (170 beats per minute) and hypotension 
(70/30 mm Hg) 10 minutes after isoflurane inhalation was initiated. Mydriasis was 
observed after four hours, so the animal was euthanized. 
One animal developed anorexia, hypoxia including cyanosis, tachycardia and 
superficial breathing 3 days after diabetes induction and insulin treatment 
initiation. The animal was euthanized, and necropsy indicated a pulmonary 
thromboemboli. Correct catheter tip location was observed. 
Main result 
The main result of setup 2 was that the catheter maintenance procedures 
employed did not prevent thromboemboli. An important result was also that 
anatomical fixpoint measurements ensured correct catheter tip placement. 
Setup 3 
The animals’ responses to training varied only little. The main difficulty was 
balancing the intensive training with the animal’s ability to focus on the session 
task objective and not only on the reward, Training 2-5 hours after feeding was 
optimal. The pigs accepted blood sampling from the catheters and insulin 
injections easily, even during nightly blood samplings. However, one pig 
developed evasive and aggressive behavior during insulin injections approximately 
one month after diabetes induction. Repetition of the initial training protocol over 
3 days restored full compliance.  
One pig developed an abscess with suppuration of approximate diameter 2 cm in 
the healed exteriorization incision 35 days after surgery. Nine days of daily 
intravenous injection of 1000 mg ampicillin cured the infection. 
All catheters were patent during the entire experiment (70 days). 
3 or 4 subcutaneous glucose sensors were used in each pig. Three sensors 
dislocated within the wear period despite no problems were observed during 
sensor insertion. 
Feeding rations of 160 g in the morning and 340 in the afternoon apparently 
provided the easiest insulin dosage without diurnal hypoglycemia or 
hyperglycemia patterns. 
The initial insulin treatment with Insulatard resulted in morning post-prandial and 
afternoon pre-prandial hyperglycemia and late afternoon/early evening 
hypoglycemia. Mixtard 50 caused late afternoon hypoglycemia and dose 
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reduction caused morning pre-prandial hyperglycemia. Short acting insulin with 
the morning feeding and intermediate acting insulin and short acting insulin with 
the afternoon feeding caused afternoon post-prandial hypoglycemia. The same 
regimen without short acting insulin with the afternoon feeding caused overall 
acceptable blood glucose control in 14 days; morning insulin doses were 0.11, 
0.13 and 0.21 IU/kg, and afternoon insulin doses were 0.23, 0.29 and 0.53 IU/kg. 
50-60 days after diabetes induction blood glucose levels began to decrease in all 
pigs, both pre-prandially and post-prandially. Insulin doses were reduced but 
hypoglycemia persisted, and insulin doses were further reduced and finally 
removed. Pre-prandial blood glucose on day 3 after insulin removal was 14-16 
mmol/l. 72 hours after the repeated procedure for induction of diabetes with STZ, 
blood glucose was 12-18 mmol/l. 
Main results 
The main results of setup 3 were that strict aseptic technique ensured catheter 
function for over two months and that blood glucose could be reasonably tightly 
controlled. However, a very important result was the decreased insulin 
requirements. The methods applied were insufficient to determine the onset of 
decreased insulin requirement and its cause. 
The results are summarized in figure 2: 
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Figure 2: The specific methods applied in each setup and the feedback from previous 
setups 
Discussion 
This paper presents an explorative approach to the implementation of a basic 
type 1 diabetes model in Göttingen minipigs with tight blood glucose by insulin 
injections and with easy, non-stressful blood sampling opportunities. The work-
intensive, chronic model is suitable for physiology studies. Three setups were 
evaluated; the two last evolving from their predecessors. 
The main results are the following: 1) intensive training is needed for the animals 
to accept the procedures, 2) very strict aseptic procedures with all catheter 
maintenance govern the survival of animals, 3) acceptable blood glucose control 
can be established, but frequent blood sampling is needed, and 4) partial recovery 
from STZ diabetes can occur and may compromise the resemblance of human 
diabetes. 
The importance of training the animals to accept the experimental procedures has 
been described in some studies employing a model similar to the basic type 1 
diabetes minipig model of the present study (92,93). The application of the setup 
3 training protocol appears safe and effective in (re-) achieving animal 
experimental procedure acceptance. 
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Strict aseptic procedures in all catheter maintenance, including surgical insertion, 
have been emphasized in the literature (90-92,94). Very strict aseptic technique in 
catheter maintenance as a key complication prophylaxis improvement has been 
reported (95). Important fatal complications in the present study were 
thrombosis-related, commonly seen in animals with central venous catheters 
(96,97), even if sepsis-related complications are avoided (95,96,98). 
Blood glucose control by insulin injections was the major difficulty encountered in 
setup 3, while other, basal, method refinements ensured pig survival. To our 
knowledge, tight blood glucose control with multiple daily injections (compared to 
insulin pump therapy) in pigs has so far not been explored. However, pre-prandial 
blood glucose of 5-10 mmol/l by two daily subcutaneous injections of Velosulin 
and NPH porcine insulins are achievable (82) but accompanied by both hypo- and 
hyperglycemia (87). Surprisingly, weight-maintaining blood glucose control has 
required higher insulin doses than we found appropriate for reasonable tight 
blood glucose control (99-101). Insulin sensitivity variations in our animals may be 
governed not only by congenital biological variation but also variations in partial 
diabetes recovery and infection status, which was not investigated. 
The partial reversibility of diabetes status was unexpected, as stable diabetes is 
achievable for periods over 3 months with different STZ regimens (84,100,102-
104). However, 1-2 months’ reversibility of diabetes is not uncommon 
(79,86,100), especially in young animals (86), and is accompanied by non-diabetic 
C-peptide levels (87,100). Reversibility is probably to some extent dose-
dependent (100), but recovery has also been seen after STZ doses larger than 125 
mg/kg as used in the present study (86,100). The efficiency of 200 mg/kg STZ for 
induction of chronic (>16 weeks) duration of C-peptide-negative diabetes was not 
established until 2008 by Hara and co-workers (100), as Liu and co-workers (105) 
did not report diabetes duration in their 200 mg/kg STZ pigs. The present failure 
of repeated STZ-injection to re-establish diabetes could indicate that the partial 
recovery is caused by isolated beta-cell or small beta-cell cluster hypertrophy, as 
they, together with immature beta-cells, are less susceptible to STZ-induced 
destruction (86). Higher STZ doses and close monitoring of diabetes status by C-
peptide or intravenous glucose tolerance tests as employed by Canavan and co-
workers (82) are indicated. 
Diabetes status and infection status are important for effective blood glucose 
control. In laboratories not experienced with advanced models, this poses 
challenges to biochemical laboratory facilities, for instance for C-peptide radio-
immunoassays. This should be considered carefully when evaluating the feasibility 
of implementing a chronic diabetes animal model. 
Different fatal outcomes or premature euthanasia causes occurred. They can be 
classified as handling-related, diabetes recovery-related or of unknown cause. 
Because a single focus area cannot be identified, several setup refinements are 
needed. Some fatal outcomes, such as handling and catheter related fatalities, 
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may be preventable. Fatalities due to partial diabetes recovery may be 
preventable, but if not, their potential effects should be considered. 
In conclusion, our results indicate the possibility of implementing a chronic 
Göttingen minipig model of type 1 diabetes with near-normal blood glucose, 
controlled by insulin injections, and easy, non-stressful venous blood sampling 
access. A high success rate can be assured with good training of the animals, use 
of appropriate surgical and catheter maintenance techniques, and systematic 
diabetes status monitoring. 
However, researchers should carefully ensure adequate experience, sufficient 
time commitments and appropriate laboratory facilities. If these resources are 
lacking, the use of animals will be highly unethical and the projects will most likely 
fail. 
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DISCUSSION AND CONCLUSIONS 
This section of the thesis gives a general 
discussion of the four works and their 
relations, suggests further work and 
provides the conclusions of the PhD-
thesis 
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10. General discussion 
Background, methods, and results 
The Somogyi effect or long-term glucose counter-regulation to hypoglycemia has 
been explored for half a century due to of the challenges that it poses to blood 
glucose control, as blood glucose control is crucial to diabetic patients (8). The 
long-term glucose counter-regulation to hypoglycemia is hypothesized to manifest 
itself as a (relative) hyperglycemia which may occur after hypoglycemia (27-
33,56,58,59), maybe following a delay of a few hours. The previous studies include 
retrospective (27,28,30,31,42) and prospective approaches (26,29,32,43,45-47). 
Both the observational (nocturnal) approach (27,28,30,31,42) and the more 
commonly applied interventional approach (26,29,32,43,45-47) to hypoglycemia 
have been applied. Despite extensive research, no consensus exists regarding the 
existence of the long-term glucose counter-regulation or regarding its quantitative 
characteristics (33,64). This is reflected in the substantial differences between the 
study protocols applied, for instance regarding study period after hypoglycemia. 
The work described in this thesis explores different methodological approaches to 
the examination of the correlation between hypoglycemia and the hypothesized 
long-term glucose counter-regulation to add to the knowledge of the relevance of 
the long-term glucose counter-regulation to hypoglycemia in diabetic individuals’ 
real lives. 
An apparently ideal study (Chapter 6) was designed. The study design considered 
the every-day life aspect of the thesis objective and the methodological problems 
in hypoglycemia induction studies. The lack of known quantitative characteristics 
of the long-term glucose counter-regulation to hypoglycemia was also considered. 
Thus, in the apparently ideal study we compared CGM sensor glucose after 
spontaneous hypoglycemia with CGM sensor glucose in control periods free from 
hypoglycemia and near-hypoglycemia. Three additional studies were designed to 
explore potential solutions to the methodological challenges of the apparently 
ideal study. First, to handle the potential lack of uniformity in every-day life 
conditions and the lack of comparable background data in hypoglycemia and 
hypoglycemia-free control data, a method was developed for balancing 
unmatched background data by the use of a metabolic model in retrospective 
observational studies. This method was presented in the background data 
balancing study (Chapter 7). Second, to substitute the potentially non-existing 
hypoglycemia-free control data, a method was applied using a metabolic model as 
a simulation tool for generation of retrospective control data in observational 
studies. This method was presented along with the results from the application of 
it in the control data substitution study (Chapter 8). Third, to proactively approach 
the potential inappropriateness in data collection caused by insufficient 
understanding of the long-term glucose counter-regulation and the lack of 
repetition opportunities in retrospective analyses, an animal model was 
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implemented as a continuous and prospective source of data. The work with the 
animal was presented in the animal study (Chapter 9). 
In the apparently ideal study (Chapter 6), the sensor glucose was similar after 
hypoglycemia and in the control period free from hypoglycemia and near-
hypoglycemia. However, the insulin intake after hypoglycemia, compared with the 
intake during the control period, was on average 17% higher and the 
carbohydrate intake was 20% lower. Both differences in background data act to 
lower the blood glucose, so with similar insulin and carbohydrate on both days,  
CGM glucose could be anticipated to be higher after hypoglycemia than during 
control periods. The unmatched background data balancing method presented 
(Chapter 7) appears to be feasible in a number of applications but currently only 
pilot use has been employed. In one subject, pilot use indicated a clear 
hypoglycemia-related hyperglycemia whereas no indications of the hypothesis 
were observed in another subject. Control data substitution by a computer model 
(Chaper 8) indicated that the measured CGM glucose was significantly higher after 
hypoglycemia than anticipated by the simulation tool, the relative hyperglycemia 
beginning 8 hours following hypoglycemia and lasting for 13 hours. The animal 
model work (Chapter 9) indicated that insufficiencies in early versions of the 
model had fatal effects, but with proper animal training, strict aseptic catheter 
maintenance and acceptable blood glucose control combined with stable and 
monitored diabetes status, a feasible experimental model could probably be 
implemented. 
Relations between the studies in the thesis 
This thesis presents four explorative methodological approaches to the analysis of 
long-term glucose counter-regulation to hypoglycemia. Two of these 
methodological approaches (Chapters 7 and 9) focused on method development 
or method implementation, which means that only two actual method 
applications have been employed; in the apparently ideal study (Chapter 6) and in 
the control substitution study (Chapter 8). 
The results of the apparently ideal study are not conclusive regarding the 
correlation between hypoglycemia and a (delayed) hyperglycemia relative to the 
non-hypoglycemia case. Background data on insulin and carbohydrate intake may 
suggest that a relative hyperglycemia would be observed if background data were 
similar after hypoglycemia and in the control period, and would consequently 
support the hypothesis of a long-term glucose counter-regulation to 
hypoglycemia. However, it is not evident in the present CGM glucose data. The 
results from the control substitution study support the suggestions in the 
apparently ideal study, as they show pronounced hyperglycemia following 
hypoglycemia compared to the simulations from the computer model. The delay 
of approximately 8 hours before onset of relative hyperglycemia in the control 
substitution study may also be argued to correspond with the insulin and 
carbohydrate intake findings in the apparently ideal study. The short acting insulin 
doses within 8 hours after hypoglycemia are mainly similar or even smaller than in 
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the first 8 hours of the control period. The higher insulin doses after 8 hours 
following hypoglycemia can be interpreted as reactions to arising apparent 
hyperglycemia. It should be stressed, however, that this is highly speculative. It 
should also be noted that the patient groups differ in glycemic control so the 
results in one study may not correspond to those of the other. 
The relevance of a method for balancing unmatched background data (Chapter 7) 
is evident from the apparently ideal study as the dissimilar background data found 
in this study prohibit direct comparison of hypoglycemia data with control data. 
Indications regarding the correlation between hypoglycemia and a subsequent 
(relative) hyperglycemia and thus the hypothesis of the long-term glucose 
counter-regulation can be found in the apparently ideal study only because the 
differences in average insulin and carbohydrate intake both have hypoglycemic 
effects. If differences with similar magnitude but opposite directions were seen, 
no indications could be argued. The method for balancing unmatched background 
data would, on a patient-specific level, aid in determining the net effect of 
unequal background data, but the method naturally requires background data 
which may be a limiting factor in its application. 
Also the relevance of control data generation by means of a computer model was 
illustrated by the apparently ideal study as control periods free from both 
hypoglycemia and near-hypoglycemia could be identified corresponding to only 
23 of 64 of the hypoglycemic events. 
Analysis of the data in the apparently ideal study revealed the relevance of a 
continuous source of data for determination of necessary precautions and 
requirements for data collection and data analysis due to insufficient present 
knowledge on the impact of previous hypoglycemia on the effect of later 
hypoglycemia and its correlation to a relative hyperglycemia in the long-term 
glucose counter-regulation. Using an animal model as a continuous data source 
(Chapter 9) could mainly help to determine whether or not interactions from 
previous hypoglycemia occur, and whether or not the strict hypoglycemia 
inclusion criteria in the apparently ideal study were required. 
The two methods for managing insufficient control data, targeting incomparability 
of background data or lack of control data, could be applied also in the animal 
model for detailed data analysis. However, their application requires the 
construction of a computer metabolic model similar to the DiasNet model used in 
the control data substitution study serving as an example in the background data 
balancing method. This construction is certainly feasible, but it may not be 
required, as very controlled and thus equal conditions may be achieved in animal 
models and this is one of such animal models’ core advantages. Hereby animals 
can provide high quality control data. 
Limitations resulting from the use of existing data sets 
The studies included in the thesis provide a first exploration of various approaches 
to the analysis of the long-term glucose counter-regulation to hypoglycemia.  
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Regarding the three human studies, this novelty of the work has enforced the use 
of existing data sets. In the apparently ideal study, the constitution of these 
existing data sets governed exclusion of otherwise includable hypoglycemic 
events due to lack of control periods. In the control data substitution study, the 
constitution of the existing data sets governed the use of subjects of poor 
glycemic control with frequent hypoglycemia. In addition to the small sample sizes 
caused by the use of existing data sets, impaired comparability of the results from 
the apparently ideal study and the control substitution study due to incomparable 
subject groups is also a consequence of the reuse of existing data sets. 
Relation to previous work 
The long-term glucose counter-regulation has been studied previously but 
without the study designs presented in this thesis (analyzing spontaneous 
hypoglycemia in CGM data with no restrictions on hypoglycemia time and with 
long study durations).  
CGM data analysis has been applied by Hoi-Hansen and colleagues (30) and 
Guillod and colleagues (28) but only for nocturnal glycemia stratification studies. 
As the control data substitution method study in this thesis indicated no 
difference in CGM to simulated glycemia difference after nocturnal and daytime 
hypoglycemia, the limitation of the analysis to only nocturnal hypoglycemia 
appears unnecessary, at least if the hypothesized long-term glucose counter-
regulation to hypoglycemia is interpreted not to relate to only nocturnal 
hypoglycemia.  
Comparison of glucose after hypoglycemia with glucose in control periods free 
from hypoglycemia (and near-hypoglycemia) as in the apparently ideal study in 
this thesis has been applied by Perriello and colleagues (43), Hirsch and colleagues 
(29), and Tordjman and colleagues (32) in studies applying the intervention 
glycemia control and true control study design. The use of control periods free 
from both hypoglycemia and near-hypoglycemia in the apparently ideal study 
mimics the hypoglycemia prevention by glucose infusion in the three studies just 
mentioned. However, the use of induced hypoglycemia, hospitalized subjects and 
glucose infusion for hypoglycemia prevention pose relevant differences between 
these former studies and the apparently ideal study. Considering the differences 
in carbohydrate intake found in the apparently ideal study, the glucose infusion 
for hypoglycemia prevention (and possibly higher glucose supply in the control 
day than in the hypoglycemia day) in the intervention glycemia control and true 
control studies mentioned above emphasizes the need for methods capable of 
canceling or at least minimizing the effect of different background data, like the 
background data balancing method. 
Considering the day-to-day variations in background data found in the dataset 
analyzed in the apparently ideal study and the frequency of hypoglycemia in the 
dataset analyzed in the control data substitution study, the controlled settings in 
the intervention glycemia control and true control studies and the insulin 
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resistance studies are relevant in order to ensure comparability within each 
patient. Hereby the widespread exclusion of hypoglycemic events due to lack of 
hypoglycemia-free control data in the apparently ideal study may be avoided, and 
the study is therefore more cost-effective regarding cost per includable 
hypoglycemia. This is especially relevant in studies of hospitalized subjects, but 
the introduction of methods for background data balancing or control data 
substitution reduces this cost per includable hypoglycemia. More subjects can 
then be included in the study and the power of the study will subsequently 
increase. 
Considering that only a correlation between hypoglycemia and a (relative) 
hyperglycemia manifestation of a long-term glucose counter-regulation to 
hypoglycemia has been explored in the studies in this PhD-thesis, it is not relevant 
to relate to the causality-oriented studies of Kollind and colleagues (45) and 
Fowelin and colleagues (26). However, the causal relationship is definitely 
relevant for exploration, and this can be accomplished in an animal model 
implemented as described in this thesis. Animal models constituted by 
spontaneously diabetic cats and dogs have been used for the exploration of the 
long-term glucose counter-regulation (62,106). Pig models have been used for 
hypoglycemia studies, but not for studies of the long-term glucose counter-
regulation to hypoglycemia. 
Future work 
Future work should further explore the correlation between hypoglycemia and 
the long-term glucose counter-regulation to hypoglycemia as well as seek to 
establish the causal relationships governing the correlation. 
Such work could include both application of the methods presented on existing 
glucose data as presented in this PhD-thesis and collection of new data intended 
for the exploration of the long-term glucose counter-regulation to hypoglycemia.  
Regarding further exploration of the correlation between hypoglycemia and a 
manifestation of the long-term glucose counter-regulation to hypoglycemia, the 
apparently ideal study (Chapter 6) proved a feasible approach despite the high 
rate of exclusion of subjects and hypoglycemic events. Thus, access to and 
analysis of similar data sets would be relevant and should be possible with the 
increased use of continuous glucose sensors for numerous research purposes. 
Thorough application on numerous other datasets of the methods used in the 
apparently ideal study could also assist in the quantitative characterization of the 
manifestation of long-term glucose counter-regulation and the variations in 
manifestations. This is necessary to determine the relevance for diabetic patients’ 
glycemic control. Also, it appears obvious to apply the background data balancing 
method and the control data substitution method to the dataset analyzed in the 
apparently ideal study, but due to the lack of carbohydrate intake data in some of 
the subjects in this dataset, the control substitution method (Chapter 8) is the 
only one applicable. Use of an animal model to further characterize the 
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interactions between subsequent hypoglycemia and the effect of subsequent 
hypoglycemia on the correlation between hypoglycemia and relative 
hyperglycemia as in the long-term glucose counter-regulation could, however, 
increase the number of subjects with includable hypoglycemia if such interactions 
are non-existing. Then, more subjects with sufficient background data are likely to 
be included as well, allowing the use of the background data balancing and 
control data substitution methods. 
For exploration of the causal relationship governing the correlation between 
hypoglycemia and the long-term glucose counter-regulation manifestation as a 
(relative) hyperglycemia, prospective intervention studies as opposed to 
observational human studies appear relevant. However, such studies make it 
essential to overcome interference from the subject’s natural hypoglycemia 
pattern, should such a pattern exist. The animal model could serve as a 
continuous data source in determining the appropriate design and protocol for 
human studies. 
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11. Conclusion 
In this PhD-thesis the exploration of different approaches to the relative 
hyperglycemia denoting the long-term glucose counter-regulation to 
hypoglycemia is described. The long-term glucose counter-regulation to 
hypoglycemia may pose challenges to the important glucose control in type 1 
diabetes and it has not been sufficiently researched. 
In 2 of 4 studies employed, retrospective comparison of CGM glucose after 
hypoglycemia and in control data free from hypoglycemia (simulated data in one 
study) indicated a correlation between hypoglycemia and the long-term glucose 
counter-regulation. In 2 other studies employed, feasible methods for further 
exploration of the correlation, and, in one of them, also the causalities relating 
hypoglycemia and the long-term glucose counter-regulation to hypoglycemia, 
were identified. 
Through this PhD-thesis, the relevance of further studies of the long-term glucose 
counter-regulation has thus been underlined, and means for related further 
studies have been indicated. 
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Abstract 
Background:  
The hypothesis of a long-term glucose counter-regulation has gained recent interest with 
the development of continuous glucose monitoring (CGM) technologies, but no long-term 
studies have been performed. The aim of this study was to evaluate the hypothesis using 
CGM. 
Method:  
Analysis was conducted of insulin treated diabetics’ CGM data. For each patient, 
hypoglycemic events were identified when blood glucose was <54 mg/dl for >15 minutes 
and included for those cases where a hypoglycemia-free period existed within 15 hours 
before and after and where control, free of near-hypoglycemia (blood glucose <72 mg/dl 
for 15 minutes) period could be identified at the same time of the day as the hypoglycemia. 
Blood glucose profiles for each hypoglycemia with near-hypoglycemia-free control were 
compared. Insulin and carbohydrate intake were also compared. 
Results:  
10 hypoglycemic events in 10 type 1 diabetics were included. No significant difference in 
blood glucose was seen after hypoglycemia, but insulin intake was 5.7 IU (higher for the 
first 24 hours after hypoglycemia than in the control period. The carbohydrate intake was 
38 g lower after hypoglycemia than in the control periods.  
Conclusion:  
The little difference in blood glucose indicates no long-term glucose counter-regulation to 
hypoglycemia. However, the higher insulin intake and lower carbohydrate intake after 
hypoglycemia both have hypoglycemic effects, and the blood glucose would therefore 
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probably be higher after hypoglycemia than in the control period if the insulin and 
carbohydrate intakes had been similar. 
Introduction 
Hypoglycemia-induced delayed 
hyperglycemia, first hypothesized by 
Somogyi in 1951, has received renewed 
interest1;2. The recent interest is largely 
governed by the data resolution potential 
introduced by the continuous glucose 
monitoring (CGM) technologies, as these 
technologies enable reliable, long-term 
and very frequent sampling of glucose 
values comparable to blood glucose 
values3;4. 
Over the years, different labels have been 
applied to what is apparently the same 
phenomenon: ‘Somogyi phenomenon’, 
‘Somogyi effect’1;2;5-17, ‘rebound 
hyperglycemia’18, and ‘long-term 
glucose counter-regulation to 
hypoglycemia’19. This paper uses the 
latter term. 
Various study designs have been applied 
for analyzing long-term glucose counter-
regulation to hypoglycemia 1;2;5;9-13;15;17;20-
23. Study designs vary in hypoglycemia 
time, as some researchers have explored 
only nocturnal hypoglycemia, which is 
suggested to cause morning 
hyperglycemia1;2;11;13;24-26, whereas others 
have not restricted themselves to 
nocturnal hypoglycemia5;9;27-29. Study 
designs also vary regarding the extent of 
hyperglycemia, as some groups have 
considered only absolute hyperglycemia 
to indicate the existence of a long-term 
glucose counter-regulation to 
hypoglycemia5;11;24, whereas other 
designs have considered hyperglycemia 
only relative to glucose values in cases 
with no preceding hypoglycemia 13;25-27. 
Finally, study designs vary regarding 
duration, as they range from rather short 
(0-6 hours)1;5;11;16;17;28 to longer (8-24 
hours)13;15;24;26;27;30. Study designs have 
also varied due to different hypotheses 
regarding manifestations and due to 
practical methodological limitations, for 
instance regarding (blood) glucose 
sampling frequency. 
A more cautious approach to the 
exploration of the long-term glucose 
counter-regulation to hypoglycemia may 
be a long-term analysis of high-
resolution data with no assumptions 
regarding the time of day of the 
occurrence of hypoglycemia, but this has 
never been applied using the CGM 
technology. 
This paper presents a retrospective 
analysis of a blood glucose sensor data 
set for the evaluation of a hypothesis of a 
long-term glucose counter-regulation to 
hypoglycemia, manifested as a delayed 
hyperglycemia relative to control, 
hypoglycemia-free glycemia. 
Materials and methods 
The study was conducted at four centers 
(Medical Department M, Aarhus 
University Hospital, Denmark; Profil 
Institute for Metabolic Research, Neuss; 
German Diabetes Research Institute at 
the Heinrich-Heine University of 
Duesseldorf; and Department of 
Pharmaceutical Technology and 
Biopharmacy, University Center of 
Pharmacy, University of Groningen, The 
Netherlands). The four centers 
participated in the clinical in vivo 
evaluation of the SCGM 1 system 
(Roche Diagnostics, Mannheim, 
Germany). 
Patients who participated in the 
experiment were recruited from their 
respective outpatient clinics. Both type 1 
and type 2 diabetics were included. The 
patients were encouraged to live their 
normal every-day lives with their normal 
therapy (primarily insulin), and they 
were further encouraged to perform the 
same amount of activities on all study 
days. They were not given access to 
CGM data during data collection.  
All patients received written and oral 
information according to the Declaration 
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of Helsinki II and signed consent forms. 
The study was approved by the local 
ethics committees of the four centers 
participating in the study and was 
performed according to Good Clinical 
Practice Guidelines. 
SCGM 1 system 
The SCGM 1 system is based on the 
glucose oxidase principle and consists of 
a sensor unit device and a belt-held 
sensor holding the microdialysis system. 
The system allows up to 120 hours of 
minutely dialysate glucose 
measurements. Data are stored by 
custom designed software, and on-line 
display of dialysate glucose is transferred 
wirelessly from the sensor unit to the 
portable data manager. Additional 
information (insulin administration, 
meals, exercise, etc.) can be entered as 
separate events in the data managing 
device. The sensor unit uses a roller 
pump that provides a push-pull flow, 
resulting in a perfusion of the 
microdialysis membrane with 0.3 µl/min. 
The perfusion fluid (Ringer chloride, 
Na+147 mmol/liter; K+ 1.4 mmol/liter; 
Ca2+ 2.3 mmol/liter; Cl- 156 mmol/liter, 
pH 6; osmolality 290 mosmol/kg) passes 
through the catheter, achieving 
approximately 95% equilibration with 
the interstitial fluid 31. Glucose oxidase is 
mixed with the dialysate and passes the 
ex vivo sensor, creating a current in the 
nanoampere range. The current is 
averaged over 60 seconds, and data are 
stored. 
Study procedure 
The microdialysis probe was inserted 
into the subcutaneous abdominal adipose 
tissue after skin puncture with a 16-
gauge needle. The sensor was left in 
place for 4 days. For calibration of the 
SCGM 1 system, spot capillary glucose 
measurements were used. 
Data analysis 
The sensor glucose profiles were 
calibrated by fitting the paired meter data 
and sensor data to a line and adjusting 
the sensor data to the gain and offset 
identified by the fitting. 
All hypoglycemic events were identified 
in the calibrated data. An episode of 
hypoglycemia was defined to be at least 
15 minutes of sensor glucose ≤54 mg/dl, 
and at least 10 minutes of sensor glucose 
≥54 mg/dl or missing data defined the 
end of a hypoglycemic episode. All 
episodes of missing data were identified 
in the uncalibrated data. A data missing 
episode was defined to be at least 10 
minutes of missing data (the value 0 
saved by the glucose sensor), and at least 
10 minutes of non-missing data defined 
the end of a data missing episode. Near-
hypoglycemic events for definitely 
hypoglycemia-free control periods, 
despite sensor inaccuracies, were defined 
to be at least 15 minutes of sensor 
glucose ≤72 mg/dl, and at least 10 
minutes of sensor glucose ≥72 mg/dl or 
missing data defined the end of a near-
hypoglycemic episode 
Hypoglycemic events beginning ≤20 
hours after the data collection start were 
excluded. Of the hypoglycemic events 
beginning >20 after the start of data 
collection, the hypoglycemias preceded 
by missing data episodes within 15 hours 
were excluded. Of the hypoglycemic 
events not preceded too recently by data 
collection start or missing data episodes, 
hypoglycemias preceded by any 
hypoglycemia (not necessarily without 
too recent data collection start or missing 
data episode) within 15 hours were 
excluded. Of the hypoglycemic events 
free of recent data start, missing data 
episodes or hypoglycemia, 
hypoglycemias followed by any 
hypoglycemia (not necessarily free of 
recent data collection start, missing data 
episodes, or hypoglycemia) within 15 
hours were excluded. Control periods 
were identified at the same time of the 
day as the hypoglycemia to which they 
corresponded. Control periods were 
excluded if they occurred <20 hours 
before data collection start, or if they 
were preceded or followed by near-
hypoglycemia or missing data episodes 
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within 15 hours (from the time of 
candidate control period start). 
Hypoglycemic events in subjects with no 
information on insulin injection during 
the data collection period were excluded, 
as were patients not treated with multiple 
insulin injections but with continuous 
subcutaneous insulin infusion (insulin 
pump). 
For each hypoglycemia, the sensor 
glucose difference between 
hypoglycemia day and control day 
(control days, if more control days were 
found for a specific hypoglycemia) was 
calculated as hypoglycemia day sensor 
glucose minus control day sensor 
glucose. 
Data calibration and hypoglycemia 
analysis was performed using Matlab 
(the Mathworks, Inc., Natick, MA). 
Hypoglycemia and control period data 
analysis was performed using the Excel 
spreadsheet program (Microsoft 
Corporation, Redmond, WA). 
Results are given as mean ±SD (range). 
Results 
159 subjects were included, of which 146 
were diabetic (135 type 1 diabetic). Of 
the diabetics, 91  were male. Age was 36 
± 12 (17-72) years, diabetes duration 15 
± 10 (0-41) years. BMI was 24.9 ± 4.4 
(17.9-44.5). HbA1C was 8.1 ± 1.7 (5.3-
14.1). Only one subject was not treated 
with insulin, and 28 were on continuous 
subcutaneous insulin infusion. 
In total, 134 hypoglycemic episodes 
were identified. Of the 134 
hypoglycemic episodes, 36 were 
excluded because they occurred <20 
hours before the start of data collection, 
none were excluded because they were 
preceded by missing data within 15 
hours, 70 were excluded because they 
were preceded or followed by other 
hypoglycemias within 15 hours. This left 
64 hypoglycemias for control period 
identification. There were 23 
hypoglycemias in 20 subjects that had 
corresponding control periods. Of these, 
11 hypoglycemias in 11 subjects (6 
female) were supported by insulin data, 
but one female was treated with 
continuous subcutaneous insulin infusion 
and excluded. Thus, 10 patients (5 
female) were included in the study. Four 
patients also had carbohydrate intake 
data. All 10 were type 1 diabetics. Age 
of included diabetics was 34 ± 12 (20-
59), diabetes duration 16 ± 9 (7-34), BMI 
24.6 ± 4 (20.4-34.0), HbA1C 7.9 ± 2 
(6.1-10.9). 
One hypoglycemia was nocturnal (12 pm 
– 6 am), one was before noon (6 am – 12 
am), 7 were after noon (12 am – 6 pm) 
and one was in the evening (6 pm – 12 
pm). No apparent difference in sensor 
glucose difference was seen with respect 
to hypoglycemia time. 
Data for insulin injections and for 
carbohydrate intake, where recorded, is 
shown in table 1. Mean total 
carbohydrate intake after hypoglycemia 
was 152 g, in the control period 190 g 
(n=4). Mean total insulin intake after 
hypoglycemia was 38.6 IU, in the control 
period 32.9 IU (n=10). 
There was no difference in long-acting 
insulin on intervention (hypoglycemia) 
and control periods. 
No difference was seen in sensor glucose 
(hypoglycemia minus control) (Figure 
1). 
Discussion 
This study employs a retrospective 
analysis of blood glucose sensor data set 
for the evaluation of a hypothesis of a 
long-term glucose counter-regulation to 
hypoglycemia. The hyperglycemia 
manifesting the long-term glucose 
counter-regulation to hypoglycemia was 
expected to be delayed and to appear  
relative to the glycemia in control, 
hypoglycemia-free cases rather than in 
absolute terms. 
The occurrence of hypoglycemia 
corresponds to the prevalence of 
hypoglycemia detected by continuous 
glucose monitoring systems in unspecific 
patient groups 32. The included number 
of hypoglycemic events, however, is low 
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and arises from the exclusion of 
hypoglycemias preceded or followed by 
hypoglycemias, indicating that patients 
rarely have a single hypoglycemia in 
otherwise non-hypoglycemic periods. 
The long required hypoglycemia-free 
period before and after the included 
hypoglycemias  is shown to be 
 
 
Table 1: Injected short acting insulin (IU) and carbohydrate intake (g) during 
24 hours of intervention or control in 2-hour time slots 
 Time slot, hours after hypoglycemia time 
Sub- 
ject 
Event 0-2 2-4 4-6 6-8  8-10 10-
12  
12-
14 
14-
16 
16-
18 
18-
20 
20-
22 
22-
24 
Sum 
1 
CHO-H 
Ins-H1 
CHO-C 
Ins-C1
  30 
8 
 20 
4 
70 
15 
 60 
12 
60 
12 
 80 
18 
85 
24 
   200 
42 
215 
51 
2 
CHO-H 
Ins-H2 
CHO-C1 
Ins-C12 
CHO-C2 
Ins-C22
50 
14 
50 
13 
70 
13 
30 
 
10 
 
15 
10 
 
10 
 
20 
 
16 
60 
16 
60 
16 
10 
 
35 
 
20 
 
 
40 
  60 
16 
10  
 
50 
16 
50 
18 
 
 
30 
170 
46 
285 
45 
235 
47 
3 
CHO-H 
Ins-H 
CHO-C1 
Ins-C1 
 
 
 
36 
82 
 
102
 12 
121
   
12 
48 
112
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
24 
22 
- 
- 
 
 
- 
- 
72 
23 
48m 
23m
4 
CHO-H 
Ins-H1 
CHO-C1 
Ins-C11
15 55 
12 
55 
 30     65 
14 
65 
12 
  
12 
50 
 
 
 
30 
165 
38 
200 
12 
5 Ins-H
1
Ins-C11 
Ins-C21
12 
12 
12 
      
 
 8 
8 
8 
 
 
- 
10 
10 
- 
 30 
30 
20m
 
6 
Ins-H1 
Ins-C11
Ins-C21
8 
8 
8 
    
 
10 
  8 
8 
- 
 
2 
- 
 
6 
- 
8 
 
- 
 
 
- 
24 
24 
18m
7 Ins-H
1 
Ins-C1
8 
 
10 
9 
     8
 
4 
4 
8 
8 
 6 
8 
44 
29 
 
8 
Ins-H1 
Ins-C11 
Ins-C21
8 
8 
8 
       
 
8 
8 
8 
 4 
4 
8 
 20 
20 
24 
 
9 
Ins-H1 
Ins-C11 
Ins-C21
10
12
 
    6   10 
12 
16 
22 
 
6 
 
12 
10 
 48 
36 
32 
 
10 
Ins-H 
Ins-C1 
Ins-C2 
 121 21 
111
51
 
101
 
 
41
  
11
102 61
81
21
51  
 
101
161
21
41 
32 
21 
–H: hypoglycaemia (intervention), –C1 (and –C2, if two control periods were found): control period(-s) 
1  Regular insulin, 2 Humalog insulin 
- No data due to short data collection period, m Total period includes missing insulin and/or meal data. 
 
reasonable considering the long duration 
of long-term glucose counter-regulation 
to hypoglycemia-like physiological 
simulation errors previously reported by 
the authors of the present paper in 2008. 
The requirement of control periods free 
of not only hypoglycemia but also near-
hypoglycemia mimics the advantages of 
prospective studies typically preventing 
hypoglycemia by glucose infusion on 
control days 9;11;13;17;25-27;29. 
The glucose difference varied between -1 
and 1 mmol/l for the 4-22 hours after 
hypoglycemia. The hypoglycemia and 
control day carbohydrate and insulin 
intakes were not comparable. The insulin 
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intake difference was, on average, 5.7 IU 
higher in the 24 hours following 
hypoglycemia compared to the 
hypoglycemia-free control period, and 
the carbohydrate intake was on average 
38 g higher.  
The little difference in glucose levels 
between hypoglycemia and control data 
indicates no apparent relative 
hyperglycemia. 
 
 
Figure 1: Sensor glucose difference after 
hypoglycemia (hypoglycemia minus control). 
Average difference is 0.1 mmol/l 
 
Also, no trend in the variations can be 
identified; thus, no indications regarding 
delay of hyperglycemia are found. This 
could initially be interpreted as 
contradictory to the hypothesis of a long-
term glucose counter-regulation to 
hypoglycemia evident as a delayed 
(relative) hyperglycemia. However, the 
rather similar glucose profiles result from 
substantially different background data 
on insulin and carbohydrate intake, both 
contributing to lowering the glucose on 
the hypoglycemia day compared to the 
control day. There is a substantially (5.7 
IU, 17%) higher intake of insulin on the 
hypoglycemia day than on the control 
day and a substantially lower 
carbohydrate intake (38 g, 20%). A 
clinical rule of thumb says that each IU 
of insulin reduces the blood glucose 18-
36 mg/dl33. Hence, the sole effect of the 
increased insulin doses following 
hypoglycemia is likely to have 
suppressed the blood glucose 
significantly to control day levels 
following hypoglycemia. Despite 
hypoglycemia and control day non-
comparability regarding carbohydrate 
and insulin intake, we therefore interpret 
the results as indicative of a long-term 
glucose counter-regulation to 
hypoglycemia. Comparability of 
independent variables on hypoglycemia 
and control days is not ensured in a 
substantial part of the previous studies of 
the long-term glucose counter-regulation 
to hypoglycemia. This may explain the 
negative findings of the effect, at least in 
some studies. However, doses and times 
of insulin injections are reported to be 
the same in the study by Hirsch and 
colleagues 13, and non-comparability of 
insulin background data can thus not 
explain the negative finding of a long-
term glucose counter-regulation. It 
should be noted that the hypoglycemias 
studied by Hirsch and colleagues 13 were 
nocturnal and induced, while the 
hypoglycemias in the current study were 
primarily in the daytime and occurred 
spontaneously. Reactions to induced 
hypoglycemia, especially in patients 
where regular subcutaneous insulin 
injections have been discontinued before 
the study, may be disrupted by a 
different native pattern of hypoglycemia. 
It appears, therefore, that a reasonable 
approach is to investigate only 
spontaneous hypoglycemias, as in the 
current study and in the studies 
conducted by Høi-Hansen and co-
workers 1, Guillod and co-workers 2, 
Gale and co-workers 11, Stephenson and 
Schernthaner 16, Havlin and co-workers 
24, or to investigate induced 
hypoglycemias only in patients with 
hypoglycemia that is also evident on an 
intervention-free control period, as in the 
study by Hirsch and co-workers 13. 
 
The limited number of  hypoglycemic 
events included and the lack of 
comparable data in hypoglycemia and 
control days in this study underline the 
weakness of retrospective analysis of 
phenomena such as the long-term 
glucose counter-regulation to 
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hypoglycemia, even in large data sets. 
Further work in the exploration of the 
long-term glucose counter-regulation to 
hypoglycemia should thus approach this 
limitation and carefully design data 
collection that takes into consideration 
comparability of days and the influence 
of native hypoglycemia patterns. 
Conclusions 
The CGM glucose after hypoglycemia 
was similar to the CGM glucose in 
hypoglycemia-free control periods, but 
larger insulin doses and smaller meals 
after hypoglycemia indicate that the 
hypothesis of a long-term glucose 
counter-regulation to hypoglycemia 
cannot be rejected but is justified for 
further research. 
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Model-based balancing of unmatched data in model-generated  
hypothesis evaluation 
Mette Dencker Johansena, Ole Hejlesena
aDepartment of Health Science and Technology, Aalborg University, Denmark 
Abstract 
Systematic deviations between data and pharmacokinetic 
models can be a source of test-relevant hypotheses. 
Incomparability of independent variables in intervention 
and control data compromises hypothesis evaluation using 
conventional statistical methods. This paper proposes a 
method for hypothesis evaluation utilizing a physiological 
model for balancing out incomparable independent 
variables. The method prescribes calculation of the 
deviation of data from model simulations in an intervention 
period featuring the event or behavior described by the 
hypothesis and in a control period not featuring it, 
resulting in two deviations. These can be compared by 
conventional statistical methods. Model inclusion of all 
independent variables except for that described by the 
hypothesis is required. An example of the use of the model 
in diabetes hypoglycemia data underlines its potential. The 
main disadvantage is the need for control data, which may 
be difficult to identify. Further evaluation is needed to 
explore the method’s appropriateness compared to 
conventional hypothesis evaluation. 
Keywords:  
Biological models, Computer Simulation, Computing 
Methodologies, Type 1 Diabetes Mellitus. 
Introduction 
Pharmacokinetic models, including physiological models 
of human metabolism of a wide range of endogenous 
compounds, have been developed to aid patients, health 
care professionals and researchers in monitoring, adjusting 
and developing treatments.  
 
Observation of systematic deviations in the simulations of 
such models can generate hypotheses if prominent 
deviations from data occur exclusively and consistently in 
relation to one particular event. We have previously used a 
physiological model of the human carbohydrate 
metabolism in diabetes as a generator of hypotheses 
regarding the effect of alcohol[1] and hypoglycemia 
(unpublished data).  
 
Evaluation of a deviation-related hypothesis can be 
performed in at least two ways: comparing intervention 
data (including the event of interest) and control data (not 
including the event of interest), and comparing intervention 
data (including the event of interest) with model 
simulations. The first approach, comparing two data 
groups, requires the groups to be extensively comparable as 
regards all other independent variables/event than the one 
of interest. This similarity may be only scarcely achieved in 
data collected from patients living their everyday lives, an 
approach often preferred over controlled, in-hospital 
experiments due to cost minimization and patient 
convenience, if patients comply inadequately with 
instructions regarding their behavior during the 
experimental period. Incomparability of control data with 
intervention data precludes reliable interpretation of any 
significant difference as resulting from the event of 
interest. Conventional comparison of intervention data with 
control data may thus not be appropriate for evaluation of 
deviation-related hypotheses. The second approach, 
comparing data with model simulations, requires the model 
to include all relevant independent variables except for the 
one of interest. This requirement is difficult to meet in 
practice, as model complexity and computability are 
opposites. Insufficient model complexity precludes reliable 
interpretation of any significant difference as resulting 
from the event of interest, as in the case of incomparable 
intervention and control data. Thus, both approaches have 
their imperfections. 
 
The aim of this paper is to present a novel model-based 
method for evaluation of hypotheses when intervention 
data and control data are not comparable regarding 
independent variables. 
Method outline 
The method utilizes comparison of deviations of dependent 
variables in data from model simulations. The basis of the 
method is to use simulations from a model as expectancies 
and by these cancel out deviations between intervention 
and control data that originate from differences in 
independent variables. Hereby, only those deviations 
originating from the investigated event or behavior affect 
the result, and the imperfections of the purely data-based 
approach to deviation-related hypothesis evaluation are 
addressed. Using model simulations as expectancies for 
both intervention and control data addresses the 
imperfections of the model-based approach to deviation-
related hypothesis evaluation, as systematic errors in model 
simulations will be present in both expectancies and 
thereby cancelled out. 
 
For each includable incident of the investigated event or 
behavior, a model simulation is calculated for intervention 
and control periods, Si and Sc, respectively, from input of 
independent variables. These model simulations serve as 
expectancies that include no incidences of the investigated 
event or behavior, as the event or behavior is not 
considered by the model. 
 
The deviation from the model simulation is calculated for 
both intervention data and control data as Di and Dc, as data 
minus model simulation in Devi and Devc: 
iii SDDev −=    (1) 
ccc SDDev −=    (2) 
 22
The deviations in Equations (1) and (2) constitute measures 
of error, error being all aspects included in the data but not 
included in the model. Thus, the deviation is due to the 
errors ei and ec as described in Equations (3) and (4): 
iii eSD −=    (3) 
ccc eSD −=    (4) 
where ei and ec are systematic errors in the model. If the 
independent variables are reasonably similar, the 
systematic errors are comparable. However, the error 
component arising from the event or behavior described by 
the tested hypothesis, ehypothesis, contributes only to ei, not 
ec: 
hypothesisci ece −=   (5) 
The error component arising from the event or behavior 
described by the tested hypothesis is then calculated for 
each includable incident by re-arranging Equation (5) and 
combining Equations (1)-(4): 
)( cciicihypothesis SDSDDevDeve −−−=−=  (6) 
This difference is a measure of aspects represented in the 
intervention data (and not in the model) but not in the 
control data (nor in the model). The differences resulting 
from all included incidences of the investigated event or 
behavior can then be analyzed using normal statistical 
methods. Equation (6) thus describes the calculations 
involved in the method. 
 
As its primary assumption, the method for comparison of 
initially non-comparable intervention and control data 
assumes similarity of all independent variables not 
included in the model in both intervention and control data 
for each incident of the investigated event or behavior. 
Method evaluation and example use 
To illustrate the method, example use of it has been 
performed on the hypothesis of a long-term glucose 
counter-regulation to hypoglycemia in diabetes suggested 
by Hejlesen et al.[2]. The hypothesis describes that a 
hypoglycemic event causes a hyperglycemia relative to if 
no hypoglycemic event occurred. The hyperglycaemia is 
hypothesized to onset 6-8 hours after hypoglycemia and to 
wear off approximately 24 hours after hypoglycemia.[2] 
 
Example use of the method outlined above involves 
comparison of posthypoglycemia blood glucose data with 
corresponding simulations of blood glucose in two patients. 
A system for continuous glucose monitoring (CGM) was 
used as blood glucose data source, and DiasNet[3,4] was 
used as the source of model simulations.  
 
CGM data (CGMS®, Medtronic-MiniMed, Northridge, 
California) was collected in type 1 diabetic patients living 
their everyday lives. 
 
Simulations were performed inputting all meal and insulin 
data and glucose data from the CGM data sampled at the 
time of hypoglycemia, and 60 and 120 minutes before and 
after the hypoglycemia (the time of hypoglycemia in 
control data). Calculations, except from DiasNet 
simulations, were performed using Microsoft Office Excel 
2003 (Microsoft Corporation, CA). 
 
Figure 1 – Deviations (CGM minus simulated glucose) 
for intervention (Di, full) and control (Dc, broken) data 
for 24 hours following an early morning hypoglycemic 
event in a female diabetic. The difference between the 
two (intervention deviation minus control deviation) is 
indicated (ehypothesis, ●) 
 
Figure 2 – Deviations (CGM minus simulated glucose) 
for intervention (Di, full) and control (Dc, broken) data 
for 24 hours following a late afternoon hypoglycemic 
event in a male diabetic. The difference between the two 
(intervention deviation minus control deviation) is 
indicated (ehypothesis, ●) 
Figures 1 and 2 depict the deviations between data and 
simulations for a single patient each, for both the 
intervention period (Devi) and the control period (Devc), 
together with the difference between the two (ehypothesis). 
The intervention period and the control period cover the 
same time of the day, and the control period is free of prior 
hypoglycemia within 24 hours. 
 
The intake of carbohydrates and insulin injections 
(according to diary data) for 24 hours before and after 
hypoglycemia and for the corresponding control period can 
be seen in tables 1 and 2. 
Table 1 – Diary data for example patient 1 
 Hypoglycemia Control 
Total CHO (g) 
 
435 470 
Total rapid-
acting insulin 
104 104 
 23
 24
IU) 
Total long-
acting insulin 
(IU) 
100 100 
Table 1 - Total intake of carbohydrates and insulin for 24 
hours before and after (total 48 hours) hypoglycemia for 
the early morning hypoglycemic event in a female 
diabetic and for the corresponding control period. Units 
of insulin per gram carbohydrate are 0.47 for 
hypoglycemia data and 0.43 for control data.
Table 2 – Diary data for example patient 2 
 Hypoglycemia Control 
Total CHO (g) 
 
488 448 
Total rapid-
acting insulin 
IU) 
86 86 
Total long-
acting insulin 
(IU) 
28 30 
Table 2: Total intake of carbohydrates and insulin for 24 
hours before and after (total 48 hours) hypoglycemia for 
the late afternoon hypoglycemic event in a male diabetic 
and for the corresponding control period. Units of insulin 
per gram carbohydrate are 0.23 for hypoglycemia data and 
0.26 for control data. 
Discussion 
A method for deviation-related hypothesis evaluation is 
presented in this paper. The method describes comparison 
of deviations of data from simulations for intervention data 
(following the event or behavior in question) and control 
data. 
The method proposed in this paper assumes comparability 
for all non-hypothesis related errors. This requires 
similarity of the independent variables not included in the 
model in both intervention and control periods. This may 
be a reasonable assumption in some habit-oriented patient 
groups such as those with Type 1 diabetes. In general, 
however, careful handling of non-included behavior should 
be stressed.  In addition, an open mind towards identifying 
any possible relevant behavior should be stressed, together 
with patients’ compliance to uniformity during data 
collection. Diary data could aid in the latter. 
 
Example application of the method on two diabetics’ data 
results in very different indications regarding the 
hypothesis of a long-term hypoglycemic counter-
regulation. One patient exhibits the expected pattern of 
hyperglycaemia relative to the simulated glucose profile for 
15 hours, beginning 4 hours after the onset of 
hypoglycemia, and has no profound deviations from 
simulated glucose profile on the control day. This is 
consistent with the hypothesis of the long-term 
hypoglycemic counter-regulation. The second patient 
exhibits a less profound and shorter hyperglycaemia 
relative to the simulated glucose profile, both after 
hypoglycemia and in the control period. This is contrary to 
the hypothesis if truly no hypoglycemia is present before or 
in the beginning of the control period, and this is not 
indicated by sensor data, at least for the first 6 hours before 
the control period. These very different results indicate the 
expected reliance of the method’s result on the patterns in 
data as well as the inappropriateness of the method when 
used on only a very small dataset. Also, the importance of 
context considerations is stressed, as the units of insulin per 
gram carbohydrate are similar within patients but nearly 
doubled for patient 1 compared to patient 2. This is 
consistent with the observed association of the 
hypothesized long-term hypoglycemic counter-regulation 
with low insulin sensitivity as calculated by DiasNet. 
 
The major limitation to the application of the method 
described is the requirement of a control period free of the 
event or behavior in question. This control period may be 
difficult to establish. However, this is no different from the 
requirement of control data in conventional retrospective 
data analysis. Inclusion of model simulations to cancel out 
incomparability of independent variables in intervention 
data compared to control data alleviates the difficulties 
herein, as no matching of independent variables is needed 
but is instead accounted for by the model. 
Conclusion 
This paper outlines a method for hypothesis evaluation 
including model simulations as expectancies to cancel out 
incomparability of independent variables other than the one 
described by the hypothesis. An example use of the model, 
without a large-scale evaluation, has been performed and 
indicates the method’s relevance in data analysis. Large-
scale evaluation is necessary to determine advantages and 
disadvantages. The evaluation should include comparison 
of results obtained with this method and results obtained 
using conventional data comparison on the same data, in 
order to determine the comparability of results. 
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Abstract 
Background:   
The DiasNet simulation tool is based on accepted principles of physiology and simulates 
blood glucose concentrations accurately in type 1 diabetics during periods with no 
hypoglycemia. However, we have observed that following hypoglycemia, model 
simulations deviate significantly and systematically from actual blood glucose data. This 
led us to generate a hypothesis that delayed and prolonged hyperglycaemia occurs 
following hypoglycemia.  This study tests that hypothesis by comparing simulated and 
continuously measured blood glucose data. 
Methods:  
CGM (CGMS®, Medtronic-MiniMed, Northridge, California) data and diary (meals, 
insulin, self-monitored blood glucose) data were collected for 2 to 5 days from 17 Type 1 
diabetics with poor glycemic control. Hypoglycemic episodes (CGM <63 mg/dl for ≥20 
minutes) were identified in valid (well-calibrated) CGM data. For 24 hours after each 
hypoglycemic episode, a simulated (DiasNet) glucose profile was compared to the CGM 
glucose. 
Results:  
52 episodes of hypoglycemia were identified in valid data. All subjects had minimum 
one hypoglycemic episode. Ten episodes of hypoglycemia from 9 subjects were eligible 
for analysis. CGM glucose was significantly (p<0.05) higher than simulated blood 
glucose for a period of 13 hours, beginning 8 hours after hypoglycemia onset. 
Conclusions:  
The present data support the hypothesis of a long-term glucose counter-regulation to 
hypoglycemia.  The onset is typically 8 hours following the hypoglycemia and the 
duration up to 16 hours. The lack of evidence for this phenomenon in previous studies 
                                                 
1 Medical Informatics Group, Department of Health Science and Technology, Aalborg University, 
Denmark 2David A. Cavan, Bournemouth Diabetes and Endocrine Centre, Bournemouth Royal 
Hospital, United Kingdom 
_____________________________ 
The basic idea was presented at the Third Diabetes Technology Meeting in San Francisco, 2003 
_____________________________ 
Abbreviations: (CGM) continuous glucose sensor, (SMBG) self-monitored blood glucose, (BMI) 
body mass index  
_____________________________ 
Keywords: Continuous glucose sensors, Hypoglycemia, Physiopathology, Type 1 diabetes 
mellitus 
_____________________________ 
Corresponding author: David A. Cavan, Bournemouth Diabetes and Endocrine Centre, 
Bournemouth Royal Hospital, email: david.cavan@rbch.nhs.uk
 1
CGM glucose overshoot after hypoglycemia 
assessed by a simulation tool 
Dencker Johansen
 
may be explained by the 8 hour delay. Further studies are required to fully determine the 
existence of the proposed long-term glucose counter-regulation to hypoglycemia. 
Introduction 
People with Type 1 diabetes mellitus 
must take over the regulation of blood 
glucose from the pancreas in order to 
avoid acute or chronic complications 
due to abnormal blood glucose levels. 
This is achieved primarily by balancing 
insulin injections, meals, and exercise. 
Suboptimal blood glucose control with 
frequent or persistent episodes of 
hyperglycemia, leads to a substantially 
increased risk of long-term 
complications, such as micro- and 
macro vascular diseases.1 Intensive 
control of the blood glucose, however, 
may increase the frequency and severity 
of hypoglycemia1, which for many 
patients is the most feared complication 
to diabetes.2;3 
To a large extent, the patient has to take 
responsibility for managing the diabetes 
4-7. Quite apart from economic 
considerations, it is not practical for 
specialists to manage patients’ diabetes 
on a day to day basis.7 Various 
approaches intended to facilitate 
patients’ everyday decisions have been 
suggested, ranging from didactic 
lectures to interactive computer 
programs.8 Among these computer 
programs are computer-based decision 
support systems such as DiasNet9, 
AIDA10, and Librae11, all of which  have 
been developed for both educational 
(general) and advisory (specific) 
purposes. These decision-support 
systems all simulate a blood glucose 
profile from input data on meals and 
insulin doses, some of which are on a 
patient-specific basis9;11;12 and some 
from information on physical activity.11 
The DiasNet simulation tool is based on 
a metabolic model, implemented as a 
compartment model of human glucose 
metabolism and insulin kinetics in a 
Bayesian network.9 The tool has been 
tested in diabetes clinics in Italy, 
Denmark and England and has been 
shown to help improve control in 
patients with poorly controlled 
diabetes.13 A study has indicated that 
systematic errors in the metabolic model 
in hypoglycemia free data are small 
compared to the day-to-day variation of 
blood glucose seen in diabetes. 12 
It should be noted, however, that these 
rather encouraging results were based 
on a basic model, implementing only 
basal, normal physiology and not taking 
into account the broad range of events 
or conditions that may affect blood 
glucose concentrations and which may 
be necessary to fully describe and 
predict blood glucose metabolism. 
These include alcohol intake, exercise, 
disease/fever and hypoglycemic 
episodes. The importance of a particular 
event or situation and its impact on 
physiology can be assessed with a 
simulation tool by comparing blood 
glucose simulations with actual 
measurements taken where the event or 
situation is present and precisely 
documented, and where the simulation 
tool is accurate in implementing all 
known relevant physiology.  Substantial 
deviation of actual data from the 
simulations would indicate that 
physiological mechanisms are affecting 
the data but not the simulations, 
implying that not all relevant 
physiology is implemented in the 
model. In this way, systematic 
deviations of data from model 
simulations can be used to generate 
hypotheses. We have earlier used this 
approach to investigate the importance 
of alcohol intake.14 
We have previously reported that in 
SMBG data with episodes of 
hypoglycemia, measured blood glucose 
levels are consistently greater than the 
levels simulated by the model for a 
period of 10-12 hours, beginning 6-8 
hours after hypoglycemic episodes.15 
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This systematic discrepancy is seen only 
in data following hypoglycemia, 
supporting the hypothesis that 
hypoglycemia leads to a long-term 
counter-regulatory effect of some sort.  
This phenomenon has been recognized 
for many years and was originally 
described by Somogyi.  It was studied 
by several groups in the 1980s and 
1990s16-19. Taken together, the findings 
have been inconclusive, due probably to 
discrepancies in the studies’ hypotheses 
regarding the temporal characteristics of 
the hyperglycemic response and in 
study design and patient selection. 
Currently, the long-term glucose 
counter-regulation to hypoglycemia is 
omitted from or even refuted in medical 
and diabetes textbooks. 
In the present work, we describe long-
term post-hypoglycemic glucose 
discrepancy between data and 
simulations using glucose sensor data in 
order to ensure maximum resolution in 
glucose data. 
Materials and methods 
Study design 
We retrospectively analyzed continuous 
glucose profiles (48-120 hours) by 
calculating the deviation in simulated 
(DiasNet) blood glucose profiles 
compared to measured CGM (CGMS®, 
Medtronic-MiniMed, Northridge, 
California) glucose profiles after 
hypoglycemic episodes. The study was 
approved by the local ethics committee.  
Patients 
17 Type 1 diabetics with poorly 
controlled diabetes (judged by their 
diabetologist) from the diabetes clinic at 
the Royal Bournemouth Hospital, 
England were included after giving 
written informed consent. The diabetics 
were referred to the study if the clinic’s 
diabetologist assessed that there was a 
clinical indication for continuous 
glucose monitoring. The mean age of 
the subjects was 39.5 years (range: 25-
63 years). Mean diabetes duration was 
11.1 years (range: 3-42 years). Mean 
BMI was 25.5 (range: 18.6-30.0). All 
subjects had multiple daily injections of 
insulin. Mean daily dose of short-acting 
insulin (primarily Humalog, Eli Lilly) 
was 34.5 IU (range: 10-56 IU), and 
mean daily dose of long-acting insulin 
(Humulin NPH, Eli Lilly or Insulatard, 
Novo Nordisk or Lantus, Sanofi-
Aventis) was 19.5 IU (range: 8-50). 
Diary 
The patients were instructed to maintain 
a diary regarding all meals (grams of 
carbohydrates and time of ingestion) 
and all insulin injections (units of 
insulin and time of injection) for three 
days and to do at least 4 daily capillary 
blood glucose measurements with their 
regular glucose meters. The diary 
should include any meal or insulin 
related action taken in connection with 
hypoglycemia. The patients were 
instructed to live as close to their 
everyday lives as possible, despite the 
sensor. 
CGM data 
A continuous glucose sensor (CGMS®, 
Medtronic-MiniMed, Northridge, 
California) was inserted into the 
subcutaneous fat in the peri-umbilical 
region, using the insertion needle 
provided with the sensor. The sensor 
utilizes the principle of glucose oxidase 
for its measurements. The sensor was 
left in place for three to five days for 
collection of data. The sensor data was 
transferred to a PC using the data 
transfer tool from the manufacturer. The 
patients were not able to see the CGM 
measurements during the collection 
period. 
Data analysis and statistics 
The sensor data was calibrated using the 
Medtronic MiniMed CGMS® software, 
which is recommended to be used with 
at least 4 capillary blood glucose 
measurements (SMBG) per day. We 
regarded days of CGM data as valid if 
the number of measurements available 
for calibration ranged from 2 to 7 (8 if a 
nocturnal (0 am-6 am) measurement 
was present). The lower limit of 2 was 
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the absolute minimum, as at least 2 
measurements are needed in order to 
determine off-set and gain in the 
Medtronic MiniMed CGMS® 
calibration algorithm. The upper limit 
was set to 7 (or 8), as diabetics doing 
frequent SMBG do up to 7 (eventually 
8, including a nocturnal) blood glucose 
measurements per day. Hereby the 
included patients, while instructed to do 
only 4 daily measurements, may 
actually have done up to 7 (or 8), and 
the additional measurements could 
indicate special situations that might 
compromise the validity of the sensor 
data. Time with missing (or low 
voltage) sensor signal was excluded as 
invalid. 
Hypoglycemic episodes were identified 
in the valid CGM data. We defined an 
episode of hypoglycemia to consist of at 
least 4 consecutive measurements 
(equivalent to 20 minutes) below 63 
mg/dl. The beginning of the 
hypoglycemic episode was defined as 
the first measurement below 63 mg/dl 
and the end of the hypoglycemic 
episode as the last measurement below 
63 mg/dl before at least 3 measurements 
equal to or above 63 mg/dl. Episodes of 
hypoglycemia preceded by confirmed or 
possible hypoglycemic episodes up to 
20 hours beforehand were excluded in 
order to avoid interference from the 
long-term effects of hypoglycemia on 
simulation error investigated in this 
study. Thus, hypoglycemic episodes 
within 20 hours after sensor insertion or 
lack of data or data invalidity were 
excluded. CGM data were averaged 
every 15 minutes (equivalent to every 
three CGM glucose measurements) in 
order to obtain the same temporal 
resolution of CGM data as of simulated 
glucose data. 
The DiasNet simulation tool9 was used 
to calculate glucose profiles that could 
be used as ‘control data’ when 
analyzing the hypoglycemia data 
collected by CGM. The input to the 
model is the diary data: meals (grams of 
carbohydrates and time of ingestion) 
and insulin injections (units of insulin 
and time of injection). The simulation 
model is calibrated to each individual 
patient using a few glucose 
measurements as described below. The 
output is blood glucose profiles 
calculated in 15 minute steps based on 
state-of-the-art knowledge of normal 
physiology. According to simulation 
theory, since the simulation tool 
calculates the average expected blood 
glucose for each patient, the intra-
patient variation in the control data is 
cancelled or reduced significantly and 
since the model is calibrated to each 
individual patient the inter-patient 
variation in the control data is cancelled 
or reduced significantly. It should be 
noted, that also the potential effect of 
different insulin types on the inter-
patient variation is cancelled or reduced 
significantly by a simulation model 
implementing average insulin 
absorption profiles for each type of 
insulin. This reduction in intra-patient 
and inter-patient variation in the 
simulated control data implies that valid 
results can be produced with a smaller 
number of hypoglycemic events in the 
CGM dataset. 
A simulated glucose profile, the 
simulated control data, was calculated 
for the entire data period for each 
included episode of hypoglycemia. For 
each of these episodes, the input was all 
diary-reported meals and insulin 
injections for the entire data period. The 
simulation model was calibrated to each 
patient using five measurements from 
the glucose sensor (each constituted by 
an average of three CGM glucose 
measurements) around the 
hypoglycemic episode (one and two 
hours before the beginning of the 
episode, at the beginning of the episode, 
and one and two hours after the 
beginning of the episode) to adjust the 
metabolic model to the specific patient. 
This adjustment is carried out with a 
patient-specific model parameter, the 
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so-called insulin sensitivity, which is 
estimated automatically by the DiasNet 
simulation tool. 
CGM and simulated glucose profiles 
were compared for 24 hours after 
hypoglycemic episodes. The average 
CGM and simulated glucose profiles 
were compared using Student’s one-
sided t-test. All analysis was performed 
using the Excel spreadsheet program 
(Microsoft Corporation, Redmond, 
WA). 
Results are given as mean±SD. 
Results 
Total monitoring time was 54 days, 
valid monitoring time 45 days. Periods 
of non-valid monitoring were caused by 
missing (or low-voltage) sensor signals 
(15 hours) or by an invalid number of 
SMBG measurements for calibration 
(approximately 8 days). 
Episodes of hypoglycemia 
All 17 patients had at least one 
hypoglycemic episode according to the 
CGM data. A total of 52 episodes of 
hypoglycemia occurred (median per 
patient: 3; range: 1-9). 42 of the 
episodes were excluded due to: (i) 
occurrence less than 20 hours after 
sensor insertion (23 episodes of 
hypoglycemia), (ii) invalid CGM data 
(3 episodes of hypoglycemia) or (iii) 
preceding hypoglycemia (16 episodes of 
hypoglycemia).  
The 10 hypoglycemic episodes included 
in this study were found in data from 9 
patients. The temporal distribution of all 
hypoglycemic episodes together with 
indications of inclusion/exclusion (and 
reason for exclusion) is shown in Figure 
1 (only patients with includable 
episodes of hypoglycemia).  
The hypoglycemic episodes were 
evenly distributed during the day 
(Figure 1); six episodes of 
hypoglycemia were found in the 
daytime (6 am-6 pm) and four at night 
(6 pm-6 am). 
Mean hypoglycemia blood glucose 
nadir was 45 ± 7 mg/dl (according to 
the CGM data). Five episodes of 
hypoglycemia with nadir=40 mg/dl (the 
lower detection limit of the CGMS®) 
were found. Mean duration of the 
hypoglycemic episodes was 86±61 min 
(according to the CGM data).  
Comparison of mean glucose profiles 
after hypoglycemic episodes 
Mean glucose profiles (CGM and 
simulated) can be seen in Figure 2.  
The CGM glucose was significantly 
higher (p<0.05) than the simulated 
glucose for a period of 13 hours, 
beginning 8 hours after the onset of 
hypoglycemic episodes. No significant 
difference was recorded within the first 
8 hours after the onset of hypoglycemic 
episodes, except for one hour 
immediately after the onset of 
hypoglycemic episodes, where the 
CGM glucose is significantly lower 
(p<0.05) than the simulated glucose. 
 
 
Figure 1: The temporal distribution of 
included and excluded hypoglycemic episodes 
(CGM glucose <63 mg/dl for at least 20 
minutes) with indication of reason for 
exclusion (only profiles with included 
hypoglycemic episodes). × indicates included 
episode of hypoglycemia.  
■ indicates hypoglycemic episodes excluded 
because of prior (0-20 hours) lack of data, ♦ 
indicates hypoglycemic episodes excluded 
because of prior (0-20 hours) episodes of 
hypoglycemia, ▲ indicates hypoglycemic 
episodes excluded because of prior (0-20 
hours) start of data. Full lines designate valid 
data, dotted lines designate invalid data (days 
with <2 or >7 (8 if one is nocturnal) SMBG 
measurements). 
Discussion 
A systematic discrepancy between 
measured glucose and DiasNet 
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simulations following hypoglycemic 
episodes, measured glucose levels being 
higher than anticipated by the 
simulation tool, was investigated using 
CGM data. Episodes of hypoglycemia 
were identified in CGM data, and CGM 
data were compared to simulated blood 
glucose profiles for a period of 24 hours 
following the onset of hypoglycemic 
episodes.  
 
 
Figure 2: The mean glucose profiles 
(CGM: full line, simulated: broken line) 
for the first 24 hours after beginning of 
hypoglycemic episodes. × indicates 
significantly higher or lower measured 
blood glucose than simulated blood 
glucose (p<0.05). 
 
CGMS® has been validated as a reliable 
method for continuous glucose 
assessment, if calibrated properly with 
SMBG20-22, both in hypoglycemia21 and 
hyperglycaemia22. Further, the 
prevalence of hypoglycemia in our 
CGM data (17 of 17 patients) is 
consistent with findings of Hoi-Hansen 
et al.23 in diabetics with supra-normal 
HbA1c and, at least to some extent, 
hypoglycemia unawareness. It should be 
noted however, that although the 
general accuracy of CGM is acceptable, 
the weakest point in most sensors seems 
to be in the hypoglycemic range, and, 
therefore, future improvements in 
sensor technology in this region would 
benefit the validity of clinical studies on 
hypoglycemia. 
For the first hour after the onset of 
hypoglycemic episodes in our study, the 
CGM glucose was significantly 
(p<0.05) lower than expected by the 
simulation tool. Despite being 
significant, the limited magnitude of the 
maximum difference of 22 mg/dl 
indicates a relatively good fit with the 
simulation tool. Eight hours after 
hypoglycemia, our data revealed 
significantly higher CGM glucose than 
expected by the simulation tool for a 
period of more than 13 hours. 
Maximum difference was 139 mg/dl, 17 
hours after beginning of hypoglycemic 
episodes, and average difference during 
the time interval 8-21 hours after 
hypoglycemia onset was 104 mg/dl. 
Even in the last hour of analysis (23-24 
hours after hypoglycemic episode start), 
the CGM glucose was significantly 
higher (p<0.05) than anticipated by the 
simulation tool. 
The 8-hour delay of the pronounced 
difference between CGM measured data 
(after episodes of hypoglycemia; 
intervention data) and simulated data 
(hypoglycemia free; control data) 
reported here is consistent with the 
findings of Gale et al.17, Tordjman et 
al.19, Stephenson and Schernthaner24, 
and Havlin and Cryer25 that no 
significant differences in glucose 
concentration are seen within the first 4-
8 hours after hypoglycemia when 
comparing blood glucose profiles after 
hypoglycemic episodes with control 
blood glucose profiles. It should be 
noted, however, that though our results 
for the 0-8 hour period after the 
beginning of episodes of hypoglycemia 
are similar to these previous reports, 
these studies concluded that prolonged 
hyperglycaemia did not occur following 
hypoglycemia. Our data, based on the 8-
24 hour findings do not support this 
conclusion. The 8-21 hours overshoot of 
CGM glucose compared to the 
simulated glucose profile corresponds 
very well to the results for the 0-12 hour 
period after hypoglycemia reported by 
Bolli et al.18. The overshoot, however, is 
not in accordance with the findings of 
Hirsch16.  
Even though a simulation model 
reduces intra-patient and inter-patient 
variation, any significant systematic 
error in the simulation model would 
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decrease the validity of an analysis 
based on simulated data. The DiasNet 
simulation tool has been tested using 
data not containing hypoglycemic 
events: In capillary blood glucose (self-
monitored blood glucose, SMBG) data, 
the metabolic model predicts blood 
glucose profiles with a standard 
deviation (prediction error) which is 
about the same as the standard deviation 
of blood glucose measurements between 
days in the same data (the intra-patient 
variation).12 This indicates that 
systematic errors in the metabolic model 
in hypoglycemia free data are small 
compared to the day-to-day variation of 
blood glucose seen in diabetes, and that 
the DiasNet simulation tool therefore 
can be used to generate the control data 
in the present study. 
Our data support the hypothesis of a 
long-term glucose counter-regulation to 
hypoglycemia by comparison of CGM 
data to model simulations of glucose. 
Recognition of a long-term glucose 
counter-regulation to hypoglycemia is 
important to avoid overly aggressive 
treatment of (relative) hyperglycemia 
caused by prior hypoglycemia. We 
suggest that in order to minimize a 
possible interference from the 
simulation tool in a more thorough 
examination of the hypothesis, further 
studies of the existence and 
characteristics of the long-term glucose 
counter-regulation to hypoglycemia 
should include analysis of both 
hypoglycemia-free CGM control data 
and hypoglycemia CGM intervention 
data. The assessment could be based on 
a model/simulation tool. 
Conclusions 
In conclusion, our findings do not 
contradict the findings of previous 
studies. We consider the hypothesis of a 
long-term glucose counter-regulation to 
hypoglycemia, as indicated by the 
overshoot of CGM glucose compared to 
a verified simulation tool, to be justified 
for further analysis. 
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Abstract 
Background: 
Type 1 diabetes models have been developed in various species. The Göttingen minipig 
is a particularly well-known relevant large-model animal. We have explored the 
implementation of an intensive chronic type 1-like diabetes with insulin adjusted near-
normal blood glucose and with easy, non-stressful blood sampling possibilities in a 
laboratory experienced only with intensive acute and extensive chronic models. 
Method: 
A stepwise, explorative approach was applied consisting of three setups. The setups were 
designed from standard procedures, known protocols, principles of human surgery and 
experiments, and the experience from former setups. In addition, advice, instructions and 
researcher training offered by external experienced researchers were used. Key 
experimental procedures included animal training, surgical insertion of jugular vein 
catheter(-s), streptozotocin diabetes induction and blood glucose control by insulin 
injections. 
Results: 
Insufficiencies regarding animal training and blood sampling frequency and reliability 
were identified in setup 1. In setup 2, insufficiencies regarding extent of aseptic 
technique in catheter maintenance were identified. The feasibility of efficient animal 
training, the efficiency of strict aseptic catheter maintenance and the achievement of 
acceptable blood glucose control were identified in setup 3. Partial diabetes recovery was 
also observed in setup 3. 
Conclusion: 
These results indicate that the intended model may be implemented in an inexperienced 
laboratory, but there are considerable requirements in terms of researcher skills, 
development time, and biochemical laboratory facilities. 
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Introduction 
Models of type 1 diabetes exist in a 
variety of species, such as mice, rats, 
guinea pigs, swine and various 
miniature pigs. Such models have been 
used extensively for studies where 
human subjects are not acceptable or 
appropriate 1. This applies traditionally 
to type 1 diabetes pharmacological 
research 2;3 and to toxicology studies, 
but wide perspectives are also found 
within physiological studies. 
For much type 1 diabetes research, core 
characteristics of a suitable animal 
model include induced type 1 diabetes, 
tight glucose control with insulin 
regimens comparable to those applied in 
human diabetics, access to blood 
sampling for glucose control and 
experiment-related assays and minimal 
stress induction in all experimental 
procedures. In many applications, the 
animal model is established in 
Göttingen minipigs because of their 
resemblance to human physiology and 
their appropriate size 1. We call this 
model a “basic type 1 diabetes minipig 
model”, and it can be used to 
intensively study physiological events 
such as hypoglycemia and exercise, 
where a stable pathological model with 
good resemblance to human diabetic 
conditions is required. 
Various aspects of such Göttingen 
minipig type 1 diabetes models are 
well-described in the literature, and the 
model has been implemented in various 
facilities 1;4-7, also in the pharmaceutical 
industry 6. In general, however, long-
term tight blood glucose control is not 
addressed in the models employed and 
described. Despite the substantial 
literature, it appears to be a considerable 
challenge to implement a “basic type 1 
diabetes minipig model” in a biomedical 
laboratory with no prior experience in 
chronic disease models requiring 
frequent and rather complicated 
procedures as those involved in the 
model described above. This has at least 
two explanations. First, scientific papers 
reporting development or use of animal 
models with characteristics similar to 
the basic type 1 diabetes minipig model 
report their methods rather 
unspecifically, leaving open questions 
regarding the extent and execution of, 
for example, aseptic techniques. 
Second, the model work is so complex 
that continuing assistance is needed 
from friendly external colleagues 
experienced in working with models 
like the “basic type 1 diabetes minipig 
model”. Researchers unfamiliar with the 
model work need to learn the necessary 
precautions and principles of the 
intensive work required for daily 
management (blood glucose control and 
blood sampling possibility maintenance) 
of the model, so that the precise efforts 
needed for success can be established. 
This paper demonstrates how a 
laboratory that did not have prior 
experience in intensive chronic 
experiments implemented the “basic 
type 1 diabetes minipig model”, an 
intensive chronic type 1 diabetes model 
in Göttingen minipigs.  
Materials and methods 
Methodological approach 
We applied a stepwise, exploratory 
approach to refining the experimental 
implementation of a chronic type 1 
diabetes model in Göttingen minipigs in 
a facility that had prior experience only 
with acute intensive or chronic 
extensive experiments. Refinement of 
the experimental implementation from 
one setup to the next was aimed at 
addressing the problems that arose in 
the previous setup. Each setup 
evaluation included three animals. A 
summary of the methodological 
approach is shown in Figure 1. 
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The procedures involved in the 
implementations were approved by the 
Animal Experiments Inspectorate of the 
Danish Ministry of Justice. 
 
 
Figure 1: The experimental design with 
iterative process of the three setups, each 
involving an implementation of the model 
 
The implementations in the three setups 
were designed stepwise on the basis of, 
particularly, the experience gained from 
previous setups, consulting relevant 
literature, the laboratory’s prior 
experience with intensive acute or 
extensive chronic experiments, formal 
and informal training of researchers and 
from assistance offered by external 
researchers experienced with the model. 
The design basis of each 
implementation can be seen in Table 1. 
Materials 
Animals 
A total of nine Göttingen minipigs were 
used; three in each setup. All were 
obtained from the barrier unit of 
Ellegaard Göttingen minipigs (Dalmose, 
Denmark) and acclimated for at least 
two weeks prior to experiment start. The 
minipigs were housed in single pens 
with holes for snout contact, under 
controlled conditions (temperature 18-
22°C, relative air humidity 30-70%, 
12:12 hours light-dark cycles) and fed 
twice daily with SDS minipig diet 
(Special Diets Services, Essex, United 
Kingdom) at 7:00-7:30 and 14:00-
14:30, respectively and had access to 
water ad libitum. The animals were all 
acquainted to humans and observed by 
trained animal technicians and a researcher 
as to their health status (weight, appetite, 
behavior, color). 
 
 
 
 
Methods applied in all three setups 
Surgical technique for implantation 
of central venous catheters 
Anesthesia was induced with 
intramuscular injection of 1 ml/10 kg 
pig zoletil-mixture (xylazin 12.5 mg/ml 
(Rompun Vet, Bayer Health Care, 
Leverkusen, Germany), ketamin 12.5 
mg/ml (Ketaminol, Intervet 
International, Boxmeer, Holland), 
butorphanol 2.5 mg/ml (Torbugesic 
Vet., ScanVet Animal Health A/S, 
Fredensborg, Denmark), tiletamin 25 
mg/ml (Zoletil 50 Vet., Virbac, Carros, 
France), zolazepam 25 mg/ml (Zoletil 
50 Vet. Virbac, Carros, France)). The 
animals were intubated and maintained 
with isoflurane 1-2% in 50% oxygen. 
An ear vein was cannulated for infusion 
of perioperative analgesia and muscle 
relaxation with fentanyl 250 µg 
(Fentanyl “Hameln”, Hameln 
Pharmaceuticals, Germany) and 
rocuronium bromide 50 mg (Esmeron, 
Organon, Oss, Holland). Postoperative 
analgesia was provided with 
intramuscular injections of 100 mg 
ketoprofen (Orudis, Sanofi-Aventis, 
Paris, France) for 4 days. Postoperative 
infection was prevented with 
intramuscular injection of 2 mill. units 
of benzylpenicillin (Benzylpenicillin, 
Panpharma, Fougéres, France) 
immediately before surgery and for the 
following 4 days. Animals were shaved 
carefully, washed and prepared with 
iodine alcohol. During open surgery and 
aiming at aseptic procedures (sterile 
gloves, sterile unpacking of utensils, 
sterile draping of the entire field), one 
or two 6.5 Fr catheters (Cook Medical, 
Bloomington, IN), depending on setup 
number, were inserted, pre-filled with 
heparin 5000 U/ml (Heparin SAD, 
SAD, Copenhagen, Denmark). The 
catheters were exteriorized via an 
incision in the dorsal midline, 
approximately 6-10 cm cranial to the 
scapulae, and fastened by suture loops 
and the catheters’ Dacron cuffs. The 
catheters were tunneled subcutically to a 
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ventral caudal-cranial jugular furrow 
catheter introduction incision. Blunt 
dissection to the vena jugularis exterior 
(and in setup 2 also interior) was 
performed and the catheters were 
introduced in them using the insertion 
kit provided with the catheters. 
The intended position of the catheter tip 
was in the anterior vena cava. The vein 
was ligated around the catheter caudally 
to the insertion site, and a catheter 
 
Table 1: Design basis of each setup 
 
 Design basis Outcome input to next setup 
Setup 
1 
 Protocols for diabetes induction from 
external researchers experienced with 
chronic models similar to the “basic 
type 1 diabetes minipig model” 
 Standard procedures from intensive 
acute and extensive chronic 
experiments 
 Experimental protocols as described 
in the literature 
 Mandatory laboratory animal science 
course 
 Training of animals to accept all 
procedures was insufficient 
 Blood glucose measurements were too 
scarce for insulin adjustment 
 Placement of catheter tip was imprecise 
Setup 
2 
 Experience from setup 1 
 General advice from external 
researchers experienced with chronic 
models similar to the “basic type 1 
diabetes minipig model” 
 Efforts to ensure aseptic technique with 
catheter placement and maintenance 
were insufficient 
Setup 
3 
 Experience from setup 2 
 Training of researcher by external 
animal facility staff experienced in 
surgery and catheter maintenance in a 
similar animal model 
 Principles of human surgery, catheter 
maintenance and blood glucose 
control 
 
 
loop was fastened by sutures. Both 
incision sites were closed in the muscle 
and cutical layers. A pouch fastened to 
the neck using adhesive bands held the 
exteriorized catheters.  
Measurement of baseline blood 
glucose 
The blood glucose was measured pre-
prandially and at two hours after 
feeding on three consecutive days 
before diabetes induction.  
Diabetes induction 
The animals were fasted 18 hours 
before diabetes induction. Type 1-like 
diabetes was induced by a single 
infusion of streptozotocin (STZ) (S-
0130, Sigma-Aldrich, St. Louis, MO), 
125 mg/kg, dissolved in sodium citrate 
buffer (pH 4.5), 2 ml/kg, over 5 minutes 
in one of the catheters. Doses of STZ 
between 100 and 150 mg/kg are 
commonly used for type 1-like diabetes 
induction 2;8-11. Isotonic sterile saline 
was infused before (5 ml) and after (20 
ml) STZ infusion. 
Animals were offered their normal 
morning feed with 2 g/kg glucose 
(Glukose, Matas, Allerød, Denmark) in 
1 dl yogurt 3 hours after STZ 
administration and at normal feeding 
times for the following 48 hours. During 
this period, the animals were observed 
carefully, and blood glucose was 
measured every 1-4 hours for detection 
of hypoglycemia due to 
hyperinsulinemia resulting from β-cell 
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destruction. Hypoglycemia < 2.5 
mmol/l was treated with 20 g of glucose 
in 1 dl yogurt. 
Blood glucose measurements 
Blood glucose was measured by an 
ABL725 (Radiometer, Copenhagen, 
Denmark) with 90 µL or 150 µL glass 
capillaries (Clinitubes, Radiometer, 
Copenhagen, Denmark). The ABL725 
was calibrated and maintained 
according to the manufacturer’s 
instructions. 1.5 ml of catheter lock 
solution and blood was drawn prior to 
sampling of blood for analysis. 
Insulin treatment 
Insulin treatment was initiated after STZ 
infusion when pre-prandial blood 
glucose >20 mmol/l. Insulin treatment 
aimed at pre-prandial blood glucose <7 
mmol/l and 2 hours post-prandial blood 
glucose <10 mmol/l. 
Insulin was injected subcutaneously 
approximately 2-5 cm caudal to the ear, 
from ear height to approximately 5 cm 
ventral to the ear. Both sides were used, 
and injection sites were varied to avoid 
infiltrates. 
For all insulin injections, we used a 
NovoPen Junior insulin pen (Novo 
Nordisk, Bagsværd, Denmark) with 
12.7 mm needles (BD Ultra-Fine, BD, 
New Jersey, USA). 
Euthanasia 
The animals were euthanized with a 
bolus of 20 ml of pentobarbitone (200 
mg/ml; Pharmacy of the Royal 
Veterinary and Agricultural University, 
Copenhagen, Denmark) in the central 
venous catheter. 
Methods applied specifically in each 
setup 
Setup 1 
The first group consisted of 3 female 
pigs aged 7-8 months, weight 17-18 kg.  
No other training in addition to human 
acquaintance was performed, so the pigs 
were placed in a box 50x80 cm for 
restraint during blood sampling and 
insulin injection. 
The animals were fed 110 g at each 
feeding before diabetes induction and 
140-150 g after diabetes induction for 
weight maintenance. 
One catheter was implanted. This was 
done with the pig first in ventral 
recumbency for exteriorization incision 
and catheter tunneling, then in dorsal 
recumbency for insertion incision, 
catheter insertion and incision closure, 
and again in ventral recumbency for 
exteriorization incision closure. The pig 
and also the sterile drapes were thus 
manipulated twice. Catheter tip location 
in the anterior vena cava was 
determined by a sensation of catheter 
reluctance to blood withdraw using a 
syringe, indicating a position of the 
catheter tip in the heart 12 and 
subsequent catheter retraction of 1-2 
cm. The catheter was implanted in its 
full length with excess catheter length 
coiled and placed in a muscle/subcutical 
fat pocket dissected in the dorsal 
incision. 
The catheter lock solution and blood 
drawn before sampling of blood from 
the catheter for analysis was re-injected 
before injection of new lock solution 
(5000 U/ml). 
Baseline blood glucose level 
measurements were initiated 6 days 
after catheter implantation. 
Diabetes was induced 10 days after 
surgical catheter insertion. 
Blood glucose was measured pre-
prandially each day following diabetes 
induction. 
Insulatard (Novo Nordisk, Bagsværd, 
Denmark, 100 IE/ml), initial dose 0.2 
IU/kg/feeding, was injected 
subcutaneously immediately before 
feeding. Subsequently, insulin doses 
were adjusted in steps of 0.1/IU at each 
feeding according to pre-prandial blood 
glucose. 
For an hourly blood sampling session of 
32 hours duration for detailed blood 
glucose profile purposes, a 1.5 m 
extension of the catheter was 
constructed to allow for blood sampling 
without animal contact. For the entire 
system, 3.1 ml of lock solution (5000 
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U/ml) was used, and the lock solution 
withdrawn before blood sampling for 
analysis was injected before the new 
lock solution. 
Setup 2 
The second group consisted of 3 female 
pigs aged 9-10 months, weight 21-24 
kg.  
The animals were trained over a 3-week 
period to accept blood sampling and 
insulin injections before surgical 
catheter implantation.  
The animals were fed 130 g at each 
feeding prior to diabetes induction. 
Two catheters were implanted to ensure 
blood sampling possibility. The 
catheters were implanted and 
maintained as in setup 1, but with the 
extra catheter in the right vena jugularis 
exterior and applying distances 
measured by necropsy measurements on 
setup 1 pigs for catheter tip placement. 
Baseline blood glucose levels were 
determined 4 days after catheter 
insertion. 
Diabetes was induced 9 days after 
catheter insertion. 
Blood glucose was measured pre-
prandially every day after insulin 
induction. 
Insulatard (Novo Nordisk, Bagsværd, 
Denmark, 100 IE/ml), initial dose 0.2 
IU/kg/feeding, was injected 
subcutaneously immediately before 
feeding. No insulin dose adjustment was 
relevant. 
Setup 3 
The third group consisted of 3 male pigs 
aged 9-10 months, weight 20-22 kg.  
A staged, evaluation-centered protocol-
based training scheme was developed, 
aiming at acceptance of blood sampling 
and insulin injections. The protocol 
utilized positive reinforcement (apple 
pieces) and consisted of 14-18 
incremental sessions over 3 weeks, each 
of 15-20 minutes duration and with a 
formulated objective (protocol 
presented at the Minipig Research 
Forum Annual Meeting 2007, 
Copenhagen, Denmark).  
The animals were fed 200 g at each 
feeding prior to diabetes induction. 
During the first 30 days after diabetes 
induction, the feeding rations were 
adjusted to determine an optimal 
feeding regimen, in total 500 g on two 
feedings. 
Two catheters were implanted, both in 
the right vena jugularis exterior. The 
pigs were positioned in lateral 
recumbency during the entire surgical 
procedure. The two catheters were 
introduced via one needle puncture of 
the vein, applying two guidewires with 
a sheath each. Catheter tip location in 
the anterior vena cava was ensured 
applying necropsy measurements on a 
pig in setup 2. The catheters were cut 
with a sharp pair of sterile scissors to 
appropriate length, leaving no coiling 
necessary 13. 
Catheter maintenance aimed at aseptic 
procedures utilizing sterile surgical 
gloves, alcohol swabs for wiping the 
catheter before connecting syringes to 
it, and sustained sterility of utensils 
(syringes for catheter lock removal, 
syringes for blood sampling, syringes 
with new lock solution, catheter caps). 
The catheters were flushed 7 days after 
insertion but otherwise untouched. 
Baseline blood glucose level 
measurements were performed 12-14 
days after catheter insertion. 
Diabetes was induced 22 days after 
catheter insertion.  
Ampicillin (Pentrexyl, Bristol-Myers 
Squibb, Bromma, Sweden) 10 mg/kg 
was injected intravenously every 10 
days for infection-related complications 
prophylaxis. 
The catheter lock and blood drawn 
before blood sampling for analysis was 
discarded. The catheter was flushed 
with 2 ml of isotonic sterile saline 
before injection of lock solution 
(expected duration less than 2 hours: 
100 IU/ml, 2-5 hours: 500 IU/ml, 5-24 
hours: 1000 IU/ml, more than 24 hours: 
5000 IU/ml). One catheter was 
preferred for use, the other was flushed 
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and locked with heparin 5000 IU/ml 
every week and held in reserve. New, 
sterile catheter caps were placed after 
each blood sampling 14. 
Blood glucose was measured every 
three to four hours for 24 or 48 hours 
after insulin dosage adjustment, 
beginning on day 2. 
A continuous glucose monitoring 
system (CGMS, Medtronic, Northridge, 
United Kingdom) was used for easy and 
precise glucose monitoring for 3-4 days. 
Sensors were inserted according to the 
manufacturer’s instructions under 
anesthesia (1 ml/10 kg pig-zoletil 
mixture as for anesthesia induction 
before surgery) and calibrated with 4 or 
5 daily blood glucose measurements. 
They were placed caudally to the area of 
insulin injection and covered by first a 
sterile semi-permeable dressing, then 
the adhesive band holding the catheter 
pouch. The glucose sensor box was 
fastened in a home-made vest. Insulin 
was not injected in the side with the 
glucose sensor during wear and on the 
day before sensor insertion. 
For blood glucose control after diabetes 
induction, insulin (Insulatard, Novo 
Nordisk, Bagsværd, Denmark), initial 
dose 0.2 IU/kg/feeding, was injected 
subcutaneously immediately before 
feeding. To better control post-prandial 
and morning pre-prandial blood 
glucose, other insulin regimens were 
applied. These regimes were: 1) Mixed 
insulin (Mixtard 50, Novo Nordisk, 
Bagsværd, Denmark, 100 IE/ml), 2)  a 
combination of separate short acting 
insulin (Actrapid, Novo Nordisk, 
Bagsværd, Denmark, 100 IE/ml) and 
separate regular insulin (Insulatard, 
Novo Nordisk, Bagsværd, Denmark), 
both injected at feeding start. Insulin 
doses were adjusted in steps of 0.05 or 
0.1 IU/kg/feeding according to blood 
glucose measurements, and up to 0.2 
IU/kg/feeding in case of extensive 
hypoglycemia or hyperglycemia. Insulin 
dosages and feeding rations were 
adjusted concurrently.  
The procedure for diabetes induction 
with STZ was repeated after 62 days in 
two animals due to spontaneous, partial 
recovery from diabetes. 
Results 
Setup 1 
The pigs did not accept blood glucose 
sampling and insulin injections easily, 
and some degree of force was indicated. 
STZ caused hyperglycemia (blood 
glucose>20 mmol/l) in all animals, and 
insulin treatment was initiated. Intended 
blood glucose control was not achieved. 
One catheter lost its patency 10 days 
after diabetes induction, the others 
remained patent. The animal with the 
dysfunctional catheter was euthanized. 
Necropsy revealed unintended catheter 
tip location in a small hepatic vein. 
One animal developed epistaxis and 
rectal bleeding due to over-
heparinization during hourly blood 
sampling 25 days after diabetes 
induction and was euthanized. 
One animal became lethargic and 
developed anorexia, hypoxia, 
tachycardia and superficial breathing 30 
days after diabetes induction. The 
animal was euthanized, but the disease 
cause could not be determined by gross 
pathology. 
Main results 
The main results of setup 1 were that 
the animals were insufficiently trained 
to accept the procedures involved in the 
experiment and that the blood glucose 
was measured too rarely to allow tight 
blood glucose control. An additional 
result was that correct catheter tip 
placement could not rely solely on the 
feeling of reluctance to blood 
withdrawal. 
Setup 2 
The pigs accepted touching in the neck 
area and insulin pen needle insertion 
without injection of insulin before 
surgery, but after surgery, blood 
sampling was complicated by pig 
movement. 
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One pig died during surgery. No 
obvious cause was observed, including 
bleeding, anesthesia overdose and 
apparatus malfunction. Unfortunately, 
no necropsy was performed, so the 
cause of death remains unknown. 
One pig exhibited irreversible 
tachycardia (170 beats per minute) and 
hypotension (70/30 mm Hg) 10 minutes 
after isoflurane inhalation was initiated. 
Mydriasis was observed after four 
hours, so the animal was euthanized. 
One animal developed anorexia, 
hypoxia including cyanosis, tachycardia 
and superficial breathing 3 days after 
diabetes induction and insulin treatment 
initiation. The animal was euthanized, 
and necropsy indicated a pulmonary 
thromboemboli. Correct catheter tip 
location was observed. 
Main result 
The main result of setup 2 was that the 
catheter maintenance procedures 
employed did not prevent 
thromboemboli. An important result 
was also that anatomical fixpoint 
measurements ensured correct catheter 
tip placement. 
Setup 3 
The animals’ responses to training 
varied only little. The main difficulty 
was balancing the intensive training 
with the animal’s ability to focus on the 
session task objective and not only on 
the reward, Training 2-5 hours after 
feeding was optimal. The pigs accepted 
blood sampling from the catheters and 
insulin injections easily, even during 
nightly blood samplings. However, one 
pig developed evasive and aggressive 
behavior during insulin injections 
approximately one month after diabetes 
induction. Repetition of the initial 
training protocol over 3 days restored 
full compliance.  
One pig developed an abscess with 
suppuration of approximate diameter 2 
cm in the healed exteriorization incision 
35 days after surgery. Nine days of 
daily intravenous injection of 1000 mg 
ampicillin cured the infection. 
All catheters were patent during the 
entire experiment (70 days). 
3 or 4 subcutaneous glucose sensors 
were used in each pig. Three sensors 
dislocated within the wear period 
despite no problems were observed 
during sensor insertion. 
Feeding rations of 160 g in the morning 
and 340 in the afternoon apparently 
provided the easiest insulin dosage 
without diurnal hypoglycemia or 
hyperglycemia patterns. 
The initial insulin treatment with 
Insulatard resulted in morning post-
prandial and afternoon pre-prandial 
hyperglycemia and late afternoon/early 
evening hypoglycemia. Mixtard 50 
caused late afternoon hypoglycemia and 
dose reduction caused morning pre-
prandial hyperglycemia. Short acting 
insulin with the morning feeding and 
intermediate acting insulin and short 
acting insulin with the afternoon feeding 
caused afternoon post-prandial 
hypoglycemia. The same regimen 
without short acting insulin with the 
afternoon feeding caused overall 
acceptable blood glucose control in 14 
days; morning insulin doses were 0.11, 
0.13 and 0.21 IU/kg, and afternoon 
insulin doses were 0.23, 0.29 and 0.53 
IU/kg. 
50-60 days after diabetes induction 
blood glucose levels began to decrease 
in all pigs, both pre-prandially and post-
prandially. Insulin doses were reduced 
but hypoglycemia persisted, and insulin 
doses were further reduced and finally 
removed. Pre-prandial blood glucose on 
day 3 after insulin removal was 14-16 
mmol/l. 72 hours after the repeated 
procedure for induction of diabetes with 
STZ, blood glucose was 12-18 mmol/l. 
Main results 
The main results of setup 3 were that 
strict aseptic technique ensured catheter 
function for over two months and that 
blood glucose could be reasonably 
tightly controlled. However, a very 
important result was the decreased 
insulin requirements. The methods 
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applied were insufficient to determine 
the onset of decreased insulin 
requirement and its cause. 
The results are summarized in figure 2. 
Discussion 
This paper presents an explorative 
approach to the implementation of a 
basic type 1 diabetes model in 
Göttingen minipigs with tight blood 
glucose by insulin injections and with 
easy, non-stressful blood sampling 
opportunities. The work-intensive, 
chronic model is suitable for physiology 
studies. Three setups were evaluated; 
the two last evolving from their 
predecessors. 
The main results are the following: 1) 
intensive training is needed for the  
 
Figure 2: The specific methods applied in each setup and the feedback from 
previous setups 
 
animals to accept the procedures, 2) 
very strict aseptic procedures with all 
catheter maintenance govern the 
survival of animals, 3) acceptable blood 
glucose control can be established, but 
frequent blood sampling is needed, and 
4) partial recovery from STZ diabetes 
can occur and may compromise the 
resemblance of human diabetes. 
The importance of training the animals 
to accept the experimental procedures 
has been described in some studies 
employing a model similar to the basic 
type 1 diabetes minipig model of the 
present study 15;16. The application of 
the setup 3 training protocol appears 
safe and effective in (re-) achieving 
animal experimental procedure 
acceptance. 
Strict aseptic procedures in all catheter 
maintenance, including surgical 
insertion, have been emphasized in the 
literature 13-15;17. Very strict aseptic 
technique in catheter maintenance as a 
key complication prophylaxis 
improvement has been reported 18. 
Important fatal complications in the 
present study were thrombosis-related, 
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commonly seen in animals with central 
venous catheters 19;20, even if sepsis-
related complications are avoided 18;19;21. 
Blood glucose control by insulin 
injections was the major difficulty 
encountered in setup 3, while other, 
basal, method refinements ensured pig 
survival. To our knowledge, tight blood 
glucose control with multiple daily 
injections (compared to insulin pump 
therapy) in pigs has so far not been 
explored. However, pre-prandial blood 
glucose of 5-10 mmol/l by two daily 
subcutaneous injections of Velosulin 
and NPH porcine insulins are 
achievable 5 but accompanied by both 
hypo- and hyperglycemia 10. 
Surprisingly, weight-maintaining blood 
glucose control has required higher 
insulin doses than we found appropriate 
for reasonable tight blood glucose 
control 22-24. Insulin sensitivity 
variations in our animals may be 
governed not only by congenital 
biological variation but also variations 
in partial diabetes recovery and 
infection status, which was not 
investigated. 
The partial reversibility of diabetes 
status was unexpected, as stable 
diabetes is achievable for periods over 3 
months with different STZ regimens 
7;23;25-27. However, 1-2 months’ 
reversibility of diabetes is not 
uncommon 2;9;23, especially in young 
animals 9, and is accompanied by non-
diabetic C-peptide levels 10;23. 
Reversibility is probably to some extent 
dose-dependent 23, but recovery has also 
been seen after STZ doses larger than 
125 mg/kg as used in the present study 
9;23. The efficiency of 200 mg/kg STZ 
for induction of chronic (>16 weeks) 
duration of C-peptide-negative diabetes 
was not established until 2008 by Hara 
and co-workers 23, as Liu and co-
workers 28 did not report diabetes 
duration in their 200 mg/kg STZ pigs. 
The present failure of repeated STZ-
injection to re-establish diabetes could 
indicate that the partial recovery is 
caused by isolated beta-cell or small 
beta-cell cluster hypertrophy, as they, 
together with immature beta-cells, are 
less susceptible to STZ-induced 
destruction 9. Higher STZ doses and 
close monitoring of diabetes status by 
C-peptide or intravenous glucose 
tolerance tests as employed by Canavan 
and co-workers 5 are indicated. 
Diabetes status and infection status are 
important for effective blood glucose 
control. In laboratories not experienced 
with advanced models, this poses 
challenges to biochemical laboratory 
facilities, for instance for C-peptide 
radio-immunoassays. This should be 
considered carefully when evaluating 
the feasibility of implementing a 
chronic diabetes animal model. 
Different fatal outcomes or premature 
euthanasia causes occurred. They can be 
classified as handling-related, diabetes 
recovery-related or of unknown cause. 
Because a single focus area cannot be 
identified, several setup refinements are 
needed. Some fatal outcomes, such as 
handling and catheter related fatalities, 
may be preventable. Fatalities due to 
partial diabetes recovery may be 
preventable, but if not, their potential 
effects should be considered. 
Conclusions 
In conclusion, our results indicate the 
possibility of implementing a chronic 
Göttingen minipig model of type 1 
diabetes with near-normal blood 
glucose, controlled by insulin injections, 
and easy, non-stressful venous blood 
sampling access. A high success rate 
can be assured with good training of the 
animals, use of appropriate surgical and 
catheter maintenance techniques, and 
systematic diabetes status monitoring.
However, researchers should carefully 
ensure adequate experience, sufficient 
time commitments and appropriate 
laboratory facilities. If these resources 
are lacking, the use of animals will be 
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highly unethical and the projects will 
most likely fail. 
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